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ABSTRACT 
 
The aryl hydrocarbon receptor (AhR) is a steroid-like transcription factor that mediates 
the toxicity of various environmental pollutants, including 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) and TCDD-like compounds. Exposure to environmentally relevant levels 
of TCDD and TCDD congeners has been shown to cause immune suppression, yet the 
mechanisms underlying TCDD-induced immune suppression remain poorly understood. 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) that play an 
integral role in both innate and adaptive immune responses. DCs constitutively express 
AhR and represent a highly sensitive immune cell population to AhR activation by 
environmental pollutants. In a murine inflammatory bone marrow-derived DC (BMDC) 
model, AhR activation has been shown to alter surface molecule expression and induce 
immnuoregulatory genes. To further these studies, we examined AhR activation in 
murine steady-state BMDCs, DCs that in vitro closely resemble DCs found in peripheral 
immune tissues in vivo. We found that similar to inflammatory BMDCs, TCDD-induced 
AhR activation disrupts steady-state BMDC differentiation, responsiveness to innate 
danger signals, and induces immunoregulatory gene expression. AhR activation has been 
implicated in the polarization of regulatory T cells (Tregs), which are capable of 
inhibiting immune responses and may contribute to the observed immune suppression 
following exposure to TCDD. Because both inflammatory and steady-state BMDCs 
upregulated immunoregulatory gene expression in response to TCDD, their potential to 
suppress CD4+ T cells responses was examined in antigen-specific DC:CD4+ T cell co-
cultures in vitro. Both inflammatory and steady-state AhR activated BMDCs altered 
antigen-specific CD4+ T cell responses and induced Foxp3+ Tregs when compared to 
vehicle-treated BMDCs. These in vitro studies were followed by a series of in vivo 
studies, in which we demonstrated that TCDD-exposed mice immunized with antigen-
laden BMDCs, or antigen with adjuvant generated an increased frequency of Foxp3+ 
Tregs and subsequently dampened antigen-specific CD4+ effector T cell responses. 
Furthermore, DCs from TCDD-treated mice displayed increased expression of 
immunoregulatory genes, suggesting that they may be contributing to deficient CD4+ 
effector T cells responses and the generation of Tregs as observed in our in vitro studies. 
Overall, these studies significantly advance our understanding of how AhR activation by 
TCDD and TCDD-like chemicals induces immune suppression.  
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CHAPTER 1 
 
INTRODUCTION 
This dissertation describes the effects of aryl hydrocarbon receptor (AhR) 
activation in two distinct dendritic cell populations. The introduction will provide: 1) an 
overview of the immune system, 2) an in depth review of dendritic cell biology and T cell 
activation, and 3) describe the immune toxicity of environmental toxicants that activate 
the AhR. 
 
The Immune System 
The immune system is designed to protect against foreign pathogens and provide 
tolerance to self. Through the process of evolution the immune system has formed two 
distinct branches, the innate and adaptive immune systems. These two systems often 
work in concert to recognize, alert and remove invading microorganisms to provide full 
protection to the host. The innate immune system provides the first line of defense, while 
the adaptive immune system provides additional defense and memory.  
Innate Immunity 
The innate immune system, being the first line of defense is designed to 1) 
provide a barrier, 2) recognize a wide range of foreign organisms or xenobiotics and 3) 
effectively remove foreign organisms or xenobiotics with minimal damage to the host. 
The skin and mucosal surfaces make up the general barriers of the innate immune system, 
acting as shields to keep pathogens from gaining entry into the body. If the barrier 
function is compromised, various innate immune cells have the ability to broadly 
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recognize pathogens, mount a rapid response against the pathogen and remove it from the 
body.  
The leukocytes that constitute the innate immune system are neutrophils, 
basophils and mast cells, eosinphils, natural killer cells, macrophages and dendritic cells, 
with secondary support from cells that make up epithelial and mucosal layers (Figure 
1.1). The innate immune system also contains specific innate lymphocyte populations 
such as B1 B cells, γδ T cells and natural killer T cells. Neutrophils or 
polymorphonuclear cells (PMNs) are professional phagocytes that engulf microorganisms 
and damaged cells. Neutrophils are short-lived and make up ~50% of the circulating 
leukocyte population. They are recruited from circulation to damaged sites by 
chemokines and various microbial products. Neutrophils have the ability to destroy 
pathogens through phagocytosis, breakdown via intracellular endosomal/lysosomal 
pathways and the production of antimicrobial proteins. Neutrophils also secrete reactive 
oxygen species during oxidative bursts to destroy extracellular pathogens. Basophils and 
mast cells are circulating and tissue resident non-phagocytic leukocytes, respectively, that 
aid in the defense against parasites through the release of cytoplasmic granules containing 
compounds such as proteases, major basic protein and cytokines. Basophils and mast 
cells make up ~1% of the leukocyte population and are also effector cells in allergic 
responses, secreting histamine and other pro-inflammatory compounds following IgE-
mediated Fc receptor activation. Eosinophils are circulating weakly phagocytic cells that 
release cytotoxic granules to defend against extracellular parasites, primarily helminths. 
Eosinophils are mainly tissue resident leukocytes and make up ~3% of the total immune 
cell population. Natural killer (NK) cells are derived from lymphoid progenitor cells, but 
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they contribute to innate immune responses. NK cells recognize virally infected cells and 
tumor cells and induce their apoptosis through the release of lytic granules. In addition to 
neutrophils, macrophages help ingest and clear microorganisms, as well as clear 
apoptotic cells to help control cellular turnover and support self-tolerance. Derived from 
monocytes in the blood, macrophages are rapidly recruited to sites of inflammation to 
provide additional help in clearing infected or dying cells and aid in the inflammatory 
response through the production and secretion of pro-inflammatory cytokines such as IL-
6 and TNFα and various chemokines. Within tissues, macrophages take on specialized 
roles. For example, macrophages present in the liver, known as Kupffer cells, and in the 
spleen primarily scavenge senescent cells, whereas alveolar macrophages present in the 
lung phagocytose inhaled particles and regulate inflammation. Within the innate immune 
system, similar to macrophages, dendritic cells also help in the recognition and removal 
of pathogens. Pathogen recognition in the innate immune system is achieved through a 
highly evolved receptor network. 
Innate immune cells use a class of receptors known as pathogen recognition 
receptors (PRRs) to identify foreign organisms. PRRs recognize pathogen-associated 
molecular patterns (PAMPs) that are widely expressed on different microorganisms. 
PRRs are primarily expressed in neutrophils, macrophages, natural killer cells and 
dendritic cells as well as B lymphocytes (Janeway and Medzhitov, 2002; Janssens and 
Beyaert, 2003). The power of PRRs and the innate immune system comes from its ability 
to recognize a wide variety of PAMPs. This recognition is accomplished through the 
expression of different PRRs including: scavenger receptors that recognize low-density 
lipoproteins; mannose receptors that bind mannose-containing carbohydrates found on 
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various fungal and protozoan pathogens; C-type lectin receptors that recognize foreign 
glucan structures; and Toll-like receptors (TLRs) and nucleotide oligomerization domain 
receptors (NODs), which recognize both extracellular and intracellular PAMPs.  
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Figure 1.1 
 
 
 
 
 
Figure 1.1.  Cells of the innate and adaptive immune systems and their basic function. 
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There are 13 TLRs described in mice and 10 in humans (Janssens and Beyaert, 
2003). TLRs can be broken into two groups based on location and substance recognized: 
extracellular membrane-bound and intracellular TLRs (Figure 1.2). Membrane-bound 
TLRs include TLR 1, 2, 4, 5 and 6 and function to recognize bacterial and fungal cell 
wall components and motor proteins such as flagellin. TLRs 3, 7 and 9 are intracellular 
PRRs contained in endosomes, binding mainly viral nucleic acids. Specifically, TLR2 
recognizes lipoteichoic acid and peptiglycans on gram-positive bacteria and is 
constitutively expressed on macrophages, dendritic cells and B lymphocytes. TLR2 also 
forms heterodimeric complexes with TLR1 and TLR6, effectively increasing the number 
of foreign ligands detected by TLR2. TLR4 is responsible for detecting lipopolysassricde 
(LPS), a constituent of gram-negative bacterial cell walls, and is expressed on 
macrophages, dendritic cells, neutrophils, mast cells, as well as B lymphocytes and 
various non-immune cells. Flagellin, a bacterial protein used in propulsion, is detected by 
TLR5, which is expressed on macrophages and dendritic cells. The intracellular TLRs 3, 
7 and 9 recognize viral double-stranded DNA (dsDNA), viral ssRNA and unmethylated 
cytosine-phosphate-guanine (CpG) viral DNA motifs, respectively, and are expressed in 
macrophages, dendritic cells and B lymphocytes at varying levels (Medzhitov, 2001; 
Janeway and Medzhitov, 2002). TLR11, 12 and 13 in mice are less characterized, but are 
thought to play a role in the detection of pathogenic organisms of the urinary tract 
(Medzhitov, 2001; Janssens and Beyaert, 2003).  
The NOD receptor family consists of over 20 intracellular NOD receptors. NOD1 
and NOD2 are the best characterized and considered prototypical NOD receptors. NOD1 
and NOD2 receptors recognize peptidoglycans expressed on both gram-positive and 
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gram-negative bacteria. In addition to membrane-bound and intracellular PRRs, the 
innate immune system also employs secreted PRRs to detect foreign organisms and elicit 
immune responses. 
Similar to membrane-bound and intracellular PRRs, secreted PRRs recognize 
PAMPs to help activate the complement system and to opsonize pathogens for 
phagocytosis. Secreted PRRs, also known as acute-phase proteins, are integral to acute-
phase responses induced by early systemic inflammation in response to infection 
(Janeway, 2008). Acute-phase proteins are classified into four groups: collectins, 
pentraxins, lipid transferases and peptidoglycan recognition proteins (PGRPs). Each 
group consists of a large number of proteins with the more common acute-phase proteins 
being C-reactive protein, serum amyloid A and serum amyloid P, mannose-binding 
lectin, fibrinogen, and the surfactants SP-A and SP-D. These acute-phase proteins 
orchestrate the activation of the complement system and overall aid in pathogen 
recognition and destruction. In addition, many secreted PRRs have bactericidal properties 
to help destroy or weaken bacteria (Janeway and Medzhitov, 2002; Janeway, 2008; 
Murphy et al., 2008).  
Overall, the innate immune system employs highly efficient mechanisms to 
detect, destroy and remove injurious foreign organisms. As the first line of defense, the 
innate immune system effectively clears the majority of harmful microorganisms. While 
the innate immune system provides rapid host protection, it lacks two important 
characteristics, specificity and memory. Fortunately, these attributes are what define the 
adaptive immune system.  
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Figure 1.2 
 
 
 
 
 
Figure 1.2. Toll-like receptors and their common ligands. 
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Adaptive Immunity 
To provide more comprehensive host recognition of both foreign and self-
antigens, mammals as well as various non-mammal species have developed a second line 
of defense known as the adaptive immune system. This second branch consists of 
specialized immune cells that interact with one another and can communicate with the 
innate immune system. Initial adaptive immune responses are slower than those of the 
innate immune system, taking from 5-7 days to initiate a response and 7-14+ days to clear 
a pathogen. However, during the course of the immune response, memory cells develop 
and upon secondary exposure the adaptive immune response is rapid, taking only a few 
days to mount a robust full response. The leukocytes involved in adaptive immune 
responses are T cells and B cells and macrophages and dendritic cells (Figure 1.1).  
T and B lymphocytes are derived from common lymphoid progenitors and are 
unique in that they are the only cells in the body that express antigen receptors designed 
to recognize only a single specific antigen and are capable of clonal expansion following 
recognition and activation. T lymphocytes develop in the thymus from CD8- CD4- 
precursor cells into committed CD4+ T cells or CD8+ T cells following a complex process 
of positive and negative selection. The selection process is designed to produce 
individual T cells that recognize only antigens processed and presented on major 
histocompatibility complex (MHC) molecules by antigen presenting cells (APCs) and to 
limit the generation of autoreactive T cells that respond to self-antigens. B lymphocytes 
develop in the medulla ossium rubra of the bone marrow and, similar to T cell 
development, the generation of self-reactive B cells is minimized before exodus from the 
bone marrow. In contrast to T cells, which only recognize processed antigens on MHC 
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molecules presented primarily by APCs, B cells recognize antigen in its natural 
unprocessed form. In the periphery, T cells and B cells in circulation and in secondary 
and tertiary lymphoid tissues coordinate effective humoral and cell-mediated immune 
responses to a diverse range of pathogens. 
B cells are responsible for the production of antibodies, which are the defining 
quality of humoral immunity. B cells express surface immunoglobulin B cell receptors 
(BCR) that recognize antigens in their natural form, whether soluble or bound to 
receptors on other immune cells. Activation through the BCR occurs in response to 
thymus-independent antigens (TI) or thymus-dependent antigens (TD). B cell activation 
through TI antigens is mediated through BCR signaling and TLR-antigen recognition or 
extensive BCR cross-linking, whereas TD activation requires BCR signaling and T helper 
cell interactions that deliver a second requisite activation signal. There are three main 
classes of B cells: B1, marginal zone and follicular B cells. B1 and marginal zone B cells 
are primarily responsible for antibody production in response to TI antigens, while 
follicular B cells are primarily involved in TD antigen responses. Activated B cells in the 
spleen or lymph nodes clonally expand following BCR antigen recognition and cognate 
antigen T cell help. T cells move into primary B cell follicles and help form germinal 
centers where B cells go through a process of class-switching and affinity maturation, 
ultimately forming plasma cells or memory B cells. The majority of the plasma cells 
formed in the germinal center travel to the bone marrow where they produce and secrete 
high-affinity antigen-specific antibodies.  
Initial antibody responses are characterized by IgM production, which requires no 
class switching. However, IgG is the most abundant antibody found in the plasma, 
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secreted following B cell activation and subsequent class switching. IgA and IgE are also 
produced following class switching, in response to different antigens and specific signals 
from T cells. IgD is not secreted but rather a surface-bound antibody. Antibodies perform 
three main functions to help clear pathogens. First, they can bind and neutralize bacteria 
and toxins in the blood, effectively blocking their entry into cells. Second, antibodies can 
opsonize pathogens targeting and making them suitable for phagocytosis and destruction. 
Third, antibodies can activate the complement pathway. Overall, B cell antibody 
production is integral to adaptive humoral immune responses and often complements 
cell-mediated immune responses.  
CD8+ T cells are responsible for the majority of cell-mediated responses designed 
to detect and destroy host cells infected with an intracellular pathogen. Upon recognizing 
their cognate antigen, primarily viral and intracellular bacterial antigens, presented in the 
context of MHC class I, CD8+ T cells become activated and develop into CD8+ effector 
cells also known as cytotoxic T lymphocytes (CTLs). In turn, CTLs target infected cells 
expressing viral components on MHC class I and initiate cell death through the release of 
cytotoxic granules containing perforin and granzymes and through apoptotic signaling 
interactions between Fas ligand expressed on the CTL and Fas expressed on the target 
cell. While CD8+ effector cells are highly efficient and specific cytotoxic T cells, they 
often require help from CD4+ T cells to become fully activated or for the generation of 
CD8+ memory T cells.  
In contrast to CD8+ T cells, CD4+ T cells have the ability to differentiate into 
discrete CD4+ effector or T helper (Th) cells. The role of CD4+ T cells following 
activation is not to lyse infected cells, but rather to help other immune cells mount 
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specific immune responses. Naïve CD4+ T cells that recognize antigen presented via 
MHC class II can develop into either Th1, Th2, Th17 or regulatory T cells (Tregs) 
(Figure 1.3). In addition to these classical Th cells, in humans Th22 cells have recently 
been described that characteristically produce IL-22 (Wolk et al., 2010). In mice the 
current state of affairs is that a subset of Th17 cells produce IL-22, rather than a distinct 
Th22 cell (Wolk et al., 2010). CD4+ T cell polarization is dependent on the type of 
antigen and the prevailing cytokine environment (Figure 1.3). Once differentiated, Th1 
cells help alert and activate macrophages to the presence of intracellular bacteria, 
effectively enabling macrophages to destroy infected cells. In response to intracellular 
pathogens, Th1 cells secrete IFNγ and IL-2 to help stimulate macrophages and CD8+ 
effector cells. During Th1-mediated immune responses B cells following interactions 
with Th1 cells produce IgG1 and IgG3 antibodies in humans and IgG2a and IgG2b in 
mice to aid in the detection and clearance of infected cells. Th2 cells help elicit responses 
to extracellular parasites through the production of IL-4, IL-5, IL-10, IL-13 and IL-25, 
which recruit and activate mast cells, basophils and eosinophils. Th2 cells instruct B cells 
to produce IgE, which allows eosinophils to target and destroy extracellular parasites and 
activates mast cells and basiophils. Recently discovered and characterized, Th17 cells 
function in the defense against extracellular bacteria and fungi by producing the 
characteristic cytokine IL-17 as well as IL-21, IL-22 and IL-23. IL-17 helps recruit 
neutrophils to sites of inflammation and bacterial burden. Th1 and Th17 cells also 
contribute to the pathology of various autoimmune diseases, allergy and asthma. 
Regulatory T cells help coordinate appropriate responses and restrain adverse pathologic 
responses throughout the course of an immune response.  
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Figure 1.3 
 
 
 
 
 
Figure 1.3. CD4+ effector T cell polarization. 
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Regulatory T cells are separated into two categories, induced Tregs (iTregs) and 
natural Tregs (nTregs). The later are formed in the thymus during T cell development and 
play a key role in preventing autoimmune disease by maintaining peripheral T cell 
tolerance. CD4+ nTregs have a diverse T cell receptor (TCR) repertoire and are defined 
by the lineage specific transcription factor Forkhead box P3 (Foxp3) and various surface 
molecules, including CD25, cytotoxic T-lymphocyte antigen 4 (CTLA-4), Helios and 
glucocorticoid-induced tumor necrosis factor receptor (GITR). Induced Tregs, also 
known as adaptive Tregs, develop from naïve CD4+ T cells in the periphery following 
interactions with tolerogenic DCs. Classical iTregs, once formed, express Foxp3 and high 
levels of CD25, CTLA-4 and GITR. However, there are well-defined iTreg subsets that 
do not express Foxp3, such as regulatory type 1 (Tr1) and Th3 Tregs (Table 1.1) (Li and 
Boussiotis, 2011). Tr1 cells are characterized by their production of IL-10, while Th3 
Tregs produce significant amounts of TGFβ.  
Tregs help control ongoing immune responses and reactions to self-antigens 
through the production of inhibitory cytokines, metabolic disruption of effector 
responses, cytolysis and APC modulation (Vignali et al., 2008). IL-10, IL-35 and TGFβ 
produced by Tregs act as anti-inflammatory and inhibitory cytokines that dampen 
effector immune cell responses. TGFβ is also essential in instructing naïve T cells to 
become iTregs. High levels of CD25, the high-affinity IL-2 receptor (IL-2Rα), expressed 
on Tregs allows them to efficiently sequester IL-2, which is required by effector T cells 
for proper proliferation and expansion. In addition to sequestering IL-2, Tregs express the 
ectoenzymes CD39 and CD73 that generate extracellular adenosine. Adenosine binds 
A2AR receptors on effector T cells and inhibits effector T cell proliferation and induces 
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TGFβ expression (Ernst et al., 2010). Metabolic disruption also occurs through the 
transfer of cAMP from Tregs to effector cells, effectively inhibiting effector T cell 
cytokine response and proliferation (Bopp et al., 2007; Ernst et al., 2010). Furthermore, 
CTLA4 and LAG3 expressed on Tregs inhibit DC function through interactions with 
CD80/86 and MHC class II molecules expressed on DCs, respectively (Vignali et al., 
2008).  
Overall, the adaptive immune system with both cell-mediated and humoral 
immune responses offers protection against a wide variety of pathogens. With the rapid 
responses of the innate immune system and the specificity and memory of the adaptive 
immune system, mammals are well suited to fend off harmful microorganisms. Moreover 
these systems effectively control ongoing responses and provide tolerance to self-proteins 
and detect tumorogenic cells. All of this is accomplished through coordinated 
communication between the innate and adaptive arms of the immune system. Dendritic 
cells are the only leukocytes to play a fundamental role in both innate and adaptive 
immune responses and in doing so link the two systems together. 
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Table 1.1 
 
 
 
 
Table 1.1. Regulatory T cell classification and function. 
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Dendritic Cells 
Dendritic cells are integral in mounting proper immune responses and regulating 
autoimmune reactions to maintain self-tolerance. They are important cells in both innate 
and adaptive immune responses and provide distinct functions to each system.  
Dendritic Cell Lineage and Subsets 
Dendritic cells, referred to as DCs hereafter, are derived from both myeloid and 
lymphoid progenitor cells (Banchereau et al., 2000). The vast majority of DCs are of 
myeloid origin, while DCs derived from lymphoid precursors represent a small fraction 
of the total DC population (Yang et al., 2005; Shortman and Naik, 2007a; Naik, 2008a). 
DCs are highly specialized immune cells and are commonly classified into distinct 
subsets depending on their phenotype, function and location. While there is ongoing 
discussion and research regarding DC classification, DCs are commonly classified into 
three categories: plasmacytoid DCs, conventional or classical DCs and inflammatory 
DCs (Figure 1.4). There is an additional class of DCs that develop from pre-DCs and 
circulating monocytes, depending on the tissue and inflammatory milieu. Both pre-DCs 
and monocytes have a unique surface molecule phenotype before their recruitment to DC 
status. However, pre-DCs or monocytes upon maturation typically develop into 
inflammatory DCs. In mice, all DC classes express the DC lineage marker CD11c and 
MHC class II, to varying degrees (Table 1.2). Each DC class is further identified through 
the expression of specific surface molecules (Table 1.2). Each class of DCs also has a 
specialized function, providing unique support to both innate and adaptive immune 
responses. 
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Table 1.2 
 
 
 
 
Table 1.2. Dendritic cell subsets, phenotype, and basic function. 
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Plasmacytoid DCs (pDCs) characteristically produce type-I interferons in 
response to viral infections and are derived from both lymphoid and myeloid progenitor 
cells (Shortman and Naik, 2007a; Geissmann et al., 2010). Immature pDCs are found in 
the bone marrow, circulation and in peripheral organs. In the spleen and lymph nodes, 
pDCs reside in the marginal zone and T cell rich microenvironments, respectively. 
Compared to conventional or inflammatory DCs, pDCs are long-lived and constitutively 
express high levels of TLR7 to recognize viral RNA. Viral recognition causes pDC 
activation; in turn, activated pDCs produce copious amounts of IFNα/β and IL-10. While 
essential in viral detection, pDCs in the steady state are tolerogenic, presenting largely 
non-viral antigens to T cells in a fashion that induces regulatory T cells and/or dampens T 
cell activation (Yang et al., 2005; Shortman and Naik, 2007a). Their tolerogenic function 
is in part due to their inherent production of TGFβ and IL-10 and their constitutive 
expression of indoleamine 2,3 dioxygenase (IDO), a known immune regulatory enzyme 
(Mellor and Munn, 2004). The pDC lineage in mice is identified as 
CD11clow/CD11cintermdiate, MHC class IIlow, B220+, Ly6C/Gr1+, CD11b-  (Table 1.2) 
(Geissmann et al., 2010). In mice, pDCs are also identified by their surface expression of 
mouse pDC antigen 1 (mPDCA-1). Overall, pDCs offer innate protection against viral 
pathogens and provide tolerogenic signals to adaptive immune responses. However, 
pDCs are poor antigen presenting cell as compared to conventional DCs.  
Conventional or classical DCs (cDCs) are myeloid-derived DCs that upon further 
differentiation make up the majority of circulating/migratory and specialized tissue-
resident DCs. Conventional DCs are further separated into two categories, migratory DCs 
and interstitial DCs (Shortman and Naik, 2007a; Naik, 2008a; Geissmann et al., 2010). 
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Migratory DCs are the classical DC population, in that they survey peripheral tissues and 
upon recognition of foreign antigen, migrate to draining lymph nodes and present antigen 
to T cells, effectively eliciting an antigen-specific immune response. Examples of 
migratory cDCs include dermal DCs and Langerhans cells. Dermal DCs are present in the 
dermis of the skin and express CD11cHigh, CD11b and DEC205 on their surface (Table 
1.2). Langerhans cells are abundant in the skin and express CD11cHigh, DEC205 and 
langerin (Table 1.2). Dermal and Langerhans cells are often the first DCs to encounter 
antigens following a compromise in the skin’s barrier function. They provide 
inflammatory signals to help modulate innate immune responses as well as initiate 
adaptive immune responses by rapidly migrating to skin draining lymph nodes to present 
foreign antigens to both CD8+ and CD4+ T cells.   
In contrast to migratory DCs, interstitial DCs, also known as lymphoid-resident 
DCs, are abundant in all lymphoid tissues. As their name implies they rarely travel out of 
their resident lymphoid tissue. Interstitial DCs function by sampling antigens passing 
through the lymphatics and subsequently provide immunogenic and/or tolerogenic 
signals to T cells. Interstitial DCs are further classified into CD8+, CD8- and CD8- CD4- 
DCs (Figure 1.4). CD8+ cDCs are CD11cHigh, MHC class II+, DEC205+, 33D1-, CD11b- 
and CD4+ expressing, while CD8- express CD11cHigh, MHC class II+, DEC205-, 33D1+, 
CD11b+ and CD4+ (Table 1.2). Double negative CD8- CD4- DCs express CD11cHigh, 
MHC class II+, DEC205- and 33D1+ (Table 1.2) (Wu and Liu, 2007; Pulendran et al., 
2008). All three interstitial DC subsets, CD8+, CD8- and CD8- CD4- express the co-
stimulatory molecules CD40, OX40 ligand, CD80 and CD86 and the cell adhesion 
molecules CD54 and CD11a (Lipscomb and Masten, 2002; Geissmann et al., 2010). 
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CD8+ DCs are found predominately in T cell rich areas of the spleen, lymph nodes and 
Peyer’s patches of the small intestine. CD8- DCs reside in the marginal zones of the 
spleen and in subcapsular regions of lymph nodes. CD8- CD4- DCs are mostly 
concentrated in B cell follicles and T cell rich areas in the spleen and lymph nodes 
(Lipscomb and Masten, 2002).  
Similar to migratory DCs, interstitial DCs, upon antigen recognition and 
activation present antigens to CD4+ T cells, evoke antigen-specific immune responses. In 
the spleen, conventional CD8+ DCs are known to induce Th1 responses, while CD8- DCs 
generate Th2 effector cells following antigen-specific interactions with naïve Th cells 
(Pulendran et al., 2008; Yamazaki et al., 2008). CD8+ DCs also specialize in cross 
presentation, i.e. the internalization of extracellular antigens intended for presentation on 
MHC class II are instead process and presented on MHC class I to CD8+ T cells. In 
addition, CD8+ DCs expressing DEC205+ are known inducers of regulatory T cells in the 
spleen. In contrast, CD8- DCs expressing 33D1+ are ineffective at inducing regulatory T 
cells (Naik, 2008a; Yamazaki et al., 2008; Geissmann et al., 2010).   
Inflammatory DCs are a separate class of DCs that provide inflammatory signals 
in response to various bacteria, viruses and parasites. A key distinction between 
inflammatory DCs and conventional DCs is that inflammatory DCs are not present in the 
steady state. Inflammatory DCs arise and are present during periods of increased 
inflammation resulting from infection or autoimmune disease (Shortman and Naik, 
2007a; Naik, 2008a; Simones et al., 2010). Inflammatory DCs develop from myeloid pre-
DCs and monocytes in the blood during inflammation and are recruited to sites of 
inflammation via chemokine receptor CCR2 signaling (Jia et al., 2008; Bosschaerts et al., 
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2010). Once developed, inflammatory DCs are identified as CD11cIntermediate CD8- CD4- 
CD11b+ and DEC205+ (Table 1.2). During periods of increased inflammation they are 
found in the spleen, lymph nodes and at the site(s) of inflammation. Inflammatory DCs 
produce significant amounts of TNFα and nitric oxide (NO) generated by inducible nitric 
oxide synthase (iNOS) (Naik, 2008a; Simones et al., 2010). Consequently, inflammatory 
DCs are also known as TNFα/iNOS producing DCs (TIP-DCs) (Figure 1.4). In vivo, 
inflammatory DCs are weak antigen presenting cells as compared to cDCs and they are 
not required for the induction of T helper cells. Instead inflammatory DCs provide 
inflammatory signals such as TNFα, IL-6 and NO to help in the clearance of 
microorganisms through phagocytosis. Inflammatory DCs are generated in response to a 
variety of bacterial infections such as Listeria monocytogenes, Brucella menitensis and 
Salmonella typhimurium (Naik, 2008a; Simones et al., 2010). They are also present 
during response to parasitic Leishmania major, and lymphocytic choriomeningitis and 
influenza viruses (Naik, 2008a). Due to the inherent inflammatory nature of many 
autoimmune diseases, inflammatory DCs also often contribute to the increased 
inflammation and overall disease pathology of many autoimmune diseases including 
type-1 diabetes and psoriasis (Naik, 2008a).  
While DCs are commonly segregated into plasmacytoid, conventional and 
inflammatory DC classes, there are a number of specialized DCs present in different 
organs such as the lung, liver and intestinal tract. These specialized DCs are most likely 
conventional DCs. However, there is ongoing research to completely define the origin, 
phenotype and unique function of many of these organ-specific specialized DCs 
(Pulendran et al., 2008).  
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Figure 1.4 
 
 
 
 
Figure 1.4. Dendritic cell subsets. 
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In vitro DC Model Systems 
Due to the low frequency of DCs in humans and mice, in vitro model systems 
have been developed to greatly expand the number of DCs to utilize in scientific 
investigations. The most common method for deriving DCs from humans is to isolate 
CD14+ peripheral blood mononuclear cells (PBMCs) or CD34+ hematopoietic progenitor 
cells from the blood and drive them to become immature DCs ex vivo with granulocyte 
macrophage colony stimulating factor (GM-CSF) and IL-4 (Thomas et al., 1993). In 
mice, progenitor cells are typically isolated from the bone marrow and induced to become 
immature DCs using GM-CSF with or without IL-4 (Inaba et al., 1992). In vitro GM-
CSF-derived DCs are well characterized and most closely resemble inflammatory DCs 
found in vivo during periods of inflammation (Inaba et al., 1992; Naik et al., 2007; Xu et 
al., 2007). In contrast to the inflammatory DC model system, FMS-like tyrosine kinase 
receptor-3 ligand  (Flt3 ligand) is used to derive DCs from bone marrow progenitor cells 
that emulate in vivo steady state DCs (Brasel et al., 2000). The Flt3L model generates 
DCs similar to both plasmacytoid DCs and conventional DCs in mice (Xu et al., 2007). 
Both inflammatory and steady state model systems have been used extensively to study 
the various facets of DCs. 
Dendritic Cell Activation and Maturation 
Before encountering antigen or danger signals, DCs usually persist in an 
immature state of differentiation. Immature DCs are highly mobile and survey the 
periphery or local microenvironment for antigens and PAMPs. Immature DCs are 
efficient at internalizing and processing antigens, but are poor T cell stimulators. Upon 
antigen recognition and uptake and/or PAMP recognition, DCs migrate to draining lymph 
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nodes or sites of inflammation. DC migration is mediated by an increased expression of 
chemokine receptors, primarily CCR7 (Banchereau et al., 2000). Maturing DCs lose their 
ability to internalize and process antigens and in route to their final destination increase 
expression of MHC class I and MHC class II molecules, the co-stimulatory molecules 
CD80 and CD86, CD40 and OX40 ligand, and the adhesion proteins CD54 and CD11a as 
well as other surface molecules. During maturation, DCs increase gene expression and 
upregulate intracellular cytokines. Gene expression and cytokine profiles of maturing 
DCs are largely dependent on the type of DC and the maturation signal encounterd 
(Tureci et al., 2003; Zhong et al., 2009). Once mature, DCs are less mobile than their 
immature counterparts and are fully capable of activating T cells. 
DC-Mediated CD4 T Cell Activation and Polarization 
CD4+ T cell activation and polarization into effector cells is accomplished 
through a series of steps that requires specific instruction from antigen presenting cells, 
hereafter referred to as APCs. Complete CD4+ T cell activation is dependent on three 
signals (Figure 1.5).  
First, a naïve CD4+ T cell must recognize its cognate antigen via interactions 
between the T cell receptor (TCR) on the T cell surface and antigen properly presented 
on MHC class II by the APC. TCR engagement with cognate antigen presented on MHC 
class II and the cross-linking of CD4 induces a series of intracellular signaling events 
beginning with the phosphorylation of immunoreceptor tyrosine-based activation motifs 
(ITAMs) by the Src kinases Lck and Fyn. In turn, ITAM phosphorylation signals ZAP-70 
to bind phosphorylated ITAM tyrosine residues and become activated by Lck-mediated 
phoshorylation. ZAP-70 then phosporylates LAT and SLP-76, which binds and activates 
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phospholipase C-γ (PLC-γ) resulting in a host of downstream signaling events ultimately 
activating NF-κB, NFAT and AP-1 transcription factors and inducing gene expression 
(Janeway, 2008).  
Second, the CD4+ T cell must receive co-stimulation through interactions between 
CD28 on the T cell and CD80/CD86 on the APC. CD28:CD80/CD86 interactions induce 
a number of intracellular signaling pathways including the phosphatidyl inositol-3 kinase 
(PI3K)/AKT pathway to help increase TCR signaling. Alternatively, CD80/CD86 can 
interact with CTLA4 expressed on the T cell, which induces inhibitory pathways and 
dampens T cell activation. If a T cell receives only signal 1, TCR activation, without 
signal 2 it becomes anergic, i.e. unresponsive and will be unable to fully activate and 
differentiate. If a T cell receives signal 1 and signal 2, TCR activation and co-stimulation, 
it will properly activate and begin the process of differentiation and clonal expansion. 
However, for full differentiation into effector status a third signal is required. 
The third signal required for full differentiation comes from both the activating T 
cell and the APC. For example, IL-2 is required for proper clonal expansion and T cell 
activation. Primarily T cells produce IL-2 and depending on the type of CD4+ effector 
response IL-2 is used in an autocrine fashion. The APC provides polarizing cytokines 
such as IL-1β, IL-2, IL-6, IL-10, IL-12, IL-23 and TGFβ, all of which affect T cell 
polarization in a specific manner (Figure 1.3). Following polarization, CD4+ effector T 
cells secrete cytokines such as IFNγ, IL-4, IL-17 and IL-23 and TGFβ to maintain their 
Th1, Th2, Th17 or Treg status, respectively (Figure 1.3). DCs are the primary APCs 
responsible for inducing the majority of T cell-mediated immune responses. DCs also 
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play an important role in T cell tolerance and immune regulation through the induction 
and expansion of regulatory T cells. 
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Figure 1.5 
 
 
 
 
 
Figure 1.5.  Signals required for proper T cell activation and polarization. 
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Immune Tolerance 
Tolerance is the ability of the immune system to distinguish between self and 
non-self antigens, such that an immune response against self-proteins and tissues should 
not occur. Complete tolerance is established by both central tolerance and peripheral 
tolerance. Central tolerance is strictly maintained during lymphocyte development and is 
designed to remove T cells and B cells that react to self-antigens during their 
development in the thymus and bone marrow, respectively. Peripheral tolerance is 
maintained following lymphocyte development and migration into the periphery, where a 
handful of T cells that recognize self-antigens may have escaped deletion during central 
tolerance. Moreover, regulating and ending effective immune responses are key 
components of peripheral tolerance. Peripheral tolerance mechanisms include T cell 
apoptosis, T cell anergy and the induction of regulatory T cells.  
T cell apoptosis and T cell anergy are commonly induced when CD4+ T cells 
interact with immature DCs or via transient or unsuccessful DC:T cell interactions. 
Immature DCs lack the ability to fully stimulate a T cell through co-stimulation, the 
second signal required for full T cell activation. The deficiency in co-stimulatory signals 
coupled with TCR signaling causes T cells to become apoptotic or anergic (Shortman and 
Naik, 2007a). Mature DCs can also induce T cell apoptosis or anergy through specific 
interactions and signaling through CD80/CD86 and programmed cell death 1 (PD-1) 
expressed on the DC and CTLA-4 and PD-Ligand 1 or PD-Ligand 2 (PD-L1, PD-L2) 
expressed on T cells (Carter and Carreno, 2003; Fife and Bluestone, 2008). These same 
signals can also lead to the generation of active tolerance through the induction of 
regulatory T cells (Fife and Bluestone, 2008; Maldonado and von Andrian, 2010).  
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Tolerogenic DCs 
The generation of regulatory T cells, whether classical iTregs, Tr1 and Th3 Tregs 
or the expansion of nTregs is largely dependent on interactions with tolerogenic DCs. 
Tolerogenic DCs inhibit the generation of CD4+ effector responses and can directly 
induce regulatory T cells. Due to the heterogeneity of DC populations, tolerogenic DCs 
are present in all DC subpopulations, with varying degrees of tolerogenic capacity. For 
example, plasmacytoid DCs, CD103+ DCs in the gut and CD8+ DEC205+ DCs in the 
spleen are highly tolerogenic (Pulendran et al., 2008; Yamazaki et al., 2008; Maldonado 
and von Andrian, 2010). CD8- 33D1+ DCs in the spleen, CD103+ DCs in the skin and 
CD11b+ dermal DCs and Langerhans cells are relatively non-tolerogenic, but rather 
highly stimulatory (Pulendran et al., 2008; Maldonado and von Andrian, 2010). 
Regardless of the DC subtype, the tolerogenic or regulatory capacity of a DC is defined 
by the expression of specific inhibitory cytokines, enzymes and surface molecules. 
The most common molecules produced by tolerogenic DCs are IL-10, TGFβ, 
retinoic acid, and IDO1/IDO2. IL-10 is an anti-inflammatory cytokine that dampens 
ongoing T cell responses and helps polarize iTregs. TGFβ is essential to both nTreg and 
iTreg development and survival in the periphery. TGFβ modulates T cell differentiation, 
inhibits T cell proliferation, induces Treg generation and dampens the stimulatory 
capacity of APCs (Li et al., 2006; Yoshimura et al., 2010). Moreover, mice that lack 
TGFβ1 suffer from serve multiorgan autoimmune disease and die shortly after birth, 
highlighting the importance of TGFβ in immune tolerance (Kulkarni et al., 1993). 
Retinoic acid in the presence of TGFβ contributes towards the generation of regulatory T 
cells rather than Th17 cells, cells that also require TGFβ for their differentiation (Weiner 
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et al., 2011). IDO1 and IDO2 are involved in tryptophan catabolism, which has a two-
fold effect on effector T cells. First, tryptophan is required for proper effector T cell 
proliferation. Thus, decreasing levels of tryptophan help limit effector T cell expansion 
and activation. Second IDO-mediated tryptophan catabolism generates kynurenine. 
Kynurenine can instruct naïve T cells to become regulatory T cells (Mezrich et al., 2010). 
DCs express and utilize these tolerogenic mediators in various fashions. For instance, 
CD103+ DCs in the gut constitutively express aldehyde dehydroxygenase (Aldh1a1 and 
Aldh1a2), which converts vitamin A present at high levels in the gut to retinoic acid 
(Coombes et al., 2007; Del Rio et al., 2010). Plasmacytoid DCs express higher levels of 
IDO1 and IDO2 than do conventional DCs, contributing to their enhanced capacity to 
induce Tregs in the periphery (Mellor and Munn, 2004; Yang et al., 2005). Plasmacytoid 
DCs also produce TGFβ to aid in their tolerogenic responses. CD8+ DEC205+ DCs in the 
spleen produce copious amounts of TGFβ, effectively inducing iTregs, while maintaining 
nTreg populations (Naik, 2008a; Yamazaki et al., 2008; Shortman and Heath, 2010). 
Although they have different phenotypes and tolerogenic capacities, tolerogenic DCs can 
be found in almost all tissues and organs and are present in the steady state and 
throughout the course of various immune responses and disease states. Over the past 
twenty years, there has been a concerted effort to identify or generate compounds that 
induce tolerogenic DCs in order to intentionally regulate immune responses and treat 
autoimmune diseases. 
Various biological and pharmacological agents, natural compounds and 
environmental pollutants are capable of generating tolerogenic DCs that can subsequently 
induce regulatory T cells. The two most common biological agents used to generate 
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tolerogenic DCs are TGFβ and IL-10. In general, both TGFβ and IL-10 are anti-
inflammatory cytokines. In DCs, active TGFβ induces both SMAD-dependent and 
SMAD-independent pathways, which control the expression of regulatory genes 
including IL-10, IDO and TGFβ (Fainaru et al., 2007). TGFβ can also inhibit NF-κB 
signaling, causing DCs to remain in an immature state and function as tolerogenic DCs 
(Fainaru et al., 2007). Similar to TGFβ, IL-10 signaling via the IL-10 receptor and 
JAK/Stat3 helps maintain an immature DC phenotype (Murray, 2006). Furthermore, IL-
10 signaling induces suppressor of cytokine signaling 3 (SOCS3), which negatively 
regulates the production of inflammatory IL-6 in DCs (Murray, 2006). In addition to 
TGFβ and IL-10, anti-inflammatory glucocorticoids such as dexamethasone are used to 
generate tolerogenic DCs. As a pharmacological agent, dexamethasone binds the 
glucocorticoid receptor (GCR). In DCs, GCR activation upregulates the expression of 
genes that dampen inflammatory signals by inhibiting canonical NF-κB signaling and 
inducing the expression of anti-inflammatory mediators including IL-10, TGFβ, IDO and 
GITR ligand (Leung and Bloom, 2003; Iruretagoyena et al., 2006). Collectively, 
dexamethasone and other glucocorticoids inhibit DC maturation and increase levels of 
anti-inflammatory molecules, effectively generating tolerogenic DCs capable of inducing 
regulatory T cells and dampening autoimmune diseases. In addition to glucocorticorids, 
other pharmacological and natural compounds such as aspirin, 1,25-dihydroxyvitamin D3 
(the reactive metabolite of vitamin D3), resveratrol and curcumin can also induce 
toloerogenic DCs (Maldonado and von Andrian, 2010). Moreover, antibodies against 
CD200R on DCs can generate tolerogenic DCs, which are capable of inducing regulatory 
T cells (Maldonado and von Andrian, 2010). Many of these compounds work to increase 
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the expression of anti-inflammatory/regulatory mediators in DCs and inhibit DC 
maturation. More recently, chemicals known to activate the aryl hydrocarbon receptor 
have been reported to induce regulatory T cells and tolerogenic DCs.  
 
Aryl Hydrocarbon Receptor Biology, Toxicity and Immune Modulation 
The aryl hydrocarbon receptor (AhR) is an evolutionarily conserved, steroid-like 
orphan receptor. Depending on the species, the AhR gene encodes a 95-110kDa protein. 
The AhR is part of the basic helix-loop-helix-Per-ARNT-Sim (PAS)-containing 
transcription factor family and plays a role in many physiological functions including 
circadian rhythm, cell cycle, fetal development, tumorogenesis, lipid metabolism, 
cardiovascular function and immune responses (Nguyen and Bradfield, 2008; Denison et 
al., 2011; Stejskalova et al., 2011; Zhang, 2011).   
AhR Signaling  
AhR signaling is ligand-activated and includes both canonical and non-canonical 
pathways. The canonical AhR signaling pathway is well defined (Figure 1.6). The AhR is 
held quiescent in the cytoplasm by heat shock protein 90 (HSP90), HBV X-associated 
protein 2 (XAP2) and p23 chaperone proteins. Upon ligand binding, the AhR sheds its 
chaperone proteins exposing an N-terminal nuclear localization sequence (NLS). The 
NLS facilitates nuclear entry and the ligand:AhR complex moves into the nucleus bound 
to  importin-β. Inside the nucleus, the ligand:AhR complex heterodimerizes with AhR 
nuclear translocator (ARNT). The ligand:AhR:ARNT complex then binds dioxin 
response elements (DREs) consisting of a core GCGTG sequence in the DNA. Upon 
DRE binding the AhR:ARNT complex recruits transcriptional co-activators and/or co-
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repressors and modulates target gene expression. Prototypical AhR target genes include 
the phase I drug-metabolizing enzymes cytochrome P450 CYP1A1, CYP1A2 and 
CYP1B1 and phase II enzymes NQO1, GSTA2, UGT1A1 and UGT1A6 all of which 
contain multiple DREs in their promotor/enhacer regions (Denison et al., 2002; Kohle 
and Bock, 2007). AhR signaling is controlled through a self-initiating feedback loop, 
where ligand:AhR:ARNT complexes induce AhR repressor (AhRR) expression. AhRR 
negatively controls AhR signal transduction by competing for ARNT and AhRR:ARNT 
in turn bind DREs, effectively blocking AhR 
ARNT binding and gene transcription (Nguyen and Bradfield, 2008). Following 
gene transcription, the ligand:AhR:ARNT complex is exported into the cytosol, mediated 
by the AhR nuclear export signal (NES) and CRM1 export protein, and ubiquitin-tagged 
for proteosomal degradation (Nguyen and Bradfield, 2008).  
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Figure 1.6 
 
 
 
 
 
 
Figure 1.6. Canonical AhR signaling pathway. 
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Non-canonical AhR pathways are less well understood and involve interactions 
with multiple intracellular signaling pathways that control cell cycle, inflammation and 
hormone signaling (Vogel and Matsumura, 2009; Swedenborg and Pongratz, 2010; 
Denison et al., 2011). Canonical DRE-depdendent AhR signaling can drive the 
expression of p27kip1, an inhibitory cell cycle-dependent kinase (CDK) that contributes to 
retinoblastoma protein (Rb) inactivation and cell cycle arrest (Pang et al., 2008). In a 
non-canonical fashion, ligand-activated AhR can directly bind Rb and disrupt Rb 
phosphorylation and subsequent activation required for cell cycle progression (Ma et al., 
2009).  
Ligand-activated AhR can also physically interact with NF-κB family members 
and Signal Transducer and Activator of Transcription (STAT) proteins to control immune 
and inflammatory gene expression. Early work done by Ruby and co-workers 
demonstrated that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure decreases NF-
κB/RelA binding and NF-κB/RelA entry into the nucleus in DC2.4 cells following TNFα 
or anti-CD40 activation (Ruby et al., 2002). These studies also demonstrated that 
transfected AhR physically associated with RelA in DC2.4 cells in response to TNFα 
stimulation (Ruby et al., 2002). Recently, Vogel and colleagues using the human 
macrophage cell line U937 were able to demonstrate that TCDD induces IL-8 through an 
AhR-dependent mechanism that involved direct interactions between AhR and RelB 
(Vogel et al., 2007a). In these studies ligand activated-AhR was shown to physically 
interact with RelB, forming AhR/RelB complexes that bound DRE/NF-κB like response 
elements in the promoter region of the IL-8 gene (Vogel et al., 2007a). In addition to 
AhR/NF-κB crosstalk, the AhR has been shown to interact with various STAT proteins. 
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In peritoneal macrophages the AhR was shown to interact with STAT1 and p50 
following LPS stimulation (Kimura et al., 2009). The AhR/STAT1/p50 complexes were 
shown to reduce LPS-induced IL-6 production by binding specific sites upstream of the 
IL-6 transcriptional start site and inhibiting promoter activity (Kimura et al., 2009). 
Furthermore, under Th17 polarizing conditions Kimura and colleagues demonstrated that 
the AhR contributed to the induction of Th17 cells through direct physical interactions 
with STAT1 and STAT5 (Kimura et al., 2008). AhR:STAT4 interactions have also been 
observed during acute graft vs. host responses in CD4+ T cells following TCDD exposure 
(Marshall et al., 2008). 
Non-canonical AhR/estrogen receptor (ER) interactions and signaling have also 
been described. The majority of AhR:ER interactions are anti-estrogenic (Ohtake et al., 
2007; Swedenborg and Pongratz, 2010; Denison et al., 2011) Since the AhR is a steroid-
like receptor, it competes for transcriptional co-activators used by ERα and ERβ and can 
dampen ER-mediated gene transcription (Denison et al., 2011). In a similar fashion, AhR 
competes for ARNT, which is also used by ERα and ERβ to enhance ER target gene 
transcription (Ruegg et al., 2008). Ohtake and colleagues also demonstrated that ligand-
activated AhR can directly interact with ERα/ERα subunits, which causes ER 
polyubiquitination and subsequent proteosomal degradation (Ohtake et al., 2003). The 
ubiquitination and proteosomal degradation is due to the ability of ligand-activated AhR 
to recruit E3 ubiquitin ligase complexes (Ohtake et al., 2003; Ohtake et al., 2007). In 
turn, the E3 ligase complex recruits E2 which ubiquitinates ERα, effectively inducing 
ERα degradation through the 26S proteosomal pathway. ER degradation is not observed 
in AhR null mice, suggesting that the AhR is required for ER degradation following 
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exposure to AhR ligands (Mimura and Fujii-Kuriyama, 2003; Ohtake et al., 2009). In 
contrast to the anti-estrogenic effects of ligand-activated AhR, AhR:ER interactions have 
also been shown to increase ER target gene transcription (Denison et al., 2011). It is 
thought that ligand-activated AhR:ARNT complexes bind ERα/ERα bound to estrogen 
response elements (EREs), which then  recruits transcriptional co-activators to enhance 
ER target gene expression (Ohtake et al., 2009; Swedenborg and Pongratz, 2010). In a 
similar but reverse fashion, ERα/ERα can bind ligand:AhR:ARNT complexes bound to 
DREs and help recruit transcriptional regulators to control DRE-mediated gene 
transcription (Ohtake et al., 2009; Denison et al., 2011).  
In addition to the above-mentioned non-canonical signaling pathways, the AhR 
has been described to interact with mitogen-activated and calcium/calmodulin-dependent 
protein kinases and Nrf2 and TGFβ signaling proteins (Gomez-Duran et al., 2009; 
Denison et al., 2011). However, AhR crosstalk with various intracellular signaling 
pathways tends to be cell-type and tissue-dependent. Moreover, there are AhR ligand-
specific effects associated with both canonical and non-canonical AhR signaling.    
AhR Ligands 
Halogenated aromatic hydrocarbons (HAHs) were the first chemicals shown to 
bind and activate the AhR (Harris et al., 1973). Within the family of HAHs, TCDD binds 
the AhR with the highest affinity. TCDD remains in the environment for extended 
periods of time and is broken down slowly through UV degradation. Moreover, TCDD is 
is poorly metabolized and can bioaccumulate in humans and animals, with a half-life in 
of approximately 7-10 years in humans and 7-10 days in mice. For these reasons, TCDD 
is considered the prototypical AhR ligand. Many TCDD-congeners, such as 2,3,7,8-
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tetrachlorodibenozofuran and 2,3,6,7-tetrachloronapthalene are capable of binding and 
activating the AhR, albeit with lower affinity than TCDD (Figure 1.7). Various 
polycyclic aromatic hydrocarbons (PAHs) can also bind and activate the AhR. 3-
methylcholanthrene, benzo[a]pyrene (BaP) and 7,12-dimethylbenzanthracene (DMBA) 
are common PAH AhR ligands. BaP and DMBA are unique PAHs in that their metabolic 
activation into carcinogenic compounds is mediated by AhR-activated CYP1A1 
expression. Furthermore, various polychlorinated biphenyls (PCBs) such as 3,3’,4,4’,5-
pentachlorobiphenyl (PCB 126) can bind and activate the AhR. In comparison to TCDD, 
the PAHs and PCBs listed above are approximately 10-1000 times less potent that TCDD 
at inducing AhR activation (Nguyen and Bradfield, 2008). These anthropogenic 
compounds are considered exogenous AhR ligands.  
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Figure 1.7 
 
 
 
 
 
Figure 1.7. Environmental pollutants and AhR ligands. 
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Recently, many endogenous and natural AhR ligands have also been described. 
Some of the more common endogenous ligands include indirubin, bilirubin, and the 
arachidonic acid metabolites lipoxin A4 and prostaglandin G2 (Nguyen and Bradfield, 
2008; Stejskalova et al., 2011). The catabolism of tryptophan by IDO produces 
kynurenine that is capable of activating the AhR (Nguyen and Bradfield, 2008; Mezrich 
et al., 2010). In addition, the tryptophan UV- and visible light-catabolite, 6-
formylindolo[3,2-b]carbazole (FICZ), has an affinity for the AhR close to that of TCDD 
(Oberg et al., 2005; Wincent et al., 2009). 2-(1’H-Indole-3’-carbonyl)-thiazole-4-
carboxylic acid methyl ester (ITE) also has a high AhR affinity, but it is not clear whether 
ITE is an endogenous AhR ligand or an artifact produced during isolation from biological 
tissues (Henry et al., 2006; Nguyen and Bradfield, 2008). AhR ligands are also found in 
natural dietary sources. Known natural AhR ligands include compounds found in 
cruciferous vegetables such as indole-3-carbinol (I3C) and 3,3’-diindolymethane (DIM) 
and various flavones such as quercetin and genistein that are found in a variety of fruits 
and vegetables (Nguyen and Bradfield, 2008; Kerkvliet, 2009). Furthermore, various 
pharmacological compounds including: leflunomide, omeprazole, lansoprazole, 
primaquine and VAF347 have been shown to bind and activate the AhR (Hauben et al., 
2008; Kerkvliet, 2009; Stejskalova et al., 2011).  
A number of AhR antagonists have also been described. Within the flavone 
compound group, α-naphthoflavone is a known AhR antagonist, while β-naphthoflavone 
is an AhR agonist (Stejskalova et al., 2011). Resveratrol, a polyphenolic antioxidant 
compound found primarily in grapes, is a well known AhR antagonist (Stejskalova et al., 
2011). New synthetic AhR antagonists have also been developed such as CH223191, 
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GNF351 and SR1 (Denison et al., 2011). Many of the well-known and newly synthesized 
AhR antagonists work as ligand-dependent antagonists. Ligand-dependent antagonists 
block specific classes of AhR ligands while permitting other classes to freely bind and 
activate the AhR. For example, α-naphthoflavone and CH223191 effectively inhibit 
TCDD and other HAHs from binding and activating the AhR, while allowing different 
flavonoids, indirubin and various PAHs to bind and activate the AhR (Zhao et al., 2010; 
Smith et al., 2011). In contrast, GNF351 is a complete AhR antagonist, in that it 
effectively inhibits all AhR binding and activation no matter the class of AhR ligand 
(Smith et al., 2011). StemRegenin 1, known as SR1, was shown to greatly enhance the 
proliferation and engraftment of human CD34+ hematopoietic stem cells by antagonizing 
the AhR (Boitano et al., 2010). SR1 effectively inhibited TCDD-mediated CYP1B1 gene 
expression and was shown to directly interact with the AhR in competitive binding assays 
with indirubin, suggesting that SR1 may be a complete AhR antagonist (Boitano et al., 
2010).  
Another class of AhR ligands has been recently described as selective AhR 
modulators (SAhRMs). SAhRMs bind and activate the AhR in a pathway specific 
fashion. For example, the known AhR agonists DIM and 6-methyl-1,3,8-
trichlorordibenzofuran (MCDF) were shown to work as SAhRMs by activating the AhR 
and exclusively inducing anti-estrogenic effects without inducing canonical AhR 
signaling and CYP1A1 expression (Denison et al., 2011). Moreover, binding and 
activation of the AhR with the SAhRMs 3’,4’-dimethoxy-α-naphthoflavone (DMF), 
SGA360 or WAY-169916 causes suppression of acute phase proteins in an AhR-
dependent, but AhR:ARNT:DRE-independent fashion (Murray et al., 2010). The exact 
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mechanisms of action of SAhRMs are currently unknown. Moreover, there exist 
interspecies differences in the binding affinity and relative involvement of non-canonical 
and canonical AhR pathways with various AhR agonist, antagonists and SAhRMs.  
AhR polymorphisms and AhR-/- and Mutant Mice 
In mice there exists a ~10-fold difference in TCDD sensitivity between different 
strains (Ema et al., 1994; Okey et al., 2005). This difference occurs between mouse 
strains on a low affinity background such as DBA2 mice and high affinity backgrounds 
such as C57BL/6 mice (Ema et al., 1994). DBA2 mice express an allelic variation termed 
AhRd. The AhRd low affinity receptor has two single nucleotide polymorphisms (SNPs), 
one at codon 375, which causes a valine to alanine variant and a second in the stop 
codon, which lengthens the C-terminal end of the AhR protein as compared to the 
C57BL/6 AhRb encoded protein (Ema et al., 1994). The high affinity background in 
CD57B/6 (AhRb-1) and Balb/c (AhRb-2) mice is the dominant responsive allele. 
Interestingly, sequencing studies have shown that most humans carry an equivalent low 
affinity AhRd with an equivalent valine to alanine  SNP in codon 381 (Okey et al., 2005). 
The AhR is highly conserved evolutionarily and mammalian species as diverse as rats, 
guinea pigs, hamsters and humans all harbor AhR polymorphisms similar to DBA2 mice 
(Garte and Sogawa, 1999; Harper et al., 2002; Okey et al., 2005).  
AhR knockout mice (AhR-/-) have been integral in defining the AhR signaling 
pathways and the toxicity of various AhR ligands. AhR-/- mice were developed in 1996 in 
two separate laboratories (Fernandez-Salguero et al., 1996; Schmidt et al., 1996). Since 
the development of AhR-/-, additional AhR mutant mice including AhRdbd/dbd and 
AhRnls/nls mice have been generated to gain a better understanding of AhR signaling and 
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ligand-specific affects (Bunger et al., 2003; Bunger et al., 2008). AhRdbd/dbd mice have a 
mutation in the DNA binding domain (DBD) sequence of the AhR, disrupting AhR 
binding to DREs within target genes (Bunger et al., 2008). These mice have been 
essential in describing DRE-independent signaling events. AhRnls/nls mice carry a 
mutation in the nuclear localization sequence (NLS) of the AhR; hence the AhR doesn’t 
traffic into the nucleus (Bunger et al., 2003). AhRnls/nls mice have been used to define 
non-canonical signaling events that occur in the cytoplasm, such as the increase in Ca 
flux following TCDD exposure, and to better understand the requirement for 
AhR/nuclear protein interactions. Recently, conditional AhR-/- mice have been 
developed, in which the the AhR allele is floxed by loxP sites and upon crossing with Cre 
expressing mice the AhR can be eliminated in specific tissues or cell types (Walisser et 
al., 2005). 
AhR Associated Toxicity in Humans 
TCDD is the most widely studied AhR ligand and over the last half century a 
large amount of data has been collected regarding its toxicity in humans. Humans are 
usually exposed to low levels of TCDD and other AhR ligands mainly through the food 
chain, especially from through foods rich in fats (Sweeney and Mocarelli, 2000; 
Baccarelli et al., 2002; White and Birnbaum, 2009). It is important to note that TCDD 
has a long half-life in humans (~7-10 years) and can accumulate in adipose tissue. Thus, 
daily exposures can cause chronic long-term health affects. However, the majority of 
human data regarding TCDD exposure comes from retrospective studies following acute 
industrial accidental exposures. The first recorded exposure to TCDD was in 1949 
following a trichlorophenol reactor explosion in Nitro, West Virginia. Between 1962 and 
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1970 the American military used a TCDD-contaminated herbicide known as Agent 
Orange. Consequently, service men were exposed to high levels of TCDD throughout the 
course of the Vietnam War. In 1971 to keep dust levels in check, roads in Times Beach, 
Missouri were sprayed with TCDD-contaminated oil and people and animals within the 
surrounding area came into direct contact with TCDD. Workers as well as townspeople 
were exposed to high levels of TCDD following an explosion at a chemical plant in 
Seveso, Italy in 1976. More recently in 2008, pork products from Ireland were recalled 
worldwide due to a TCDD contamination from the animal feed. In addition, levels of 
TCDD can be higher in farmed raised fish, particularly salmon, when compared to wild 
caught fish (Bethune et al., 2006). Assessing populations from these exposures as well as 
many others, TCDD exposure has been shown to cause chloracne, a skin condition 
characterized by excessive blackheads and fluid filled cysts, cardiovascular disease, 
cancer, diabetes and reproductive and immune system aberrations (Sweeney and 
Mocarelli, 2000; White and Birnbaum, 2009). The best-documented and studied endpoint 
in humans exposed to TCDD is cancer. Retrospective cancer studies have been conducted 
in nearly all TCDD exposed cohorts and collectively the data shows a significant increase 
in all-cancer risk following TCDD exposure (White and Birnbaum, 2009; Boffetta et al., 
2011). Subsequently, the International Agency for Research (IARC) has classified TCDD 
as a known human carcinogen (NTP, 2006).  
AhR Activation and Immune Modulation 
Similar to the effects seen in humans, TCDD-induced AhR activation in animals 
has been shown to cause various cancers, liver injury, cardiovascular inflammation and 
damage, adverse developmental and reproductive effects, skin abnormalities and immune 
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alterations. With the use of various animal models, many of the mechanisms underlying 
the toxic effects of TCDD-induced AhR activation have been firmly established. While 
there is a considerable amount of research, both past and present, regarding TCDD-
induced immune alterations, it is still not fully understood how AhR activation alters 
immune responses. Perhaps more importantly, the doses of TCDD and TCDD-congeners 
required to initiate cancer and organ-specific toxicities are well above day-to-day, 
physiological relevant, exposure levels. In contrast, the immune system has been shown 
to be highly sensitive to low dose TCDD exposures as well as other AhR ligands 
(Kerkvliet, 2002; Kerkvliet, 2012).  
Over the last 35 years, TCDD and TCDD-congeners as well as prominent PAHs, 
such as BaP, have been shown to disrupt both innate and adaptive immune responses in 
various animal models. Early work done by Vos and Thigpen demonstrated that mice 
exposed to TCDD had an increased susceptibility to bacterial and viral infections (Harris 
et al., 1973; Thigpen et al., 1975). For example, influenza infections are exacerbated in 
mice exposed to TCDD, leading to an increased rate of mortality in mice exposed to 
TCDD (Burleson et al., 1996; Vorderstrasse et al., 2003). In fact, influenza host 
resistance is one of the most sensitive readouts of TCDD-induced immune suppression, 
with effects seen with doses as low as 10ng/kg TCDD (House et al., 1990; Burleson et 
al., 1996; Warren et al., 2000). In response to influenza A, TCDD-exposed mice display 
lower IgM, IgG1, IgG2a and IgG2b levels in the plasma, decreased percent and number 
of CD4+ and CD8+ viral-specific lymphocytes in lung draining lymph nodes and 
dampened lung DC function (House et al., 1990; Burleson et al., 1996; Warren et al., 
2000; Jin et al., 2010). Similar to decreased immune responses to influenza, TCDD has 
 47 
been shown to quell immune responses in a P815 tumor graft vs. host model (Kerkvliet et 
al., 1996). Following transfer of allogeneic P815 mastocytoma cells into C57BL/6 mice, 
TCDD-exposed mice displayed decreased IgM and IgG2a P815-specifc antibody levels 
and dampened CD4+ Th1-mediated and CD8+ CTL-mediated responses (Kerkvliet et al., 
1996). Furthermore, ex vivo spleoncytes from P815-injected mice produced significantly 
less IL-2 and IFNγ in response to P815 cells (Kerkvliet et al., 1996). Interestingly, the IL-
2 gene in mice contains functional DREs in its promoter region and increased IL-2 levels 
in response to TCDD exposure have been observed in different experimental systems 
(Kerkvliet, 2002; Kerkvliet, 2009). Taken together, data from host resistance and graft vs. 
host models as well as other models have shown that TCDD exposure significantly 
suppresses adaptive immune responses through direct effects on T cell, B cells and DCs. 
More recently, exposure to low doses of TCDD as well as other AhR ligands has been 
shown to induce the generation of functional regulatory T cells that are capable of 
suppressing ongoing immune responses (Funatake et al., 2005b; Marshall et al., 2008; 
Quintana et al., 2008b; Quintana et al., 2010).  
Investigating the P815 graft vs. host further, Kerkvliet and colleagues 
demonstrated that TCDD exposure induced CD4+ CD25+ CD62Llow T cells that 
suppressed the proliferation of naïve CD4+ CD25- T cells in vitro, indicating that these 
TCDD-induced CD4+ CD25+ CD62Llow T cells were regulatory in function (Funatake et 
al., 2005b; Marshall et al., 2008). This was a novel finding, in that AhR activation 
following TCDD exposure leads to the generation of Tregs, which may be responsible for 
dampening the acute graft vs. host inflammatory response. Seminal studies by Weiner 
and co-workers showed that TCDD exposure generated Foxp3+ Tregs in an autoimmune 
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mouse model of multiple sclerosis (Quintana et al., 2008b). Mice treated with TCDD and 
immunized with myelin oligodendrocyte glycoprotein (MOG) with complete Freund’s 
adjuvant (CFA) to induce experimental autoimmune encephalomyelitis (EAE) displayed 
significant increases in CD4+ Foxp3+ Tregs when compared to vehicle-treated mice 
(Quintana et al., 2008b). Using Foxp3GFP reporter mice it was demonstrated that a portion 
of naïve CD4+ T cells converted to CD4+ Foxp3+ Tregs following TCDD exposure 
(Quintana et al., 2008b). However, FICZ, the UV tryptophan catabolite shown to bind the 
AhR with similar affinity as TCDD, promoted the generation of Th17 cells in vitro 
instead of Foxp3+ Tregs (Quintana et al., 2008b). These studies demonstrated that 
TCDD-induced AhR activation leads to the generation of suppressive CD4+ Foxp3+ 
Tregs. In contrast, FICZ-induced AhR activation may promote the generation of 
inflammatory Th17 cells (Quintana et al., 2008b). In addition to T cells, the effects of 
AhR activation in DCs and the subsequent generation of tolerogenic DCs are currently 
under intense investigation.  
AhR Activation in DCs 
AhR is constitutively expressed in DCs, while it is only expressed in lymphocytes 
following activation. It is likely that following exposure to an AhR ligand such as TCDD 
that DCs will be amongst the first cells in the immune system to respond and display 
AhR-activated alterations. Studies using murine DCs have shown that AhR activation in 
DCs causes both phenotypic and functional alterations (Hwang et al., 2007; Vogel et al., 
2008; Bankoti et al., 2010b; Simones and Shepherd, 2011). In U937 monocyte-derived 
DCs, TCDD and FICZ augmented MHC class II and CD86 expression and upregulated 
the expression of the immunoregulatory enzymes IDO1 and IDO2 (Vogel et al., 2008). 
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Bankoti and colleagues demonstrated that TCDD exposure in murine inflammatory DCs 
generated with GM-CSF TCDD exposure altered DC differentiation and increased IDO 
and TGFβ gene expression, while altering NF-κB signaling in an AhR dependent fashion 
(Bankoti et al., 2010b). Similar to TCDD, FICZ, BaP, ITE and VAF347 exposure has 
been shown to disrupt murine DC surface molecule expression and gene expression, 
inducing a potential tolerogenic DC phenotype (Hwang et al., 2007; Bankoti et al., 
2010b; Quintana et al., 2010; Simones and Shepherd, 2011). While a number of studies 
have demonstrated that AhR activation can modulate DC phenotype and alter 
intracellular signaling, to date only two studies have shown that AhR activation in DCs 
leads to the induction of regulatory DCs capable of inducing regulatory T cells and/or 
dampening autoimmune disease responses. 
Studies using VAF347, a high-affinity pharmaceutical ligand for the AhR, have 
shown that VAF347-treated bone marrow-derived DCs (BMDCs) when injected into 
mice suppress the rejection of grafted pancreatic islet cells and increases graft survival 
rates (Hauben et al., 2008). Furthermore, when VAF347-treated BMDCs were injected 
into mice immunized with ovalbumin (Ova) in CFA they generated anergic T cells that 
remained refractory to restimulation with Ova (Hauben et al., 2008). These data suggest 
that AhR activation in DCs alone can suppress T cell mediated immune responses. 
Corroborating this idea, Quintana and colleagues demonstrated that GM-CSF + IL-4-
derived BMDCs exposed to ITE and loaded with MOG-specific peptide and transferred 
into mice pre-EAE induction, dampened clinical EAE severity and increased the percent 
of splenic CD4+ Foxp3+ Tregs, while decreasing CD4+ IL-17 and CD4+ IFNγ populations 
(Quintana et al., 2010). They also showed that splenic DCs from ITE-exposed mice and 
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ITE-exposed GM-CSF + IL-4-derived BMDCs were capable of inducing CD4+ Foxp3+ 
Tregs from naïve MOG-specific 2D2+ CD4+ T cells (Quintana et al., 2010). These studies 
demonstrated that AhR activation with ITE can directly generate tolerogenic DCs that are 
functionally suppressive. To date, it is unknown if TCDD-induced AhR activation in DCs 
generates tolerogenic DCs and whether DCs are responsible for the observed immune 
suppression and generation of regulatory T cells following exposure to TCDD. 
 
Hypothesis 
The aryl hydrocarbon receptor (AhR) is a steroid-like transcription factor that 
mediates the toxicity of various environmental pollutants, including 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) and TCDD-like compounds. Exposure to 
environmentally relevant levels of TCDD and TCDD congeners have been shown to 
cause immune suppression and influence the course of an immune response by altering 
effector T cell responses and through the induction of regulatory T cells (Tregs) 
(Marshall et al., 2008; Quintana et al., 2008b; Quintana et al., 2010). However, the 
mechanisms underlying TCDD-induced immune suppression and Treg induction remain 
poorly understood. Dendritic cells (DCs) are professional antigen presenting cells (APCs) 
that play an integral role in both innate and adaptive immune responses. DCs 
constitutively express high levels of the AhR and represent a highly sensitive immune 
cell population to AhR activation by environmental pollutants (Kerkvliet, 2009; Bankoti 
et al., 2010b; Marshall and Kerkvliet, 2010). DCs can differ in phenotype and function 
depending on the tissue location, environmental milieu and ongoing immune responses 
(Banchereau et al., 2000). DCs are commonly classified as steady-state DCs or 
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inflammatory DCs (Shortman and Naik, 2007b; Naik, 2008b). Steady-state DCs exist in 
various tissues as sentinels and primary APCs; where as inflammatory DCs arise in 
response to inflammation and contribute to inflammatory responses. Both DC groups 
contain various subpopulations with specialized functions, including immune regulation 
(Naik et al., 2005; Shortman and Naik, 2007b; Naik, 2008b). AhR activation has been 
characterized in murine inflammatory BMDCs, yet little is known about the 
consequences of AhR activation in steady-state DCs (Lee et al., 2007; Bankoti et al., 
2010b). Using a GM-CSF murine bone marrow-derived DCs (BMDCs) model to 
generate inflammatory DCs, Bankoti and co-workers demonstrated that TCDD-induced 
AhR activation altered DC differentiation, NF-κB signaling, TLR-induced cytokine 
production and antigen uptake (Bankoti et al., 2010b). TCDD-treated inflammatory 
BMDCs also displayed significant increases in regulatory gene expression, suggesting 
that AhR-activation leads to the generation of tolerogenic DCs that could potentially alter 
effector T cell responses (Bankoti et al., 2010b). However, it is unclear whether TCDD-
induced AhR activation in inflammatory BMDCs alters their functional capacity to elicit 
antigen-specific immune responses. Moreover, the effects of AhR activation in steady-
state DCs, both in vitro and in vivo, remain to be defined. We hypothesize that AhR-
activation will alter DC function and that TCDD-induced AhR activation in DCs 
leads to the induction of tolerogenic DCs capable of dampening T cell responses. Our 
studies will investigate the role of AhR activation in both inflammatory and steady-state 
BMDCs to determine if AhR activation induces tolerogenic DCs in vitro and investigate 
whether exposure to TCDD dampens antigen-specific immune responses in vivo. 
Ultimately our goal is to better understand the underlying mechanisms involved in the 
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observed immunosuppression following exposure to TCDD and TCDD-like chemicals. 
This research is important in that it will significantly extend our understanding of how 
environmental pollutants capable of activating the AhR can disrupt the immune system, 
and permit better risk identification and exposure characterization.  
 
Specific Aim 1: Characterize the effects of AhR activation in steady-state DCs. 
(Chapter 2) 
We hypothesized that AhR activation alters the differentiation and function of 
steady-state BMDCs. To test this hypothesis we determined whether AhR activation 
disrupts steady-state DC surface molecule expression, responsiveness to TLR agonists, 
NF-κB binding activity, antigen uptake and regulatory gene expression and examined the 
capacity of AhR-activated steady-state DCs to elicit antigen-specific immune responses 
in vitro and in vivo.  
 
Specific Aim 2: Determine whether AhR activation in inflammatory DCs leads to 
the generation of tolerogenic DCs capable of altering effector T cell responses. 
(Chapter 3) 
We hypothesized that TCDD-induced AhR activation in inflammatory BMDCs 
induces tolerogenic DCs that are capable of dampening effector T cell responses. To test 
this hypothesis we examined antigen-specific OTII CD4+ T cell responses following 
interactions with AhR-activated Ovap-loaded inflammatory BMDCs.   
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Specific Aim 3: Determine whether in vivo exposure to TCDD leads to the 
generation of Foxp3+ Tregs and tolerogenic DCs during antigen-specific immune 
responses.  (Chapter 4) 
We hypothesized that AhR activation by TCDD generates both tolerogenic DCs 
and Tregs in vivo. To test this hypothesis we utilized two separate in vivo OTII CD4+ T 
cell models, in which mice were exposed to vehicle or TCDD and the generation of 
Ovap-specific Foxp3+ T cells and tolerogenic DCs analyzed following Ovap-DC footpad 
immunizations or Ovap/adjuvant immunizations.  
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ABSTRACT 
TCDD is the prototypical AhR ligand and a potent immunotoxicant. However, the 
mechanisms underlying TCDD-induced immunomodulation remain to be defined. 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) that constitutively 
express the AhR and are sensitive to TCDD-induced AhR activation. We hypothesized 
that AhR activation alters the differentiation and function of steady-state BMDCs. To test 
this hypothesis, steady-state bone marrow-derived DCs (BMDCs) from C57BL/6 mice 
were grown in the presence of TCDD or vehicle. TCDD-treated steady-state BMDCs 
(TCDD-BMDCs) displayed decreased expression of CD11c and CD11a, while increasing 
the frequency of MHC class II, CD86, CD80, and CD54. Similar phenotypic alterations 
were observed with the AhR ligands 6-formylindolo[3,2-b]carbazole (FICZ) and 2-(1H-
indole-3’-carbonyl)-thiazole-4-carboxylic acid (ITE). TCDD-BMDCs from AhR-/- mice 
were refractory to TCDD-induced surface marker alterations, whereas TCDD-BMDCs 
from AhRdbd/dbd mice displayed similar phenotypic alterations as AhR+/+ TCDD-BMDCs. 
Following LPS, CpG or Imiquimod stimulation, TCDD-BMDCs secreted less IL-6, 
TNFα, IL-10 and IL-12. TCDD also altered NF-κB family member binding activity in 
unstimulated and LPS- or CpG-stimulated steady-state BMDCs. The internalization of 
the soluble antigens, ovalbumin and acetylated LDL, was decreased while internalization 
of latex beads was increased in TCDD-BMDCs when compared to vehicle-BMDCs. 
TCDD-BMDCs displayed increased mRNA expression of the regulatory gene IDO2 and 
following LPS stimulation upregulated IDO1, IDO2, TGFβ1 and TGFβ3 gene 
expression. Additionally, TCDD-BMDCs increased the generation of CD4+ CD25+ 
Foxp3+ Tregs in vitro in an IDO-dependent fashion. However, TCDD-treated BMDCs 
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did not alter antigen-specific T cell activation in vivo. Overall, TCDD-induced AhR 
activation alters the differentiation, activation, innate and immunoregulatory function, but 
not the T cell-activating capacity of steady-state BMDCs.  
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INTRODUCTION 
Many environmental pollutants exert their toxic effects via activation of the aryl 
hydrocarbon receptor (AhR). The ligand-activated AhR translocates into the nucleus 
where it binds the AhR nuclear translocater (ARNT). Subsequently, in the canonical 
signaling pathway the ligand-bound AhR/ARNT heterodimeric complex binds target 
genes containing dioxin response elements (DREs) and modulates gene expression. 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is the prototypical AhR ligand and a potent 
environmental toxicant. Low level TCDD exposure causes immune suppression in a 
number of animal species and increases susceptibility to infections and cancer (Kerkvliet, 
2002). The immunosuppressive effects of TCDD, as well as many other TCDD-like 
chemicals, are predominantly mediated via the AhR. Within the immune system, TCDD-
induced AhR activation affects many cell populations, including antigen presenting cells 
(APCs) and CD4+ T cells (Vorderstrasse and Kerkvliet, 2001a; Kerkvliet, 2002; 
Kerkvliet et al., 2002; Funatake et al., 2004; Ruby et al., 2005; Hauben et al., 2008; 
Lawrence et al., 2008; Jin et al., 2010). Recently, the induction of regulatory T cells 
(Tregs) has been linked to TCDD-induced AhR activation, and may underlie the 
immunosuppressive effects of TCDD. (Funatake CJ, 2005; Quintana FJ, 2008). In 
contrast, the high-affinity natural AhR ligand 6-formylindolo[3,2-b]carbozole (FICZ) has 
been shown to induce Th17 cells during the course of autoimmune encephalomyelitis in 
mice (Quintana FJ, 2008). However, Kimura et al. demonstrated that in the presence of 
TGFβ both TCDD and FICZ induce Foxp3+ Tregs in an AhR-dependent manner (Kimura 
et al., 2008). While TCDD-induced AhR activation has been characterized in T cell 
populations, less is known about the role of AhR activation in dendritic cells.  
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Dendritic cells (DCs) are professional APCs that function in both the innate and 
adaptive branches of the immune system. DCs act as sentinels to survey and detect 
foreign pathogens and can elicit multifarious immune responses. As part of their innate 
functions, DCs recognize pathogen-associated molecular patterns through pathogen 
recognition receptors, such as Toll-like Receptors (TLRs), and can help clear 
extracellular pathogens through phagocytosis. Following pathogen recognition, DCs 
become activated and increase their expression of various accessory molecules including 
MHC class I and class II, CD80, CD86 and CD54. Activated DCs secrete cytokines that 
tailor the generation of both innate and adaptive immune responses. DCs are considered 
“professional APCs” based on their constitutive expression of accessory molecules, 
mobility, and ability to internalize, process and present antigens to T cells. In 
unimmunized animals, DCs typically exist as pre-DCs or steady-state DCs (Shotman and 
Naik, 2007; Geissmann et al., 2010). Pre-DCs do not display a DC phenotype, but have 
the capacity to develop into DCs upon inflammatory or pathogenic encounter (Shotman 
and Naik, 2007; Naik, 2008a; Geissmann et al., 2010). These DCs are referred to as 
“inflammatory DCs” or “TNF and iNOS producing DCs” (Tip DCs) (Naik, 2008a; 
Geissmann et al., 2010). In vitro, GM-CSF is used to generate DCs, which model 
inflammatory/Tip DCs in vivo (Shotman and Naik, 2007; Wu L, 2007; Xu Y, 2007; 
Kimura et al., 2008; Naik, 2008a). In contrast, immature steady-state DCs consist of both 
migratory and lymphoid-tissue-resident conventional DC populations (Shotman and 
Naik, 2007; Naik, 2008a). The generation of steady-state DCs in vitro is achieved using 
the growth factor Fms-like tyrosine kinase 3 ligand (Flt3L) and represent DCs residing in 
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peripheral immune tissues (Inaba et al., 1992; Brasel et al., 2000; Naik SH, 2007; 
Vremec D, 2008).  
Previously, Vorderstrasse et al. reported that splenic CD11chigh DC numbers were 
reduced and their immunophenotypes altered in mice exposed to immunosuppressive 
doses of TCDD (Vorderstrasse and Kerkvliet, 2001a; Vorderstrasse et al., 2002). Bankoti 
and colleagues further characterized AhR activation in naïve DCs, both in the spleen and 
peripheral lymph nodes, and demonstrated that TCDD selectively affected splenic 
CD11chigh CD8α- 33D1+ DCs, but not the CD11chigh CD8α+ DEC205+ DCs (Bankoti et 
al., 2010a). In inflammatory bone marrow-derived DCs (BMDCs) AhR activation 
induced surface marker alterations, impaired antigen uptake and enhanced secretion of 
TNFα and IL-6, following stimulation with LPS or CpG (Bankoti et al., 2010c). 
Moreover, TCDD-induced AhR activation in inflammatory DCs caused NF-κB p65 
binding to decrease, while upregulating RelB binding (Bankoti et al., 2010c). 
Surprisingly, TCDD did not alter the ability of inflammatory BMDCs to activate antigen-
specific CD4+ T cells in vivo (Bankoti et al., 2010c).  
In this study, we have evaluated the role of AhR activation in steady-state DCs. 
We hypothesized that similar to inflammatory BMDCs, AhR activation would modulate 
the phenotype and function of steady-state BMDCs. Phenotypic status, TLR 
responsiveness, NF-κB activity, gene expression, antigen uptake and CD4+ T cell 
stimulatory capacity were assessed and steady-state BMDCs from AhR null and AhR 
DRE-binding deficient mice were used to mechanistically determine the role of the AhR 
in steady-state BMDC function. Data from this study advance our understanding of how 
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AhR activation modulates conventional DCs, an effect that undoubtedly contributes to 
immune modulation following exposure to AhR ligands.  
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METHODS AND MATERIALS 
Animals 6-8 week old male and female C57Bl/6 mice were purchased from Jackson 
Laboratory (Bar Harbor, ME) and bred at the University of Montana (UM). AhR-/- mice 
(Schmidt et al., 1996) were a kind gift from Dr. Paige Lawrence (University of Rochester 
Medical Center, Rochester, NY). AhRdbd/dbd mutant mice (Bunger et al., 2008) were 
generously provided by Dr. Chris Bradfield and Dr. Ed Glover (University of Wisconsin, 
Madison, WI). OTII Foxp3eGFP mice were kindly provided by Dr. Randolph Noelle 
(Dartmouth Medical School, Lebanon, NH) who originally obtained these mice from Dr. 
Alexander Rudensky (University of Washington School of Medicine, Seattle, WA). All 
animals were housed and maintained at UM and provided water and chow ad libitum. All 
animal experiments were approved by the UM IACUC and adhered to the current NIH 
guidelines for animal usage. 
 
Chemicals and Reagents TCDD was purchased from Cambridge Isotope Laboratories 
(Andover, MA). FICZ was purchased from BIOMOL International (Plymouth Meeting, 
PA). 2-(1H-indole-3’-carbonyl)-thiazole-4-carboxylic acid (ITE) was obtained from 
Tocris Bioscience (Ellisville, MO). All AhR ligands were supplied or suspended in tissue 
culture grade DMSO (Sigma-Aldrich St Louis, MO). Bone marrow-derived dendritic 
cells (BMDCs) were grown in complete RPMI (cRPMI): 20mM HEPES, 1.5mM sodium 
pyruvate, 50ug/ml gentamicin and 10% fetal bovine serum (Hyclone Thermo Fisher 
Scientific Waltman, MA). BMDC:T cells were cultured in cRPMI or F10 media: F-10 
Nutrient Mixture, 20mM HEPES, 50ug/mL gentamicin, and 10% fetal bovine serum 
(Hyclone). All other media reagents were obtained from Invitrogen (Carlsbad, CA).  
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Whole chicken ovalbumin (Ova; Grade V) and 1-methyl-DL-tryptophan (1-MT) were 
purchased from Sigma-Aldrich. Ova-peptide, Ova323-339, was obtained from Mimotopes 
(Clayton, Victoria Australia).  LPS (Escherichia coli; 055:B5) was obtained from Sigma-
Aldrich and CpG (ODN 1826; type B) and Imiquimod (R837) were purchased from 
Invivogen (San Diego, CA). 
 
Generation of Steady-State BMDCs BMDCs were generated using methods as 
previously described (Inaba et al., 1992; Brasel et al., 2000). Briefly, bone marrow cells 
from the tibia and femur were flushed using cRPMI. Progenitor cells were separated from 
RBCs and debris by centrifugation using lympholyte M (Cederlane Laboratories; 
Burlington, NC) and were grown in cRPMI supplemented with 10% conditioned media 
and 300ng/mL human fms-like tyrosine kinase 3 ligand (Flt3L) purchased from 
PeproTech (Rocky Hill, NJ). The conditioned media was generated by culturing 
splenocytes from unmanipulated C57Bl/6 mice in cRPMI for 10 days. Levels of IL-6 in 
the conditioned media were used standardize each batch and ranged between 2 - 5ng/mL. 
On day 5, non-adherent cells were removed, washed and reseeded in fresh media 
containing Flt3L, conditioned media and vehicle or TCDD. On day 10 non-adherent and 
adherent immature BMDCs were harvested, enumerated and cell viability assessed using 
Trypan Blue (Sigma-Aldrich). Unless specified, BMDCs were grown in the presence of 
10nM TCDD or vehicle control (0.01% DMSO), treatments that caused no significant 
effects on BMDC viability (data not shown). 
  
 70 
Phenotypic Analysis BMDCs were analyzed by flow cytometry as described previously 
(Shepherd et al., 2001). Briefly, 1x105 - 1x106 cells were washed with PBS containing 
1% bovine serum albumin and 0.1% NaN3 and resuspended in IgG to block non-specific 
binding (Jackson Laboratory; Bar Harbor, ME). The cells were then stained with 
fluorochrome-conjugated antibodies for 10min on ice. Appropriate isotype controls were 
used in conjunction with the primary antibody staining. The following antibodies were 
used: CD11c-APC (N418) from Invitrogen; MHC class II-PE (M5/114.15.12), CD80-PE 
(16-10A1), CD86-Pacific Blue (GL-1) from Biolegend (San Diego, CA); and CD54-
FITC (3E2), CD11a-PECy7 (2D7) from BDPharmingen (San Diego, CA). Samples were 
analyzed on a FACSAria flow cytometer using BD FACS Diva software, version 4.0 (BD 
Biosciences San Jose, CA). Figures were generated using FlowJo, version 8.8.6 (Tree 
Star Inc, Ashland OR).  
 
TLR Ligand Activation and Cytokine Measurement Immature BMDCs grown in the 
presence of TCDD or vehicle were aliquoted into six-well plates (Corning St. Louis, 
MO), at a density of 1x106 cells/mL and stimulated with 1µg/ml LPS (Sigma-Aldrich), 
0.5µM CpG (Invivogen) or 30µg/ml Imiquimod (Invivogen) for 24h. Following 
stimulation, BMDCs were harvested and analyzed via flow cytometry as described 
above. Supernatants from individual samples were collected and stored at -20oC until 
further analysis. TNFα, IL-6, IL-10 and IL-12p70 cytokine production was measured 
using ELISAs per the manufacturer’s instructions (BD Biosciences).  
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NF-κB Activity Steady-state BMDCs (2x106) were seeded into six-well plates and 
stimulated with LPS (1µg/mL) or CpG (0.5µM) for 45min. The cells were then harvested 
washed and nuclear extracts isolated using the Active Motif’s Nuclear Extract Kit (Active 
Motif, Carlsbad, CA). Protein levels from the nuclear extracts were quantified using a 
BCA protein assay (Pierce, Rockford, IL). The binding activity of NF-κB family 
members (p65, p50, p52, and RelB) was measured using the Active Motif TransAM NF-
κB Family kit per the manufacturer’s instructions. 
 
Quantitative Real-Time Reverse Transcription-polymerase Chain Reaction (qRT-
PCR) To determine the levels of gene expression in BMDCs, qRT-PCR studies were 
conducted as previously described (Bankoti et al., 2010c). BMDCs were harvested on 
day 10, washed twice in PBS and resuspended in Trizol (Invitrogen) to isolate RNA. 
Primers for indoleamine 2,3-dioxygenase 1 (Ido1) and Ido2, transforming growth factor 
β1 (Tgfβ1), Tgfβ2 and Tgfβ3, latent Tgfβ binding protein (Ltbp3), tissue plasminogen 
activator (Platzer et al.), thrombospondin 1 (Thbs1), aldehyde dehydrogenase family 1, 
subfamily A2 (Aldh1a2), aryl hydrocarbon receptor (Ahr) and toll-like receptor 4 (Tlr4) 
were purchased from SABiosciences (Frederick, MD). mRNA levels were determined 
using SYBR green in qRT-PCR reactions (SABiosciences) on a BIO-RAD IQ 5 Light 
Cycler (BIO-RAD; Hercules, CA).  
 
Antigen Uptake To assess antigen uptake, Alexa Fluor 488 (AF488)-labeled ova, 
AF488-labeled acetylated-LDL (Invitrogen) or 7-9µm FITC-labeled latex beads 
(Polysciences, Warrington, PA) were added to 1x106 BMDCs in six-well plates and 
 72 
incubated at 37oC for 12, 1.5 or 6h, respectively. Following incubation, the BMDCs were 
harvested, washed 2X and antigen uptake determined by flow cytometry.  
 
BMDC CD4+ T cell Co-cultures CD4+ T cells from the spleen and popliteal and 
brachial lymph nodes of OTII Foxp3eGFP mice were purified to >75% CD4+ using an 
autoMACS Cell Separator (Miltenyi Biotec Inc, Auburn, CA) and a CD4+ T cell isolation 
kit according to the manufacturer’s instructions (Miltenyi Biotec Inc.). BMDCs were 
treated with 100µM 1-MT on day 9 of culture. On day 10, the BMDCs were harvested, 
washed and cultured with ova-peptide (2µg/mL). After 2.5h exposure to ova-peptide, 
BMDCs were washed 2X and placed with purified CD4+ T cells at a 1:5 DC to T cell 
ratio in 96-well plates in cRPMI or F10 media. The co-cultures were harvested on day 3 
and the frequency of CD4+ CD25+ Foxp3eGFP T cells determined by flow cytometry. 
 
T Cell Activation The capacity of BMDCs to activate ova-specific CD4+ T cells in vivo 
was assessed using the OTII adoptive transfer model as previously described (Bankoti et 
al., 2010c). Briefly, CD45.2+ BMDCs were generated in the presence of Flt3L and 
vehicle or TCDD. On day 10, the BMDCs were harvested, washed and cultured with 
whole ovalbumin (50µg/mL) to load them with antigen. After overnight exposure to 
ovalbumin, BMDCs were washed 2X and then injected (2x106) into each of the hind 
footpads of CD45.1+ host mice that had received ova-specific OTII Thy1.1+ CD4+ T cells 
(2x106) intravenously 24h earlier. The popliteal and brachial lymph nodes were harvested 
5 days post-BMDC injection and the ova-loaded donor BMDC (CD11c+ CD45.2+) and 
OTII T cell (CD4+ Thy1.1+) populations analyzed by flow cytometry.   
 73 
Statistical Analysis Student’s t tests were used to compare two individual samples and 
fold changes. One-way analysis of variance (ANOVA) was used to analyze data with 
more than two groups, with Bonferroni post-hoc analysis. p values ≤ 0.05 were 
considered significant. 
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RESULTS 
AhR activation alters immature steady-state BMDC growth and differentiation 
Exogenous Flt3L when added to bone marrow progenitor cultures in vitro has 
been shown to produce immature DCs, which closely resemble steady-state DCs in vivo 
(Inaba et al., 1992; Brasel et al., 2000; Naik SH, 2007). To assess AhR activation in 
steady-state DCs, Flt3L-BMDCs were exposed to the prototypical AhR ligand, TCDD. 
On day 10, the immature (non-adherent) and mature (adherent) BMDC populations were 
harvested and enumerated. TCDD significantly reduced the number of immature steady-
state BMDCs after 10 days in culture (Vehicle = 60 x 106 ± 5.3; TCDD = 45 x 106 ± 
1.3*). However, there was no difference observed in the number of vehicle- and TCDD-
treated mature BMDCs (Vehicle = 4.8 x 106 ± 0.5; TCDD = 3.7 x 106 ± 0.8). Steady-state 
BMDCs were identified using CD11c, the murine DC lineage marker, and were more 
than 90 percent CD11c+ (Figure 2.1). Previous studies have shown that TCDD modulates 
costimulatory surface marker expression on steady-state splenic DCs in unimmunized 
mice (Vorderstrasse et al., 2002; Bankoti et al., 2010a). TCDD altered the expression of 
accessory molecules on steady-state BMDCs, as assessed by flow cytometry (Figure 2.1). 
TCDD decreased the frequency of BMDCs (TCDD-BMDCs) that expressed CD11c and 
its relative expression when compared to the vehicle-treated controls (vehicle-BMDCs). 
MHC class II (MHC II) expression was significantly decreased, while the percentage of 
cells expressing MHC II was slightly increased following TCDD exposure (Figure 2.1). 
Furthermore, TCDD decreased the expression and frequency of CD11a (Figure 2.1). In 
contrast, both the expression and frequency of the costimulatory molecules CD80 and 
CD86, as well as the adhesion molecule CD54, were significantly upregulated on TCDD-
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BMDCs (Figure 2.1). To determine if these TCDD-induced effects were concentration 
dependent, steady-state BMDCs were exposed to 0.1nM, 1nM, and 10nM TCDD. 
Significant changes in the expression and frequency of CD11c, MHC II, CD86 and CD54 
were observed on BMDCs exposed to TCDD concentrations as low as 0.1nM (Figure 
2.2). Recently, a number of natural compounds including FIZC and ITE have been shown 
to bind and activate the AhR with similar affinity as TCDD (Oberg et al., 2005; Henry et 
al., 2006) To determine if these natural AhR ligands could modulate BMDC 
differentiation, steady-state BMDCs were exposed to FICZ or ITE.  Similar to TCDD, 
both FICZ and ITE decreased the frequency of steady-state BMDCs expressing CD11c 
(Figure 2.3). Conversely, FICZ and ITE increased the percentage of MHC II, CD86 and 
CD54 on steady-state CD11c+ BMDCs when compared to vehicle-treated controls 
(Figure 2.3). 
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Figure 2.1 
 
Figure 2.1.  TCDD-induced alteration of steady-state BMDC surface marker expression. 
Steady-state BMDCs were treated with vehicle (solid black line) or 10nM TCDD (dashed 
line). Isotype staining is represented by gray lines. Immature vehicle- and TCDD-
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BMDCs were harvested on day 10 and surface marker expression analyzed by flow 
cytometry. MHC class II, CD86, CD80, CD54 and CD11a expression was characterized 
on CD11c+ BMDCs. Data is represented as a table showing surface marker percentage 
and mean fluorescent intensity (MFI) values with corresponding SEM values and is 
representative of three separate experiments with n = 3-6. * p ≤ 0.05 indicates significant 
differences between vehicle- and TCDD-treated groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
Figure 2.2 
 
Figure 2.2.  TCDD-induced surface marker alterations are concentration-dependent. 
Steady-state BMDCs were generated in the presence of vehicle control or varying 
concentrations of TCDD (0.1, 1.0, and 10nM). CD11c+ BMDCs were harvested on day 
10 and stained for CD11c, MHC class II, CD86 and CD54 expression as described in the 
Materials and Methods. Data is representative of three independent experiments with n = 
4. * p ≤ 0.05 indicates significant differences between vehicle- and TCDD-treated 
groups.  
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Figure 2.3 
 
Figure 2.3.  Natural AhR ligands alter BMDC accessory molecules. BMDCs were 
treated with vehicle, (A) 10nM FICZ or (B) 10nM ITE and harvested on day 10. CD11c, 
MHC II, CD86 and CD54 expression was evaluated on CD11c+ BMDCs. (A) Data 
represents two independent experiments with n = 4-6 and (B) represents one experiment 
with n = 4. * p ≤ 0.05 indicates significant differences between vehicle- and TCDD-
treated groups.  
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TCDD-induced phenotypic alterations are AhR-dependent but not exclusively DRE-
mediated  
TCDD-induced phenotypic alterations were previously shown to be AhR-
dependent in inflammatory BMDCs and steady-state splenic DCs (Vorderstrasse and 
Kerkvliet, 2001a; Lee et al., 2007; Bankoti et al., 2010a; Bankoti et al., 2010c). As 
expected, steady-state BMDCs derived from AhR-/- mice were insensitive to the effects of 
TCDD (Table 2.1). The frequency of BMDCs expressing CD11c, MHC II, CD86 and 
CD54 remained unchanged, as did the relative expression of CD11c, MHC II, CD86, and 
CD54 on AhR-/- TCDD-BMDCs, when compared to AhR-/- vehicle-BMDCs (Table 2.1). 
On the other hand BMDCs derived from AhRdbd/dbd mice, which lack the ability to bind 
DRE sequences in AhR target genes, were not insensitive to TCDD when compared to 
the AhR-/- BMDCs (Table 2.1). AhRdbd/dbd TCDD-BMDCs displayed an increased 
frequency and relative expression of CD11c (Table 2.1). Similar to the effects observed 
in TCDD-BMDCs from AhR+/+ mice, the frequency and relative expression of MHC II, 
CD86 and CD54 on AhRdbd/dbd TCDD-BMDCs were increased when compared to 
AhRdbd/dbd vehicle-BMDCs. 
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Table 2.1   
 
 
Table 2.1.  The effects of TCDD on accessory molecule expression on BMDCs from 
AhR-/- and AhRdbd/dbd mice. Expression of accessory molecules on vehicle- and TCDD-
treated steady-state BMDCs derived from AhR-/- or AhRdbd/dbd mice. BMDCs were 
generated in vehicle or 10nM TCDD as described in the Materials and Methods. BMDCs 
were harvested on day 10 and CD11c, MHC II, CD86 and CD54 expression evaluated by 
flow cytometry. AhR-/- data is representative of two experiments with n = 3-4 and 
AhRdbd/dbd data represents one experiment with n = 5. * indicates p ≤ 0.05 when 
compared to the representative vehicle-treated controls.  
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TCDD disrupts the TLR responsiveness of steady-state BMDCs  
Innate immune responses can be initiated via stimulation of TLRs, an event that 
leads to DC maturation and activation. Subsequently, activated DCs produce 
inflammatory cytokines that contribute to the development of tailored immune responses. 
To determine if TCDD-induced AhR activation disrupts steady-state DC activation 
and/or cytokine production, immature steady-state BMDCs treated with TCDD or vehicle 
were stimulated for 24h with three TLR agonists; LPS (TLR4), CPG (TLR9) or 
Imiquimod (TLR7). As expected, TLR activation of immature BMDCs induced increased 
expression of CD11c, MHC II and CD86 when compared to unstimulated BMDCs (Table 
2.2). It should be noted that after growth in cRPMI supplemented with conditioned media 
and Flt3L, TCDD-BMDCs placed in cRPMI for 24h without growth factors experienced 
changes in the expression of CD11c and MHC II when compared to the unstimulated 
vehicle-treated BMDCs (Table 2.2). TCDD-BMDCs stimulated with LPS, CpG or 
Imiquimod displayed decreased levels of CD11c (Table 2.2). In contrast to CD11c, 
TCDD-BMDCs expressed higher levels of MHC II, CD86 and CD54 (Table 2.2). In 
addition, TLR-stimulated TCDD-BMDCs displayed increased frequencies of MHC II, 
CD86 and CD54 when compared to the TLR-stimulated vehicle-BMDCs. Furthermore, 
the production of IL-6, TNFα, IL-12 and IL-10 was assessed following TLR stimulation 
to determine if TCDD disrupts cytokine production by steady-state BMDCs. Small, but 
detectable amounts of IL-12, were produced by unstimulated BMDCs, while IL-6, TNFα, 
and IL-10 levels were undetectable (Figure 2.4). Following LPS or CpG stimulation, 
steady-state BMDCs secreted IL-6, TNFα, IL-10 and IL-12 (Figure 2.4). Only IL-6 and 
IL-12 were detectable following stimulation with Imiquimod (Figure 2.4). BMDCs 
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treated with 10nM TCDD produced lower levels of IL-6, TNFα, IL-10 and IL-12 
following stimulation with LPS or CpG, while no significant changes were seen in 
response to Imiquimod at 10nM TCDD (Figure 2.4). Following LPS stimulation, BMDC 
production of IL-6, TNFα, and IL-10 was decreased with concentrations of TCDD as low 
as 1nM, while IL-12 production decreased following exposure to concentrations of 
TCDD as low as 0.1nM (Figure 2.4). Following Imiquimod stimulation, 0.1nM TCDD 
exposed BMDCs secreted less IL-12 when compared to Imiquimod stimulated vehicle-
BMDCs. Similar effects were observed following stimulation with CpG (Figure 2.4). 
Activated DCs also produce nitric oxide (NO), however, no differences were observed in 
the secretion of NO between vehicle-BMDCs and TCDD-BMDCs following stimulation 
with LPS, CpG or Imiquimod (data not shown). 
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Table 2.2 
 % CD11c CD11c MFI 
 Vehicle TCDD Vehicle TCDD 
Unstimulated 89.8 ± 0.1 89.1 ± 1.0 4213 ± 51.7 3570 ± 146 * 
LPS 95.9 ± 0.1 # 95.0 ± 0.4 # * 6416 ± 140 # 4268 ± 184 * 
CpG 91.9 ± 0.3 90.9 ± 0.3 * 5210 ± 61.2 # 3839 ± 75.3 * 
Imiquimod 93.6 ± 0.2 # 91.3 ± 0.2 * 3405 ± 28.8 # 3142 ± 84.0 * 
 
 % MHC II MHC II MFI 
 Vehicle TCDD Vehicle TCDD 
Unstimulated 94.7 ± 0.6  96.7 ± 0.2 *  9157 ± 378  9901 ± 534  
LPS 96.6 ± 0.2  97.8 ± 0.1 *  23030 ± 1394 #  22760 ± 851 #  
CpG 97.8 ± 0.2 #  98.1 ± 0.1 #  18610 ± 424 # 26070 ± 1444 # *  
Imiquimod 94.6 ± 0.4  97.1 ± 0.1 *  13030 ± 554 #  20560 ± 864 # *  
 
 % CD86 CD86 MFI 
 Vehicle TCDD Vehicle TCDD 
Unstimulated 16.3 ± 0.8  32.1 ± 0.7 * 306.3 ± 2.3  314.0 ± 2.2 *  
LPS 80.2 ± 0.8 #  89.6 ± 0.4 # *  970.0 ± 17.3 #  1538 ± 53.7 # *  
CpG 61.7 ± 1.2 #  80.2 ± 0.6 # *  635.0 ± 5.6  #  929.8 ± 24.1 # * 
Imiquimod 43.6 ± 0.7 # 70.5 ± 0.8 # * 805.8 ± 14.3 # 1048 ± 29.8 # * 
 
 % CD54 CD54 MFI 
 Vehicle TCDD Vehicle TCDD 
Unstimulated 33.1 ± 0.2  46.2 ± 0.6 *  260.8 ± 2.3  297.8 ± 2.4 *  
LPS 88.8 ± 0.4 # 89.3 ± 0.1 # * 887.8 ± 13.8 #  988.0 ± 21.3 # * 
CpG 72.9 ± 0.9 # 83.1 ± 0.4 # * 665.3 ± 19.7 #  901.3 ± 10.3 # * 
Imiquimod 29.6 ± 0.8  55.8 ± 0.8 # * 370.0 ± 4.1 # 524.0 ± 6.2 # * 
 
Table 2.2.  Effects of TCDD on the activation of steady-state BMDCs via TLR 
stimulation. BMDCs treated with vehicle or 10nM TCDD were stimulated with LPS 
(1µg/mL), CpG (0.5µM) or Imiquimod (30µg/mL) for 24h, harvested and CD11c, MHC 
II, CD86 and CD54 expression determined by flow cytometry. Mean values of frequency 
 85 
(%) and mean fluorescent intensity (MFI) are displayed with corresponding SEM. Data 
represents two independent experiments with n = 4-6 per treatment group. * indicates p < 
0.05 between vehicle- and TCDD-treated samples; # indicates p < 0.05 between 
unstimulated and LPS-, CpG- or Imiquimod-stimulated samples. 
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Figure 2.4 
 
Figure 2.4.  TCDD decreases BMDC cytokine production following TLR stimulation. 
Vehicle- and TCDD-BMDCs were harvested on day 10 and stimulated for 24h with (A) 
LPS (1µg/mL) or (B) CpG (0.5µM) or (C) Imiquimod (30µg/mL) or unstimulated. Cells 
were harvested, supernatants collected and IL-6, TNFα, IL-12p70 and IL-10 levels 
determined by ELISA. B.D. denotes below detection. Data is representative of two 
separate experiments with n = 4-6. * p ≤ 0.05 indicates significant differences between 
vehicle- and TCDD-treated groups.  
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NF-κB activity is altered in TCDD-BMDCs 
NF-κB signaling pathways are initiated following TLR ligation in DCs and 
subsequently mediate DC activation. Recently, it has been demonstrated that the AhR can 
directly interact with multiple NF-κB family members including RelA, RelB and p52 
(Ruby et al., 2002; Vogel et al., 2007a; Vogel et al., 2007b). Therefore, we measured the 
effects of NF-κB activity in steady-state BMDCs. Following stimulation with LPS or 
CpG the activity of p65, p52, and p50 was increased, while RelB activity remained 
constant when compared to vehicle-BMDCs (Figure 2.5). In unstimulated TCDD-
BMDCs, RelB binding was increased, while p65 and p52 levels were unchanged when 
compared to unstimulated vehicle-BMDCs (Figure 2.5). In contrast, p50 activity was 
decreased in unstimulated TCDD-BMDCs. Following LPS stimulation, TCDD-BMDCs 
displayed increases in RelB and p52 activity and decreases p65 and p50 activity when 
compared to LPS-stimulated, vehicle-BMDCs. RelB binding was unchanged following 
CpG stimulation in TCDD-BMDCs, while p52 binding increased (Figure 2.5). 
Furthermore, the binding levels of both p65 and p50 were reduced in TCDD-BMDCs 
following stimulation with CpG when compared to CpG-stimulated vehicle-BMDCs. 
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Figure 2.5 
 
Figure 2.5.  TCDD alters NF-kB activity. Vehicle- and TCDD-treated BMDCs were 
stimulated with LPS (1µg/mL) or CpG (0.5µM) for 45min. Following stimulation, 
BMDCs were harvested, nuclear lysates isolated and RelB, p65, p52, and p50 binding 
activity determined as described in the Materials and Methods. Data represents mean ± 
SEM of 4 samples per treatment group. * p ≤ 0.05 indicates significant differences 
between vehicle- and TCDD-treated groups; # indicates significance between 
unstimulated and LPS- or CpG-stimulated samples, respectively.  
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AhR activation increases regulatory gene expression in steady-state BMDCs     
Inflammatory BMDCs exposed to TCDD increase their expression of various 
immune regulatory genes, such as TGFβ and indoleamine 2,3-dioxygenase (IDO) (Vogel 
et al., 2008; Bankoti et al., 2010c). Therefore, the expression of key immunoregulatory 
genes was measured in steady-state BMDCs following TCDD exposure. While there 
were no significant fold changes in the expression of Ltbp, Ahr, Thsp1 or TLR4, IDO2 
was significantly upregulated in unstimulated TCDD-BMDCs when compared to vehicle-
BMDCs (Table 2.3). In contrast, TCDD downregulated TGFβ2 and aldehyde 
dehydrogenase family 1, subfamily A2 (Aldh1a2) expression in unstimulated steady-state 
BMDCs when compared to vehicle-BMDCs. To determine if TCDD altered the 
expression of regulatory genes in activated BMDCs, gene expression was measured in 
vehicle-BMDCs and TCDD-BMDCs stimulated with LPS (Table 2.3). TCDD-BMDCs 
upregulated IDO1, IDO2, TGFβ1 and TGFβ3 expression following LPS activation while 
tissue plasminogen activator expression was downregulated (Table 2.3). 
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Table 2.3 
 
 
Table 2.3.  Vehicle- and TCDD-BMDC regulatory gene expression. Regulatory gene 
expression in unstimulated or LPS-stimulated BMDCs was determined by qRT-PCR. 
Gene expression values represent the fold change between vehicle and TCDD treatment 
from two separate experiments with n = 4 per treatment group. * indicates statistically 
significant (p < 0.05) fold change between vehicle-BMDCs and TCDD-BMDCs. 
Indoleamine 2,3-dioxygenase 1 (Ido1) and Ido2; transforming growth factor β1 (Tgfβ1), 
Tgfβ2 and Tgfβ3; tissue plasminogen activator (Platzer et al.); latent Tgfβ binding 
protein (Ltbp3); aryl hydrocarbon receptor (Ahr); thrombospondin 1 (Thbs1); aldehyde 
dehydrogenase family 1, subfamily A2 (Aldh1a2) and toll-like receptor 4 (Tlr4). 
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TCDD modulates antigen uptake by steady-state BMDCs   
Following recognition of antigens such as ovalbumin, low-density lipoprotein 
(LDL), and latex beads, DCs internalize these compounds via macropinocytosis, 
receptor-mediated endocytosis, or phagocytosis, respectively. TCDD disrupts antigen 
uptake by splenic DCs and inflammatory BMDCs (Vorderstrasse and Kerkvliet, 2001a; 
Vorderstrasse et al., 2002; Bankoti et al., 2010c). To assess whether antigen uptake by 
steady-state BMDCs is affected by TCDD, BMDCs were exposed to Ova, acetylated 
LDL, or latex beads and internalization was determined by flow cytometry. On a per cell 
basis TCDD-BMDCs internalized less Ova and LDL antigen, while increasing the uptake 
of latex beads when compared to antigen exposed vehicle-BMDCs (Figure 2.6). The 
overall frequency of Ova-positive and latex bead-positive BMDCs was increased in 
BMDCs exposed to TCDD (Figure 2.6). The frequency of LDL-positive BMDCs was 
unchanged between vehicle-BMDCs and TCDD-BMDCs (Figure 2.6). 
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Figure 2.6 
 
Figure 2.6.  TCDD alters antigen uptake by steady-state BMDCs. AF488-Ova, AF488-
LDL and FITC-latex beads were utilized to assess antigen uptake by BMDCs. Vehicle- 
and TCDD-BMDCs were incubated with LDL (1.5h), latex beads (6h) or Ova (12h). 
Antigen uptake was assessed via flow cytometry as described in the Materials and 
Methods. Results represent three independent experiments with n = 3-4. * p ≤ 0.05 
indicates significant differences between vehicle- and TCDD-treated groups. 
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TCDD-treated BMDCs increase the frequency of CD4+ CD25+ Foxp3+ Tregs in vitro  
AhR activation has recently been linked the generation of Tregs in both graft vs. 
host and autoimmune disease settings (Funatake et al., 2005a; Hauben et al., 2008; 
Quintana et al., 2008a). To determine whether AhR-activated steady-state BMDCs can 
alter or induce Tregs in vitro, antigen-specific CD4+ OTII T cells from mice expressing 
Foxp3eGFP were utilized. Following three days in culture, Ova peptide-loaded TCDD-
treated BMDCs increased the frequency of CD4+ CD25+ Foxp3+ Tregs approximately 
15% when compared to Ova peptide-loaded Vehicle-treated BMDCs (Figure 2.7A). A 
23% increase in CD4+ CD25+ Foxp3+ Tregs with TCDD-treated BMDCs was also 
observed when BMDC:T cells were cultured in F10 media that contains lower levels of 
tryptophan (Figure 2.7B). To test whether the observed increases in IDO gene expression 
in TCDD-treated BMDCs correlated with the increased frequency of CD4+ CD25+ 
Foxp3+ Tregs, vehicle- and TCDD-treated BMDCs were exposed to 1-MT, a tryptophan 
analog and IDO enzyme inhibitor (Mellor and Munn, 2004). 1-MT pretreatment blocked 
the observed increase in CD4+ CD25+ Foxp3+ Tregs in TCDD-treated BMDC:CD4+ T 
cell co-cultures in both the conventional and tryptophan-low media (Figure 2.7).  
 
 
 
 
 
 
 
 
 
 94 
Figure 2.7 
 
Figure 2.7.  TCDD-treated BMDCs increase the frequency of CD4+ CD25+ Foxp3+ 
Tregs in an IDO-dependent manner. Vehicle- or TCDD-BMDCs were treated with 1-MT 
24h pre-harvest. The BMDCs were loaded with Ova-peptide, washed twice and seeded 
with purified Ova-specific CD4+ T cells from OTII mice expressing Foxp3eGFP in 96-well 
plates at a 1:5 DC to T cell ratio. The cultures were harvested on day 3 and the frequency 
of CD4+ CD25+ Foxp3+ Tregs cultured in (A) cRPMI and (B) F10 media were 
determined. Data is representative of one experiment with n = 4. * p ≤ 0.05 indicates 
significant differences between vehicle- and TCDD-treated groups. 
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Steady-state TCDD-BMDCs initiate successful antigen-specific CD4+ T cell activation 
in vivo  
To determine if TCDD-induced AhR activation alters the ability of steady-state 
DCs to activate CD4+ T cells in vivo, we utilized the OTII adoptive transfer model. 
CD45.1+/Thy1.2+ host mice were seeded with CD4+/ Thy1.1+ OTII T cells and injected 
with Ova-loaded CD45.2+ vehicle- or TCDD-BMDCs. Distal brachial lymph nodes and 
proximal draining popliteal lymph nodes were harvested 4 days post-DC immunization. 
Donor DCs and OTII T cells were identified from host immune cells based on dual 
expression of CD11c/CD45.2 and CD4/Thy1.1, respectively. Overall, no significant 
differences were observed in the percent or number of vehicle- or TCDD-treated donor 
DCs in the draining lymph nodes (Figure 2.8A). TCDD-treated donor DCs displayed an 
increase in CD86 expression, while MHC II expression was unchanged when compared 
to vehicle-treated donor DCs (data not shown). The percentage and overall number of 
CD4+/Thy1.1+ OTII T cells was significantly increased in the popliteal lymph node, when 
compared to the brachial lymph node, demonstrating expansion of Ova-specific T cells in 
response to the injection of Ova-loaded BMDCs (Figure 2.8B). However, no differences 
in the percent or number of OTII+ donor T cells in the draining lymph nodes were 
detected following the transfer of TCDD-BMDCs when compared to the vehicle-
BMDCs. Furthermore, no differences were observed in the activation of donor T cells 
between mice immunized with vehicle-BMDCs or TCDD-BMDCs as assessed by 
CD62L and CD44 expression (data not shown).   
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Figure 2.8 
  
Figure 2.8.  In vivo activation of Ova-specific CD4+ OTII T cells by Ova-loaded 
BMDCs. OTII+ CD4+ Thy1.1+ T cells were adoptively transferred into congenic, 
(CD45.1+) host mice on day −1 relative to immunization. On day 0, adoptively 
transferred mice were immunized with vehicle- or TCDD-BMDCs loaded with whole 
ovalbumin. On day 4 post-immunization, popliteal and brachial lymph nodes were 
harvested from host mice and analyzed by flow cytometry. The frequency and numbers 
of (A) donor DCs (CD45.2+/CD11c+) and (B) Ova-specific OTII T cells (CD4+/Thy1.1+) 
were determined. Data is representative of one experiment utilizing seven animals per 
treatment group.  
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Table 2.4 
                                                 Steady-State BMDCs                 Inflammatory BMDCs 
Surface Molecule Expression 1 
 
CD11c, MHC II, CD86, 
CD54, CD11a  
 
CD11c, MHC II, CD86,  
CD54, CD11a 
Cytokine Production 2 TNFα, IL-6, IL-12, IL-10 
TNFα, IL-6, n.s. IL-12, n.s. 
IL-10 
NF-κB Activity p65, RelB p65, n.s. RelB 
Antigen Uptake Ova, n.s. LDL, Particulate Ova, LDL, Particulate 
Immunoregulatory Gene 
Expression 
n.s. IDO1, IDO2, n.s. 
TGFβ3 IDO1, IDO2, TGFβ3 
Treg Generation Capacity 
(in vitro) CD4
+ CD25+ Foxp3+ Tregs CD4+ CD25+ Foxp3+ Tregs  
Antigen-Specific T cell 
Activation  
(in vivo) 
No effects on OTII CD4+ T 
cells No effects on OTII CD4
+ T cells 
 
 
Table 2.4.  Comparison of TCDD-induced alterations in steady-state and inflammatory 
murine BMDCs. 1 Surface molecule expression from unstimulated BMDCs as reported 
by Bankoti et al. 2010 and Lee et al. 2007. 2 BMDCs stimulated with LPS for 24h 
(cytokine production) or 30-45min (NF-κB activity). 3 Unpublished results. n.s. = not 
significant,  = increase and  = decrease. 
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DISCUSSION 
DCs are integral to the function of both the innate and adaptive branches of the 
immune system. The generation of an immune response, whether stimulatory or 
tolerogenic, is largely dependent on DC differentiation, activation and maturation 
(Banchereau et al., 2000). TCDD-induced AhR activation has been shown to disrupt DC 
differentiation (Vorderstrasse and Kerkvliet, 2001a; Lee et al., 2007; Bankoti et al., 
2010a; Bankoti et al., 2010c). Both naïve splenic DCs and inflammatory (GM-CSF-
derived) BMDCs display altered surface molecule expression following TCDD-induced 
AhR activation (Vorderstrasse and Kerkvliet, 2001a; Ruby et al., 2005; Lee et al., 2007; 
Bankoti et al., 2010a; Bankoti et al., 2010c). Similar to these studies, our data show that 
AhR activation modulates the differentiation of Flt3L-derived steady-state BMDCs. DCs 
constitutively express the murine DC lineage marker CD11c and MHC class II, while 
costimulation molecule expression including CD80, CD86 and CD54 is lower but present 
on immature DCs. However, growth in TCDD altered the differentiation of steady-state 
BMDCs causing immature BMDCs to decrease their expression of CD11c, MHC class II 
and CD11a and upregulate CD80, CD86 and CD54 costimulation molecule expression in 
the absence of a maturation signal. Overall, TCDD altered steady-state BMDC 
differentiation and induced a unique phenotype indicative of partially-matured DCs. 
Some of the TCDD-induced changes observed in steady-state BMDCs such as the 
expression of cell surface molecules and immunoregulatory genes were similar to those 
in inflammatory BMDCs, while others such as LPS-activated cytokine production 
differed significantly (Table 4). These effects may highlight the biological functions of 
both steady-state DCs and inflammatory DCs as mediators of T cell immunity and 
inflammatory responses, respectively. Moreover, altered BMDC differentiation caused by 
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AhR activation may be relevant to human exposures as AhR activation by B(a)P has been 
shown to disrupt human monocyte-derived DC differentiation and maturation in vitro 
(Laupeze et al., 2002). Furthermore, AhR activation by the anti-allergenic compound, 
VAF347, has recently been shown to upregulate AhR target gene expression in human 
monocyte-derived DCs and alter the differentiation of human myeloid progenitor cells 
and Langerhan cells (Lawrence et al., 2008; Platzer et al., 2009).  
Two natural AhR ligands, FICZ and ITE, which have recently been shown to 
affect immune cell populations and modulate specific immune responses were evaluated 
for their ability to alter steady-state BMDC differentiation (Henry et al., 2006; Kimura et 
al., 2008; Quintana FJ, 2008; Vogel et al., 2008; Bankoti et al., 2010c). FIZC and ITE 
induced similar phenotypic alterations in steady-state BMDCs when compared to TCDD-
BMDCs and vehicle controls. This suggests that high affinity exogenous ligands (TCDD) 
and high affinity endogenous ligands (FICZ and ITE) can act similarly to alter the 
differentiation of steady-state BMDCs.  
A number of studies have demonstrated that immunomodulation by TCDD and 
TCDD-like chemicals is dependent on the AhR and AhR signaling events (Vorderstrasse 
and Kerkvliet, 2001a; Kerkvliet et al., 2002; Lee et al., 2007; Bankoti et al., 2010c; Jin et 
al., 2010). Steady-state BMDCs derived from AhR-/- mice were refractory to TCDD-
induced phenotypic alterations. To determine whether canonical AhR signaling was 
involved, we investigated the role of dioxin response element (DRE) binding using 
steady-state BMDCs derived from AhRdbd/dbd mice. AhRdbd/dbd steady-state BMDCs 
displayed many similar phenotypic changes following exposure to TCDD when 
compared to AhR+/+ steady-state TCDD-BMDCs. These results indicate that canonical 
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signaling via DREs is not required for TCDD to alter the differentiation of steady-state 
DCs and suggests that non-canonical AhR signaling may mediate the observed TCDD-
induced phenotypic alterations. In inflammatory BMDCs, Bankoti et al. also 
demonstrated that the effects of TCDD were similar between AhRdbd/dbd and AhR+/+ 
TCDD-BMDCs (Bankoti et al., 2010c), suggesting that non-canonical AhR signaling 
mediates TCDD-induced defects in both inflammatory and steady-state DCs. Several 
possible alternatives exist to explain these results, such as the propensity of the activated 
AhR to physically interact with NF-κB family members or possibly STAT proteins 
(Ruby et al., 2002; Vogel et al., 2007a; Kimura et al., 2008). However, the possibility 
that activated AhR physically interacts with NF-κB or STAT proteins in steady-state 
BMDCs remains to be examined.  
As a part of the innate immune system, DCs become activated following 
pathogenic encounter increasing their expression of various surface molecules and 
secreting multiple cytokines (Banchereau et al., 2000). Studies have demonstrated that 
TCDD-induced AhR activation can alter the expression of CD11c, MHC class II and 
CD86 and cytokine production following TLR stimulation in inflammatory BMDCs (Lee 
et al., 2007; Bankoti et al., 2010c). Following stimulation of with LPS (TLR4) or CpG 
(TLR9), CD11c+ inflammatory TCDD-BMDCs increased their expression of MHC class 
II and secreted more IL-6 and TNFα, without affecting their production of IL-10 or IL-12 
(Bankoti et al., 2010c). Furthermore, Lee et al. demonstrated that inflammatory BMDCs 
derived in the presence of GM-CSF, IL-4 and TCDD downregulated CD11c expression 
and upregulated MHC class II and CD86 expression following LPS stimulation (Lee et 
al., 2007). Similar to these studies, following stimulation with LPS or CpG, TCDD-
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treated steady-state BMDCs displayed altered surface marker expression. Moreover, 
TCDD-treated steady-state BMDCs produced less IL-6, TNFα, IL-10 and IL-12 
following stimulation. This is in contrast to TCDD-treated inflammatory BMDCs that 
secreted more IL-6 and TNFα following LPS or CpG stimulation (Bankoti et al., 2010c). 
The differences in cytokine production between AhR-activated inflammatory and steady-
state BMDCs is likely due to the fact that they model different DC populations in vivo. It 
is interesting that the levels of each cytokine measured, IL-6, TNFα, IL-12 and IL-10, 
were reduced by stimulated TCDD-treated steady-state BMDCs, suggesting that AhR 
activation may disrupt DC maturation. However, the observed increased expression of 
MHC class II, CD86, and CD54 following stimulation suggests that AhR activation may 
differentially affect steady-state DC maturation by increasing costimulatory molecule 
expression, while decreasing the production of key cytokines. The molecular 
underpinnings and biological significance of such effects remain to be determined.  
The altered expression of costimulatory molecules and decreased cytokine 
production in TCDD-treated steady-state BMDCs following innate recognition of 
pathogenic components may be due to non-canonical AhR signaling. Recently, a number 
of non-canonical AhR signaling pathways have been described that include interactions 
between activated AhR and the NF-κB family member RelB (Vogel et al., 2007a; 
Kimura et al., 2008). Vogel and colleagues showed that production of the chemokines, 
BAFF, BLC, and CCL1, from TCDD-treated U937 macrophages was dependent on the 
expression of both the AhR and RelB and controlled by AhR/RelB complexes binding to 
promoter elements upstream of the BAFF, BLC, and CCL1 genes (Vogel et al., 2007b). 
Ruby et al. demonstrated that stimulation of TCDD-exposed DC2.4 cells with TNFα or 
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anti-CD40 induced a physical association between the AhR and p65, effectively blocking 
p65 activity (Ruby et al., 2002). To characterize AhR/NF-κB interactions in non-
transformed DCs, Lee et al. used inflammatory BMDCs and demonstrated that following 
LPS stimulation TCDD-treated BMDCs reduce RelB gene expression (Lee et al., 2007). 
However, Bankoti et al. showed that there was an increasing trend of RelB activity in 
TCDD-treated inflammatory BMDCs following LPS or CpG stimulation, while p65 
activity was significantly reduced (Bankoti et al., 2010c). In unstimulated and stimulated 
steady-state BMDCs treated with TCDD, NF-κB RelB, p65, p50, and p52 activity was 
altered. These data suggest that in steady-state BMDCs activated AhR may interact with 
RelB or p52 to increase DNA binding or alternatively interact with p65 or p50 to block 
target gene binding. It is currently unknown if activated AhR physically interacts with 
NF-κB family members to alter target gene binding in steady-state BMDCs or 
conventional DCs in vivo.  
DCs contribute to innate immune responses by clearing pathogens via 
phagocytosis. Two previous studies have evaluated the ability of DCs to internalize 
antigens following AhR activation (Vorderstrasse et al., 2002; Bankoti et al., 2010c). In 
the first study, splenic DCs isolated following TCDD exposure showed no difference in 
their ability to internalize FITC-labeled latex beads (Vorderstrasse et al., 2002; Bankoti et 
al., 2010c). In the second study, inflammatory BMDCs exposed to TCDD displayed 
decreases in AF488-labeled Ova and LDL antigen uptake, while increasing FITC-labeled 
latex bead uptake (Vorderstrasse et al., 2002; Bankoti et al., 2010c). In this study, TCDD 
altered the ability of steady-state BMDCs to internalize both soluble and particulate 
antigens. The inconsistencies in these results may be due to differences in the type of 
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DCs (i.e. ex vivo conventional DCs versus in vitro-derived inflammatory or steady-state 
BMDCs). Nonetheless, defects in antigen uptake following AhR activation in DCs could 
affect their innate clearance of pathogens and potentially alter antigen processing and 
presentation and subsequent T cell-mediated immune responses. 
Altering DC differentiation and antigen uptake following AhR activation may 
affect the functional capacity of DCs to induce appropriate antigen-specific T cell 
responses (Vorderstrasse et al., 2002; Lee et al., 2007). T cell activation not only requires 
TCR stimulation through antigen recognition in the context of MHC molecules, but also 
costimulation through interactions between CD86/CD80 and CD28. AhR activation in 
steady-state BMDCs decreases MHC class II expression, while increasing CD86 and 
CD80 expression, which could affect T cell activation. Recently, increases in CD86 on 
inflammatory BMDCs have been attributed to increased T cell activation in mixed 
lymphocyte reactions (Lee et al., 2007). However, interactions between CD86/CD80 
expressed on the DC and CTLA4 on T cells has been shown to inhibit T cell activation 
and may induce regulatory T cells (Lane, 1997; Funatake CJ, 2005). Furthermore, 
decreased expression of the adhesion molecule CD11a following AhR activation could 
affect interactions between T cells and antigen-bearing DCs, leading to suboptimal T cell 
stimulation. In contrast to inflammatory BMDCs, which display decreased levels of both 
CD11a and CD54 following TCDD-induced AhR activation, the increased expression of 
CD54 on steady-state TCDD-BMDCs could enhance T cell adhesion (Bankoti et al., 
2010c). However, the TCDD-induced alterations of surface molecules on steady-state 
BMDCs were modest, and thus, it remains to be determined if these changes are 
biologically significant. 
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The induction of tolerance or regulation of immune responses by DCs is 
dependent on a variety of mediators including TGFβ, IDO as well as other essential 
amino acid metabolizing enzymes and retinoic acid (Sharma MD, 2007; Yamazaki and 
Steinman, 2009; Cobbold et al., 2010; Cobbold et al., 2011). Steady-state BMDCs treated 
with TCDD upregulated the expression of IDO2 approximately 7-fold when compared to 
vehicle-treated, steady-state BMDCs. Following LPS stimulation, steady-state BMDCs 
treated with TCDD upregulated expression of IDO1, IDO2, TGFβ1 and TGFβ3. The 
TCDD-induced induction of IDO2 suggests that TCDD induces a regulatory phenotype 
in steady-state BMDCs. However, TCDD-treated inflammatory BMDCs displayed 
greater than 10-fold increases in IDO1, IDO2 and TGFβ3 (Bankoti et al., 2010c). The 
differences in regulatory gene expression between these two DC populations may be 
because these BMDCs represent separate DC populations in vivo (Shotman and Naik, 
2007; Naik, 2008a; Geissmann et al., 2010). Inflammatory DCs are hyper-responsive 
immune cells and play an integral role in the regulation of inflammation. On the other 
hand, steady-state BMDCs represent conventional DC populations that are more likely to 
be refractory to rapid environmental changes, which may account for their overall lower 
regulatory gene expression when compared to TCDD-treated inflammatory BMDCs.  
The regulatory capacity of TCDD-treated steady-state BMDCs is illustrated by 
their ability to increase the frequency of CD4+ CD25+ Foxp3+ Tregs in vitro. 
Furthermore, the increased generation of CD4+ CD25+ Foxp3+ Tregs was IDO-
dependent, as 1-MT treated AhR-activated BMDCs did not generate an increased 
frequency of CD4+ CD25+ Foxp3+ Tregs. These data demonstrate the functional capacity 
of IDO, which is induced following AhR activation in steady-state BMDCs, to contribute 
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to the generation of CD4+ CD25+ Foxp3+ regulatory T cells. It has yet to be determined if 
AhR-activated steady-state BMDCs under suboptimal T cell stimulatory conditions 
induce CD4+ CD25+ Foxp3+ Tregs, or other types of regulatory T cell such as Tr1 cells, 
in vivo.  
In contrast to our in vitro results, TCDD-treated steady-state BMDCs failed to 
suppress antigen-specific CD4+ T cell responses in vivo. This lack of an effect may be 
due to several plausible outcomes. First, the in vivo response may have been 
oversaturated with antigen (via the ova-loaded BMDCs), essentially “washing out” any 
TCDD-induced immunoregulatory effects of the BMDCs. Second, the population of 
BMDCs that are more significantly affected by TCDD may have defects in their ability to 
migrate to the draining popliteal lymph node and thus never reach that immune tissue to 
modify the subsequent T cell response. Third, TCDD-treated BMDCs may have to 
undergo some form of maturation via stimulatory signals such as LPS before they acquire 
functional immunosuppressive capabilities in vivo as was previously observed with 
VAF347-treated BMDCs (Hauben et al., 2008). Fourth, OTII adoptively transferred mice 
may need to receive TCDD-treated BMDCs via a different route of administration (ie 
intravenously and not via the footpad) to realize an immunosuppressive effect. Finally, it 
could simply be that TCDD-treated, steady-state BMDCs possess only a phenotypic, and 
not a functional, immunoregulatory capacity. However, as shown in Figure 7, it would 
appear that TCDD-treated, steady-state BMDCs do indeed possess an immunoregulatory 
capacity. In these experiments, TCDD-exposed BMDCs were loaded with ovalbumin at 
concentrations somewhat lower than had been used for the in vivo experiments. These 
BMDCs were then cultured with OTII/Foxp3egfp T cells, leading to a significant increase 
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in the generation of regulatory T cells in vitro. These experiments are consistent with the 
possibility that in our in vivo experiments: (1) the immunosuppressive BMDCs may not 
have been migrating properly to the draining lymph nodes as previously described for 
lung DCs (Jin et al., 2010); (2) injecting them intravenously may be a more effective 
“therapeutic” approach (Hauben et al., 2008); and/or (3) the concentration of ovalbumin 
used to load BMDCs for the in vivo experiments may have been inappropriate. On the 
other hand, our in vitro results indicate that TCDD-treated BMDCs are (1) functionally 
immunoregulatory, and (2) do not need to be LPS-stimulated to obtain this capability. 
Consequently, additional studies are necessary to define the optimal conditions that are 
required to translate the effects of TCDD-treated, steady-state BMDCs in vivo. These 
experiments are currently being addressed in our laboratory and will attempt to determine 
the “therapeutic” potential of AhR-activated BMDCs in several animal models of 
immune-mediated disease. 
In summary, we report here that AhR activation disrupts the differentiation, TLR 
responsiveness, NF-κB signaling, uptake of antigen, and induction of immunoregulatory 
gene expression in steady-state BMDCs. Moreover, TCDD-treated, steady-state BMDCs 
can generate CD4+ CD25+ Foxp3+ Tregs in vitro in an IDO-dependent fashion. However, 
somewhat unexpectedly, TCDD-treated steady-state BMDCs successfully activated CD4+ 
antigen-specific T cells in vivo. Overall, our study offers mechanistic data to further 
explain the immunomodulatory effects of AhR activation. Moreover, this study defines 
several specific biomarkers of immunotoxicity following exposure to toxicants that can 
activate the AhR and identifies selective AhR modulators that may possess therapeutic 
value.   
 107 
REFERENCES  
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., 
and Palucka, K. (2000). Immunobiology of dendritic cells. Annu Rev Immunol 18, 
767-811. 
Bankoti, J., Burnett, A., Navarro, S., Miller, A. K., Rase, B., and Shepherd, D. M. 
(2010a). Effects of TCDD on the fate of naive dendritic cells. Toxicol Sci 115, 
422-434. 
Bankoti, J., Rase, B., Simones, T., and Shepherd, D. M. (2010b). Functional and 
phenotypic effects of AhR activation in inflammatory dendritic cells. Toxicol 
Appl Pharmacol 246, 18-28. 
Brasel, K., De Smedt, T., Smith, J. L., and Maliszewski, C. R. (2000). Generation of 
murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. 
Blood 96, 3029-3039. 
Bunger, M. K., Glover, E., Moran, S. M., Walisser, J. A., Lahvis, G. P., Hsu, E. L., and 
Bradfield, C. A. (2008). Abnormal liver development and resistance to 2,3,7,8-
tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-
binding domain of the aryl hydrocarbon receptor. Toxicol Sci 106, 83-92. 
Cobbold, S. P., Adams, E., Nolan, K. F., Regateiro, F. S., and Waldmann, H. (2010). 
Connecting the mechanisms of T-cell regulation: dendritic cells as the missing 
link. Immunol Rev 236, 203-218. 
Funatake, C. J., Dearstyne, E. A., Steppan, L. B., Shepherd, D. M., Spanjaard, E. S., 
Marshak-Rothstein, A., and Kerkvliet, N. I. (2004). Early consequences of 
2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on the activation and survival of 
antigen-specific T cells. Toxicol. Sci. 82, 129-142. 
Funatake, C. J., Marshall, N. B., Steppan, L. B., Mourich, D. V., and Kerkvliet, N. I. 
(2005). Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-
tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with 
characteristics of regulatory T cells. J Immunol. 175, 4184-4188. 
Geissmann, F., Manz, M. G., Jung, S., Sieweke, M. H., Merad, M., and Ley, K. (2010). 
Development of monocytes, macrophages, and dendritic cells. Science 327, 656-
661. 
Hauben, E., Gregori, S., Draghici, E., Migliavacca, B., Olivieri, S., Woisetschlager, M., 
and Roncarolo, M. G. (2008). Activation of the aryl hydrocarbon receptor 
promotes allograft-specific tolerance through direct and dendritic cell-mediated 
effects on regulatory T cells. Blood 112, 1214-1222. 
Henry, E. C., Bemis, J. C., Henry, O., Kende, A. S., and Gasiewicz, T. A. (2006). A 
potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist 
activity in vitro and in vivo. Arch Biochem Biophys 450, 67-77. 
Jin, G. B., Moore, A. J., Head, J. L., Neumiller, J. J., and Lawrence, B. P. (2010). Aryl 
hydrocarbon receptor activation reduces dendritic cell function during influenza 
virus infection. Toxicol Sci 116, 514-522. 
Kerkvliet, N. I. (2002). Recent advances in understanding the mechanisms of TCDD 
immunotoxicity. Int Immunopharmacol 2, 277-291. 
Kerkvliet, N. I., Shepherd, D. M., and Baecher-Steppan, L. (2002). T lymphocytes are 
direct, aryl hydrocarbon receptor (AhR)-dependent targets of 2,3,7,8-
 108 
tetrachlorodibenzo-p-dioxin (TCDD): AhR expression in both CD4+ and CD8+ T 
cells is necessary for full suppression of a cytotoxic T lymphocyte response by 
TCDD. Toxicol. Appl. Pharmacol. 185, 146-152. 
Kimura, A., Naka, T., Nohara, K., Fujii-Kuriyama, Y., and Kishimoto, T. (2008). Aryl 
hydrocarbon receptor regulates Stat1 activation and participates in the 
development of Th17 cells. Proc Natl Acad Sci U S A 105, 9721-9726. 
Lane, P. (1997). Regulation of T and B cell responses by modulating interactions 
between CD28/CTLA4 and their ligands, CD80 and CD86. Ann N Y Acad Sci 
815, 392-400. 
Laupeze, B., Amiot, L., Sparfel, L., Le Ferrec, E., Fauchet, R., and Fardel, O. (2002). 
Polycyclic aromatic hydrocarbons affect functional differentiation and maturation 
of human monocyte-derived dendritic cells. J Immunol 168, 2652-2658. 
Lawrence, B. P., Denison, M. S., Novak, H., Vorderstrasse, B. A., Harrer, N., Neruda, 
W., Reichel, C., and Woisetschlager, M. (2008). Activation of the aryl 
hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a 
novel low-molecular-weight compound. Blood 112, 1158-1165. 
Lee, J. A., Hwang, J. A., Sung, H. N., Jeon, C. H., Gill, B. C., Youn, H. J., and Park, J. H. 
(2007). 2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates functional differentiation 
of mouse bone marrow-derived dendritic cells Downregulation of RelB by 
2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Lett 173, 31-40. 
Mellor, A. L., and Munn, D. H. (2004). IDO expression by dendritic cells: tolerance and 
tryptophan catabolism. Nat Rev Immunol 4, 762-774. 
Naik, S. H. (2008). Demystifying the development of dendritic cell subtypes, a little. 
Immunol. Cell Biol. 86, 439-452. 
Naik S. H., Sathe, P., Park, H. Y., Metcalf, D., Proietto, A. I., Dakic, A., Carotta, S., 
O'Keeffe, M., Bahlo, M., Papenfuss, A., Kwak, J. Y., Wu, L., and Shortman, K. 
(2007). Development of plasmacytoid and conventional dendritic cell subtypes 
from single precursor cells derived in vitro and in vivo. Nat. Immunol. 8, 1217-
1226. 
Oberg, M., Bergander, L., Hakansson, H., Rannug, U., and Rannug, A. (2005). 
Identification of the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, in 
cell culture medium, as a factor that controls the background aryl hydrocarbon 
receptor activity. Toxicol Sci 85, 935-943. 
Platzer, B., Richter, S., Kneidinger, D., Waltenberger, D., Woisetschlager, M., and 
Strobl, H. (2009). Aryl hydrocarbon receptor activation inhibits in vitro 
differentiation of human monocytes and Langerhans dendritic cells. J Immunol 
183, 66-74. 
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., 
Caccamo, M., Oukka, M., and Weiner, H. L. (2008). Control of T(reg) and 
T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65-71. 
Ruby, C. E., Funatake, C. J., and Kerkvliet, N. I. (2005). 2,3,7,8 Tetrachlorodibenzo-p-
Dioxin (TCDD) Directly Enhances the Maturation and Apoptosis of Dendritic 
Cells In vitro. J Immunotoxicol 1, 159-166. 
Ruby, C. E., Leid, M., and Kerkvliet, N. I. (2002). 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-
 109 
kappaB/Rel in dendritic cells: p50 homodimer activation is not affected. Mol 
Pharmacol 62, 722-728. 
Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C., and Bradfield, C. A. (1996). 
Characterization of a murine Ahr null allele: involvement of the Ah receptor in 
hepatic growth and development. Proc Natl Acad Sci U S A 93, 6731-6736. 
Sharma, M. D., Baban, B., Chandler, P., Hou, D. Y., Singh, N., Yagita, H., Azuma, M, 
Blazar, B. R., Mellor, A. L., and Munn, D. H. (2007). Plasmacytoid dendritic cells 
from mouse tumor-draining lymph nodes directly activate mature Tregs via 
indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 2570-2582. 
Shepherd, D. M., Steppan, L. B., Hedstrom, O. R., and Kerkvliet, N. I. (2001). Anti-
CD40 Treatment of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-exposed 
C57Bl/6 mice induces activation of antigen presenting cells yet fails to overcome 
TCDD-induced suppression of allograft immunity. Toxicol Appl Pharmacol 170, 
10-22. 
Shortman, K., and Naik, S. H. (2007). Steady-state and inflammatory dendritic-cell 
development. Nat. Rev. Immunol. 7, 19-30. 
Vogel, C. F., Goth, S. R., Dong, B., Pessah, I. N., and Matsumura, F. (2008). Aryl 
hydrocarbon receptor signaling mediates expression of indoleamine 2,3-
dioxygenase. Biochem Biophys Res Commun 375, 331-335. 
Vogel, C. F., Sciullo, E., Li, W., Wong, P., Lazennec, G., and Matsumura, F. (2007a). 
RelB, a new partner of aryl hydrocarbon receptor-mediated transcription. Mol 
Endocrinol 21, 2941-2955. 
Vogel, C. F., Sciullo, E., and Matsumura, F. (2007b). Involvement of RelB in aryl 
hydrocarbon receptor-mediated induction of chemokines. Biochem Biophys Res 
Commun 363, 722-726. 
Vorderstrasse, B. A., Dearstyne, E. A., and Kerkvliet, N. I. (2002). Influence of 2,3,4,8-
Tetrachlorodibenzo-p-dioxin on the antigen-presenting activity of dendritic cells 
Toxicological Sciences 72, 103-112. 
Vorderstrasse, B. A., and Kerkvliet, N. I. (2001). 2,3,7,8 Tetrachlorodibenzo-p-dioxin 
affects the number and function of murine splenic dendritic cells and their 
expression of accessory molecules. Toxicol. Appl. Pharmacol. 171, 117-125. 
Vremec, D., and Shortman, K. (2008). The isolation and identification of murine 
dendritic cell populations from lymphoid tissues and their production in culture. 
Methods Mol Biol. 415, 163-178. 
Wu, L., and Liu, Y. J. (2007). Development of dendritic-cell lineages. Immunity 26. 
Xu, Y., Zhan. Y., Lew A. M., Naik, S. H., and Kershaw, M. H. (2007). Differential 
development of murine dendritic cells by GM-CSF versus Flt3 ligand has 
implications for inflammation and trafficking. J. Immunol. 179, 7577-7584. 
Yamazaki, S., and Steinman, R. M. (2009). Dendritic cells as controllers of antigen-
specific Foxp3+ regulatory T cells. J Dermatol Sci 54, 69-75. 
 
 
 
 110 
CHAPTER 3 
 
Ah Receptor Activation in Inflammatory Murine Bone Marrow-Derived Dendritic 
Cells Disrupts Antigen-Specific CD4+ T cell Responses In vitro 
 
 
 
 
Authors 
Tom Simones and David M. Shepherd 
 
 
 
 
Corresponding Author 
Dr. David M. Shepherd 
Address: University of Montana 
Center for Environmental Health Sciences 
32 Campus Dr., Skaggs Bldg. 
Missoula, MT 59812 
Telephone: 406-243-2224 
Fax: 406-243-2807 
Email: david.shepherd@umontana.edu 
 111 
ABSTRACT 
The aryl hydrocarbon Receptor (AhR) mediates the toxic effects of various 
environmental and dietary compounds, with the immune system being one of the most 
sensitive mammalian targets of AhR-mediated toxicity. However, the mechanisms 
underlying immunomodulation following AhR activation remain to be fully defined. 
Within the immune system, dendritic cells (DCs) express high levels of the AhR and are 
sensitive to AhR activation. Previously, Bankoti and colleagues demonstrated that AhR 
activation significantly alters inflammatory bone marrow-derived DC (BMDC) surface 
molecule expression and increases the expression of known immune regulatory genes 
such as indoleamine 2,3-dioxygenase-1 and -2 (IDO1, IDO2) and TGFβ3. However, it is 
unknown whether TCDD-induced alterations in immature inflammatory BMDCs cause 
functional changes in their ability to interact with CD4+ T cells. Thus, we hypothesized 
that AhR activation in inflammatory DCs leads to the generation of tolerogenic DCs 
capable of dampening antigen-specific immune responses. To test this hypothesis, murine 
GM-CSF BMDCs were generated in the presence of TCDD or a vehicle control, loaded 
with Ovalbumin peptide (Ovap) and placed with Ovap-specific OTII+ CD4+ T cells in 
vitro. Following 3 to 5 days in culture CD4+ T cell proliferation was assessed and the 
CD4+ T cell response characterized by cytokine production. While there were minimal 
changes in CD4+ T cell proliferation, inflammatory AhR-activated BMDCs consistently 
increased IL-2 levels and decreased IFNγ and IL-10 levels in DC:T cell co-cultures. To 
explore possible mechanisms underlying these effects, the generation of Foxp3+ Tregs 
was analyzed in DC:T cell co-cultures, with TCDD-treated BMDCs variably inducing 
Foxp3+ Tregs. 
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INTRODUCTION 
The AhR is a ligand-activated transcription factor that mediates the toxic effects 
of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) as well as various other halogenated and 
polycyclic aromatic hydrocarbons. Following ligand-induced AhR activation, increased 
expression of AhR target genes results in cell- and tissue-specific toxicities. Immune cells 
are particularly sensitive to ligand-induced AhR activation and environmental pollutants 
capable of activating the AhR can alter the course on an immune response, most often 
resulting in immune suppression. However, the mechanisms underlying the observed 
immunosuppression following AhR activation remain unclear. DCs constitutively express 
the AhR and are affected by ligand-induced AhR activation. Due to the integral role of 
DCs in initiating effector T cell responses, it is likely that AhR-activated DCs play a key 
role in AhR-mediated immunosupression. Previously, Bankoti and colleagues using a 
GM-CSF-derived inflammatory BMDC model demonstrated that exposure to TCDD 
during BMDC development altered DC surface molecule expression and significantly up-
regulate the immune regulatory genes IDO1 and IDO2 and TGFβ3 (Bankoti et al., 
2010b). IDO, an amino acid metabolizing enzyme that catalyzes tryptophan breakdown, 
is known to play a role in the generation of Tregs and has been shown to be a key 
element in the modulation of CD4+ T cell responses following AhR activation in both 
DCs and CD4+ T cells (Vogel et al., 2008; Mezrich et al., 2010; Nguyen et al., 2010; 
Simones and Shepherd, 2011). In addition to IDO, the increased expression of TGFβ, a 
potent inducer of Tregs, in TCDD-treated inflammatory BMDCs suggests that AhR 
activation is inducing a tolerogenic phenotype in DCs. Whether this TCDD-induced 
tolerogenic phenotype translates into a functional phenotype in which TCDD-exposed 
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inflammatory DCs are capable of dampening CD4+ T cell responses indirectly via the 
generation of Tregs is unknown.  
Recently, AhR activation has been implicated in the generation of Tregs. 
Quintana and colleagues demonstrated that CD4+ Foxp3+ Tregs were generated from 
CD4+ Foxp3- T cells in the presence of TCDD following anti-CD3/CD28 antibody-
mediated activation (Quintana et al., 2008b). These in vitro findings were translated into 
in vivo experiments demonstrating that TCDD-induced AhR activation dampened the 
severity of experimental autoimmune encephalomyelitis (EAE) in mice through the 
induction of Foxp3+ Tregs in an AhR-dependent fashion (Quintana et al., 2008b). 
Alternatively, AhR activation with the UV tryptophan breakdown product 6-
formylindolo[3,2-b]carbazole (FICZ) caused the polarization of pro-inflammatory Th17 
cells, subsequently worsening EAE symptoms in mice (Quintana et al., 2008b; Veldhoen 
et al., 2008). Interestingly, Bradfield and colleagues observed that AhR activation with 
the tryptophan catobolite kynurenine generated Foxp3+ Tregs, while FICZ-induced AhR 
activation polarized Th17 cells following naïve CD4+ T cell activation (Mezrich et al., 
2010). In addition to its role in Foxp3+ Treg and Th17 cell polarization, the AhR may 
also be directly involved in the generation of type 1 regulatory T cells (Tr1) that 
characteristically produce large amounts of anti-inflammatory IL-10 (Apetoh et al., 
2010). The induction of Tr1 cells from naïve CD4+ T cells with IL-27 and TGFβ in vitro 
was greatly enhanced in the presence of the high affinity AhR agonists TCDD or FICZ 
(Apetoh et al., 2010). In contrast to the induction of Foxp3+ or Tr1 Tregs, Kerkvliet and 
colleagues demonstrated that TCDD-induced AhR activation generated regulatory CD4+ 
 114 
CD25+ Foxp3- T cells that were functionally suppressive during graft vs. host responses 
in mice (Funatake et al., 2005b).  
Taken together, AhR clearly plays a role in CD4+ T cell responses. However, 
naïve T lymphocytes ostensibly express undetectable levels of AhR as compared to 
immature DCs that constitutively express the AhR and are highly sensitive to AhR 
activation (Kerkvliet, 2009; Bankoti et al., 2010b; Simones and Shepherd, 2011). While 
the effects of AhR activation in T cells are well studied, the interactions between TCDD-
treated DCs and naïve CD4+ T cells and the resulting effector T cell response are not as 
well characterized. It is highly plausible that effects seen in vivo following exposure to 
TCDD are mediated in part by DCs rather than direct effects on CD4+ T cell polarization. 
In this study, we tested the hypothesis that AhR activation in inflammatory BMDCs leads 
to the generation of tolerogenic DCs capable of dampening antigen-specific immune 
responses. Overall, we show that AhR-activated inflammatory DCs alter antigen-specific 
CD4+ T cell responses in vitro, as determined by altered cytokine production, and that 
TCDD-treated inflammatory DCs have the potential to generate Foxp3+ Tregs.  
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MATERIALS AND METHODS 
Animals 6-8 week old male and female C57Bl/6, OTII Thy1.1, Balb/c and DO11.10 
mice were purchased from Jackson Laboratory (Bar Harbor, ME) and bred at the 
University of Montana. OTII Foxp3eGFP reporter mice were kindly provided by Dr. 
Randolph Noelle (Dartmouth Medical School, Lebanon, NH) who originally obtained 
these mice from Dr. Alexander Rudensky (University of Washington School of 
Medicine, Seattle, WA). All animals were housed and maintained at UM and provided 
water and chow ad libitum. All animal experiments were approved by the UM IACUC 
and adhered to the current NIH guidelines for animal usage. 
 
Chemicals and Reagents TCDD and benzo[a]pyrene (BaP) were purchased from 
Cambridge Isotope Laboratories (Andover, MA). 2-(1H-indole-3’-carbonyl)-thiazole-4-
carboxylic acid (ITE) was obtained from Tocris Bioscience (Ellisville, MO). 
Dexamethasone was purchased from Sigma-Aldrich (St Louis, MO). TCDD, BaP and 
ITE were supplied or resuspended in tissue culture grade DMSO from Sigma-Aldrich. 
Dexamethansone was suspended in Endotoxin-free water. Bone marrow-derived 
dendritic cells (BMDCs) were grown in complete RPMI (cRPMI): 20mM HEPES, 
1.5mM sodium pyruvate, 50ug/ml gentamicin and 10% fetal bovine serum (Hyclone 
Thermo Fisher Scientific Waltman, MA). BMDC:CD4+ T cells were cultured in cRPMI 
or F10 media: F-10 Nutrient Mixture, 20mM HEPES, 50ug/mL gentamicin, and 10% 
fetal bovine serum (Hyclone). All other media reagents were obtained from Invitrogen 
(Carlsbad, CA). 1-methyl-DL-tryptophan (1-MT) were purchased from Sigma-Aldrich. 
Ova-peptide, Ova323-339, was obtained from Mimotopes (Clayton, Victoria Australia). 
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LPS (Escherichia coli; 055:B5) was obtained from Sigma-Aldrich. Recombinant human 
IL-2 and TGFβ1 were purchased from Peprotech (Rocky Hill, NJ) and Biolegend (San 
Diego, CA). Low endotoxin/azide free anti-CD3 (145-2C11) and anti-CD28 (CD28.2) 
antibodies were purchased from BioLegend.  
 
Generation of Inflammatory BMDCs BMDCs were generated using methods as 
previously described (Inaba et al., 1992; Bankoti et al., 2010b). Briefly, bone marrow 
cells from the tibia and femur were flushed using cRPMI. Progenitor cells were separated 
from RBCs and debris by centrifugation using lympholyte M (Cederlane Laboratories; 
Burlington, NC) and were grown in cRPMI supplemented with 10% conditioned media 
and 30ng/mL granulocyte macrophage-colony stimulating factor (GM-CSF) purchased 
from PeproTech and Biolegend. On days 3 and 5, non-adherent cells were removed, 
washed and reseeded in fresh media containing GM-CSF and vehicle or TCDD. On day 6 
- 7 non-adherent BMDCs were harvested, enumerated and cell viability assessed using 
Trypan Blue (Sigma-Aldrich). CD11c+ DCs were purified using magnetic separation 
techniques to ≥ 95% with CD11c-MicroBeads and an autoMACS Cell Separator, 
Miltenyi Biotec Inc. (Auburn, CA). Unless specified, BMDCs were grown in the 
presence of 10nM TCDD or vehicle control (0.01% DMSO), treatments that caused no 
significant effects on BMDC viability (data not shown). For 24h exposure experiments, 
BMDCs were grown in GM-CSF supplemented media without vehicle or AhR agonists. 
On day 6, the BMDCs were harvested, purified and cultured in the presence of Ova 
peptide and vehicle (0.01% DMSO), TCDD (10nM), ITE (100nM) or Dexamethasone 
(1µM) for 24h. 
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Flow Cytometry BMDCs and T cells were analyzed by flow cytometry as described 
previously (Shepherd et al., 2001). Briefly, 1x105 - 1x106 cells were washed with PBS 
containing 1% bovine serum albumin and 0.1% NaN3 and resuspended in Fc block, anti-
CD16/CD23 antibody generated and purified from 2.4G2 hybridoma cells, to block non-
specific binding. The cells were then stained with fluorochrome-conjugated antibodies 
for 10-15min on ice. Appropriate isotype controls were used in conjunction with the 
primary antibody staining. Intracellular IL-10 cytokine levels were assessed following 
paraformaldehyde fixation and 100% methanol or 0.1% saponin permeabilization. 
Intracellular Foxp3 staining with OTII Thy1.1 CD4+ T cells was performed using a 
mouse Treg Flow Kit from BioLegend, following manufacturer’s instructions. The 
following antibodies were used for DCs: MHC class II-PE (M5/114.15.12), CD80-PE 
(16-10A1), CD86-Pacific Blue (GL-1) from BioLegend; and CD11c-APC (HL3), CD54-
FITC (3E2), CD11a-PECy7 (2D7) from BDPharmingen (San Diego, CA) and for T cells: 
CD4 APC, AF700 or Pacific Blue (GK1.5), CD25 APC or PerCpCy5.5 (PC61) and Vα2 
PE (B20.1) from BioLegend. All samples were analyzed on a FACSAria flow cytometer 
using BD FACS Diva software, version 4.0 (BD Biosciences San Jose, CA). Figures 
were generated using FlowJo, version 8.8.6 (Tree Star Inc, Ashland OR).  
 
DC:CD4+ T cell Co-cultures CD4+ T cells from the spleen and popliteal and brachial 
lymph nodes of OTII Foxp3eGFP or OTII Thy1.1 mice were purified to ~75% CD4+ using 
an autoMACS Cell Separator and a CD4+ T cell isolation kit according to the 
manufacturer’s instructions (Miltenyi Biotec Inc.). To obtain naïve CD4+ CD25- Foxp3- 
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T cells, enriched CD4+ T cells from OTII Foxp3eGFP mice were stained for CD4 and 
CD25 expression and naïve CD4+ CD25- Foxp3- T cells were FACS-purified (≥ 99%) 
using a FACSAria flow cytometer (BD Biosciences). CD11c+ BMDCs from Vehicle or 
AhR-activated cultures were cultured with ova-peptide (Ovap) (2 - 50µg/mL) for 2h-24h. 
For 24h exposures, CD11c+ BMDCs were cultured with Ovap concurrently with Vehicle, 
TCDD, ITE or Dexamethasone. After Ovap-loading, BMDCs were washed 2X and 
placed with enriched OTII+ CD4+ T cells or FACS-purified naïve OTII+ CD4+ CD25- 
Foxp3- T cells at a DC:T cell ratio of 1:5 in 96-well flat bottom plates in cRPMI only 
(Media Only) or cRPMI supplemented with 100 U/mL IL-2 and 5ng/mL TGFβ1 (+IL-
2/TGFβ). As a control enriched OTII+ CD4+ T cells or FACS-purified naïve OTII+ CD4+ 
CD25- Foxp3- T cells were stimulated with plate-bound anti-CD3/anti-CD28 in 96 well 
plates that were coated with 5µg/mL anti-CD3 and 5µg/mL anti-CD28 overnight at 4oC. 
The DC:enriched OTII+ CD4+ T cell and DC:FACS-purified naïve OTII+ CD4+ CD25- 
Foxp3- T cell co-cultures were harvested on day 3 and day 5, respectively, and the 
frequency of CD4+ CD25+ Foxp3eGFP T cells determined by flow cytometry. CD4+ T cell 
proliferation was analyzed in DC:FACS-purified naïve OTII CD4+ CD25- Foxp3- T cell 
co-cultures with naïve CD4+ T cells labeled with Cell Trace Violet Dye (Invitrogen) on 
day 0, following manufacturer’s instructions. 
 
Cytokine Measurement Supernatants from individual DC:T cell co-culture experiments  
were collected and stored at -20oC until further analysis. IL-2, IL-6, IL-10 and IFNγ 
cytokine production was measured using ELISAs per the manufacturer’s instructions (BD 
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Biosciences). IL-17, IL-22, and TGFβ1 and TGFβ3 levels were measured using ELISAs 
from R&D Systems (Minneapolis, MN) according to manufacturer’s instructions. 
 
Quantitative Real-Time Reverse Transcription-polymerase Chain Reaction (qRT-
PCR) To determine the levels of gene expression in BMDCs, qRT-PCR studies were 
conducted as previously described (Bankoti et al., 2010b). BMDCs were harvested on 
day 6-7, washed twice in PBS and resuspended in Trizol (Invitrogen) to isolate RNA. 
Primers for indoleamine 2,3-dioxygenase 1 (Ido1) and Ido2, aldehyde dehydrogenase 
family 1, subfamily A2 (Aldh1a1) and Aldh1a2, Arginase (Arg1), branched chain 
aminotransferase 1, cytosolic (Bcat1), histidine decarboxylase (Hdc), Il-4 induced protein 
(Il4i1), L-threonine dehydrogenase (Tdh), transforming growth factor β1 (Tgfβ1), Tgfβ2 
and Tgfβ3, transforming growth factor beta receptor II (TgfβRII), aryl hydrocarbon 
receptor (Ahr), aryl hydrocarbon receptor repressor (Ahrr), Cyp1a1, Il-6, Il-10, Il-27 and 
suppressor of cytokine signaling 1 (SOSC1) and SOCS3 were purchased from 
SABiosciences (Frederick, MD). mRNA levels were determined using SYBR green in 
qRT-PCR reactions (SABiosciences) on a BIO-RAD IQ 5 Light Cycler (BIO-RAD; 
Hercules, CA).  
 
Statistical Analysis Student’s t tests were used to compare two individual samples and 
fold changes. One-way analysis of variance (ANOVA) was used to analyze data with 
more than two groups, with Bonferroni post-hoc analysis. p values ≤ 0.05 were 
considered significant. 
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RESULTS 
CD4+ T cells proliferate normally following activation with AhR-activated DCs 
In response to appropriate signals provided by stimulatory DCs, CD4+ T cells 
become activated and clonally expand. Interactions with tolerogenic DCs, however, can 
dampen CD4+ T cell activation and inhibit proliferation. To determine if TCDD-DCs 
were providing requisite signals for T cell expansion, the proliferative capacity of OTII+ 
CD4+ T cells was assessed in DC:T cell co-cultures. Antigen-specific CD4+ T cells 
expanded in response to Ovap-loaded DCs as compared to DCs without antigen (Figure 
3.1A). On day 3, in DC:T cell co-cultures with enriched CD4+ T cells, the number of 
CD4+ T cells was similar between Veh- and TCDD-DC:T cell groups, whether in media 
alone or media supplemented with IL-2/TGFβ (Figure 3.1A). Similarly, there was no 
significant difference in Veh-DC and TCDD-DC induced CD4+ T cell expansion in co-
cultures with FACS-purified naïve CD4+ T cells on day 5 (Figure 3.1B). Moreover, DCs 
exposed to TCDD or ITE for 24h with concurrent Ovap-loading induced OTII+ CD4+ T 
cell expansion similar to that of Ovap-loaded Veh-DCs. In contrast, DCs treated with 
dexamethasone (Dex) significantly decreased CD4+ T cell expansion, as assessed by the 
decreased number of cells on day 5 in DC:T cell co-cultures with FACS-purified naïve 
CD4+ T cells (Figure 3.1C). Furthermore, in DC:T cell co-cultures with FACS-purified 
naïve CD4+ T cells labeled with Cell Trace Violet dye to track T cell proliferation no 
significant differences were observed between Veh-DC and TCDD-DC groups relative to 
CD4+ T cell proliferation or the ratio of division (Figure 3.1D). In this experiment, only 
Dex-treated DCs altered T cell proliferation was observed with Dex-DCs (Figure 3.1E). 
CD4+ T cells proliferated normally in cultures with DCs exposed to TCDD or ITE for 
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24h and no changes in overall proliferation or the frequency of cells in cycle was noted 
when these two groups where compared to the Veh-DC:T cell group (Figure 3.1E).  
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Figure 3.1 
 
 
 
Figure 3.1.  CD4+ T cell proliferation in DC:CD4+ T cell co-cultures. (A) DCs were 
cultured with enriched OTII+ CD4+ T cells in 96-well plates. Co-cultures were harvested 
and enumerated on day 3. (B and C) DCs were cultured with naïve OTII+ CD4+ CD25- 
Foxp3eGFP- T cells which were harvested and enumerated on day 5. Cell proliferation was 
determined on day 5 in DC:T cell co-cultures with Violet-dye labeled naïve CD4+ T cells 
(D and E). (D) Solid gray line represents Vehicle-DCs and dashed black line TCDD-DCs, 
(E) Solid gray line represents Vehicle-DCs, heavy dashed black line TCDD-DCs, dashed 
line ITE-DCs and solid black line Dex-DCs. Data are representative of (A) five and (B-E) 
two independent experiments with n = 3 – 4. * p ≤ 0.05 indicates significant difference 
between Vehicle- and Dex-treated DC:CD4+ T cell groups. # p ≤ 0.05 indicates 
significant difference between DC:CD4+ T cells with no antigen and Ovap-loaded 
DC:CD4+ T cell groups. 
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AhR-activated DCs alter CD4+ T cell effector cytokine responses 
AhR activation can directly disrupt CD4+ T cell differentiation and subsequent 
cytokine production following T cell activation (Kerkvliet et al., 1996; Quintana et al., 
2008b; Mezrich et al., 2010). However, it is unclear whether CD4+ T cell responses are 
affected following antigen-specific interactions and activation with AhR-activated DCs. 
To better understand how AhR-activated DCs influence antigen-specific T cell responses, 
BMDCs grown in the presence of Vehicle, TCDD or BaP were Ovap-loaded and cultured 
with Ova-specific OTII+ CD4+ T cells and cytokine production measured as a readout of 
the CD4+ T cell effector response. It is important to note that no AhR ligands, other than 
what may be produced by the DCs in the DC:T cell co-cultures, were present in the co-
cultures, thus, any AhR-induced alterations on the CD4+ T cell response are due solely to 
the DC. In DC:T cell co-cultures with enriched CD4+ T cells, ~ 60 – 85% OTII+ CD4+ T 
cells, IL-2 levels were significantly increased in co-cultures with TCDD- or BaP-DCs 
(Figure 3.2A). IFNγ and IL-10 levels were significantly decreased in co-cultures with 
AhR-activated DCs when compared to Veh-DC:T cell co-cultures (Figure 3.2A). TGFβ1 
and TGFβ3 levels were below detection in the DC:T cell co-cultures (data not shown). 
The pattern of increased IL-2 and decreased IFNγ and IL-10 production was observed in 
TCDD- and BaP-DC:T cell co-cultures with FACS-purified OTII+ CD4+ CD25- 
Foxp3eGFP- naïve T cells (Figure 3.2B). Altered cytokine responses were observed in 
nearly all Veh- and TCDD-DC co-culture experiments (Appendix Table A.4). However, 
DCs exposed to either TCDD or ITE for 24h failed to alter IL-2 or IFNγ production in 
DC:FACS-purified OTII+ CD4+ CD25- Foxp3eGFP- T cell co-cultures, while IL-10 levels 
were decreased when compared to Veh-DC:T cell co-cultures. In contrast, Dex-DCs 
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significantly decreased IL-2 levels, while having no effect on IFNγ or IL-10 production 
(Figure 3.2C). Similar changes in cytokine levels were seen in DC:T cells cultured in IL-
2/TGFβ supplemented media (Figure 3.2). 
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Figure 3.2 
 
 
 
 
 
 
 
Figure 3.2.  Cytokine levels in DC:CD4+ T cell co-cultures. (A) DCs were cultured with 
~80% pure CD4+ T cells enriched from OTII Foxp3eGFP reporter mice and harvested on 
day 3. (B and C) DCs were cultured with ~99% naïve CD4+ CD25- Foxp3- T cells from 
OTII Foxp3eGFP reporter and harvested on day 5. IL-2, IFNγ and IL-10 levels in culture 
supernatants determined by ELISA. Data are representative of (A) five (B), three and (C) 
two independent experiments with n = 3 – 4. * p ≤ 0.05 indicates significant difference 
between Vehicle and AhR-activated groups. 
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TCDD-induced AhR activation induces immunoregulatory genes in inflammatory 
BMDCs 
 Previously, TCDD-induced AhR activation has been shown to induce both IDO1 
and IDO2 gene expression in inflammatory BMDCs (Table 2.1) (Bankoti et al., 2010b). 
IDO mediates tryptophan catabolism and increased expression can alter immune 
responses (Mellor and Munn, 2004; Vogel and Matsumura, 2009). To determine if 
additional amino acid metabolizing enzymes are affected following AhR activation, 
Arginase (Arg1), Bcat1, Hdc, Il4i1, and Tdh mRNA levels were measured in TCDD-
treated BMDCs (TCDD-DCs). Arginase gene expression was significantly up-regulated 
in TCDD-DCs, while there were no changes in Bcat1, Il4i1 and Tdh expression when 
compared to Vehicle-treated BMDCs (Veh-DCs) (Table 3.1). In contrast to IDO, Hdc 
gene expression was significantly reduced in TCDD-DCs. AhR activation with ITE in 
BMDCs has been shown to increase Aldh1a1 gene expression and contribute to retinoic 
acid production (Quintana et al., 2010). However, TCDD-induced AhR activation failed 
to increase Aldh1a1, however, Aldh1a2 expression was significantly up-regulated in 
TCDD-DCs (Table 3.1, Appendix Table A.5). TCDD-induced AhR activation has also 
been shown to increase TGFβ3 expression in inflammatory BMDCs (Bankoti et al., 
2010b). However, TGFβ1 and TGFβ2 gene expression in inflammatory BMDCs is 
relatively unaffected, where as TGFβ receptor II (TGFβRII) gene expression is 
significantly decreased following growth in TCDD (Table 3.1). In addition to producing 
TGFβ, tolerogenic DCs secrete various cytokines to help polarize T cell effector 
responses. Therefore, IL-6, IL-10 and IL-27 gene expression was determined in Veh- and 
TCDD-DCs. TCDD did not affect BMDC IL-6, IL-10 or IL-27 gene expression, although 
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there was trend towards increased IL-6 expression (Table 3.1). As expected, there was a 
significant increase in the expression of prototypical AhR-inducible genes CYP1A1 and 
AhRR in TCDD-DCs (Table 3.1).  
Environmental pollutants other than TCDD, such as BaP, have also been shown to 
alter DC gene expression (Hwang et al., 2007; Lee et al., 2007). Similar to TCDD, 
inflammatory BMDCs derived in the presence of BaP displayed significant increases in 
IDO1 and IDO2, as well as characteristic CYP1A1 gene expression when compared to 
Veh-DCs (Table 3.1). However, BaP failed to induce TGFβ3 gene expression and 
significantly down-regulated Aldh1a2 expression (Table 3.1). BaP-induced AhR 
activation in BMDCs did not alter IL-6, IL-10, or IL-27 gene expression (Table 3.1). 
The induction of IDO is highly sensitive to AhR activation. For example, 
immature CD11c+ BMDCs exposed to TCDD or ITE for 24h significantly up-regulated 
both IDO1 and IDO2 gene expression (Table 3.1). There was no induction of IDO in 
immature CD11c+ BMDCs exposed to the glucocorticoid Dex for 24h. In fact, IDO2 
gene expression was significantly down-regulated in Dex-DCs (Table 3.1). The induction 
of TGFβ3 was less sensitive than IDO in 24h exposure experiments, as only Dex 
exposure induced TGFβ3 to appreciable levels (Table 3.1). 24h exposure to TCDD, ITE 
or Dex significantly decreased the gene expression of IL-6 and IL-10 in immature 
BMDCs. Similar to growth in TCDD or BaP, 24h exposure to TCDD or ITE significantly 
up-regulated CYP1A1 gene expression in immature BMDCs (Table 3.1). Unexpectedly, 
24h exposure to Dex caused a significant increased in CYP1A1 gene expression.   
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AhR-activated DCs effect the generation of regulatory T cells 
Recently it has been shown that AhR activation with TCDD can lead to the 
generation of Tregs during inflammatory autoimmune responses (Quintana et al., 2008b). 
In addition, exposure to ITE was shown to generate tolerogenic DCs capable of inducing 
Tregs and dampening EAE pathology (Quintana et al., 2010). However, it is unknown 
whether TCDD-induced AhR activation in DCs leads to the generation of tolerogenic 
DCs that are capable of inducing Tregs. To address this question, the induction of Foxp3+ 
Tregs was followed in DC:T cell co-cultures with CD4+ T cells isolated from OTII 
Foxp3eGFP reporter mice (Fontenot et al., 2005). On day 3, there was a slight, albeit 
significant, increase in the overall frequency of CD4+ CD25+ Foxp3eGFP+ Tregs in DC:T 
cell co-cultures with antigen-specific enriched CD4+ T cells (Figure 3.3A). The percent 
Treg increase with TCDD-DCs was observed in media alone as well as in cultures 
containing optimal Treg induction conditions with IL-2/TGFβ supplemented media 
(Figure 3.3B). Interestingly, this effect on TCDD-treated inflammatory BMDCs was not 
consistently inducible over all experiments (Table 3.2; Appendix Table A.1). In total, 17 
Veh- and TCDD-DC:T cell co-culture experiments of similar design including enriched 
OTII+ CD4+ T cells that contained both naïve CD4+ T cells and natural Treg populations 
were conducted and the frequency of Tregs analyzed on day 3 to 4. The purity of the 
OTII+ CD4+ T cells in these cultures varied between 59 and 88%. Out of these 17 
experiments, 6 displayed significant increases in the percent of CD4+ CD25+ Foxp3+ 
Tregs with TCDD-DCs when compared to Veh-DC:T cell co-cultures, while 4 displayed 
a significant reduction in the percent of CD4+ CD25+ Foxp3+ Tregs (Appendix Table 
A.1). In the remaining 7 experiments there was no significant difference in the frequency 
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of Tregs induced on day 3 or 4 between Veh-DC and TCDD-DC groups (Appendix Table 
A.1). Throughout the course of these experiments different conditions such as the 
addition of TCDD, kynurenine or anti-IL-6 into the DC:T cell co-cultures were included 
to evaluate the potential for TCDD-DCs to induce Foxp3+ Tregs. However, only the 
addition of kynurenine was observed to induce Foxp3+ Tregs in TCDD-DC:T cell co-
cultures when compared to kynurenine Veh-DC:T cell co-cultures (Appendix Table A.1). 
Surprisingly, DCs grown in the presence of increasing concentrations of TCDD (10, 50 
and 100nM) and LPS-stimulated or TGFβ1-treated TCDD-DCs failed to significantly 
increase Foxp3+ Tregs in DC:T cell co-cultures when compared to control Veh-DC:T cell 
groups (Appendix Table A.1). BMDCs grown in the presence of BaP displayed similar 
Treg induction capacities as BMDCs grown in the presence of TCDD (Appendix Table 
A.2). 
Although the induction of Tregs with TCDD-DCs was somewhat inconsistent, we 
investigated potential mechanisms by which TCDD-DCs were inducing Tregs. To 
determine if the induction of Tregs by TCDD-treated BMDCs was dependent upon IDO 
or TGFβ, we performed blocking studies with 1-methyltryptophan (1-MT) or anti-TGFβ 
(α-TGFβ) blocking antibody, respectively. In two independent experiments with 1-MT 
and α-TGFβ, there was no significant increase in the percent of CD4+ CD25+ Foxp3+ 
Tregs with TCDD-DCs on day 3 in media only (Appendix Figure A.2). However, there 
was an increase in the number of CD4+ CD25+ Foxp3+ Tregs in TCDD-DC media only 
conditions and in the presence of either 1-MT or α-TGFβ there was no change in the 
number of CD4+ CD25+ Foxp3+ Tregs when compared to Veh-DC:T cell controls 
(Appendix Figure A.2). 
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To alleviate any inconsistencies in DC:T cell co-cultures with enriched CD4+ T 
cells, which contained a small fraction of cells that were not CD4+, and to determine 
whether AhR-activated DCs were capable of generating iTregs, DCs were cultured with 
FACS-purified naïve CD4+ CD25- Foxp3- T cells from OTII Foxp3eGFP reporter mice. In 
these cultures, increases in Foxp3+ Tregs would be attributable exclusively to iTregs and 
not via an expansion of nTregs. In these DC:T cell co-cultures TCDD-DCs failed to 
induce a significant percent of iTregs in media alone or with IL-2/TGFβ when compared 
to Veh-DC:T cell co-cultures on day 5 (Figure 3.4). In three independent experiments, 
two displayed no changes in the percent and number of iTregs induced by TCDD-DCs, 
while one experiment displayed a small but a significant increase in the percent of iTregs 
with TCDD-DC:T cells in the presence of IL-2/TGFβ when compared to Veh-DC:T cell 
co-cultures controls (Table 3.2 and Appendix Table A.1).  
To determine if immature DCs exposed to AhR ligands become tolerogenic as 
reported by Quintana et. al., immature BMDCs on day 6 were purified and cultured with 
Ovap in the presence of Veh, TCDD, ITE or Dex. The Ovap-loaded, AhR agonist-treated 
DCs were harvested after 24h in culture, washed and cultured with FACS-purified naïve 
CD4+ CD25- Foxp3- T cells. In these co-cultures neither TCDD-DCs nor ITE-DCs 
induced iTregs on day 5 when compared to Veh-DC:T cell co-cultures (Figure 3.5). 
Under optimal Treg generation conditions with IL-2/TGFβ both TCDD-DCs and ITE-
DCs caused a significant reduction in the percent of iTregs present on day 5 (Figure 
3.5B).  
Overall, the induction of antigen-specific Tregs in TCDD-DC:T cell co-cultures 
with OTII+ CD4+ T cells from OTII Foxp3eGFP reporter mice was observed, but with 
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inconsistent reproducibility (Appendix Table A.3). On the other hand, in a separate 
experiment utilizing Veh- and TCDD-DCs generated from Balb/c mice and Ovap-
specific CD4+ T cells from DO11.10 mice, a significant increase in the percent of CD4+ 
CD25+ Foxp3+ T cells was observed on day 5 as determined by intracellular Foxp3 
staining (Appendix Figure A.1). 
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Figure 3.3 
 
 
 
 
Figure 3.3.  CD4+ CD25+ Foxp3+ Treg generation in DC:T cell co-cultures. Vehicle-DC 
and TCDD-DCs were co-cultured with enriched OTII+ CD4+ T cells and the frequency of 
CD4+ CD25+ Foxp3+ Tregs in (A) media alone or (B) media supplemented with IL-
2/TGFβ assessed on day 3. (C) Plate-bound anti-CD3/CD28 stimulation controls with 
enriched OTII+ CD4+ T cells in media only or IL-2/TGFβ supplemented media. * p ≤ 
0.05 indicates significant difference between Vehicle-DC:T cell and TCDD-DC:T cell 
groups. # p ≤ 0.05 indicates significant difference between anti-CD3/CD28 stimulated 
CD4+ T cells in media alone and IL-2/TGFβ supplemented media. 
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Figure 3.4 
 
 
 
Figure 3.4.  CD4+ CD25+ Foxp3+ iTreg generation in DC:T cell co-cultures. Vehicle-DC 
and TCDD-DCs were co-cultured with FACS-purified naïve OTII+ CD4+ CD25- 
Foxp3eGFP- T cells and the percent of iTregs in (A) media alone or (B) media 
supplemented with IL-2/TGFβ assessed on day 5. (C) Plate-bound anti-CD3/CD28 
stimulated FACS-purified OTII CD4+ T cells in media only or media supplemented with 
IL-2/TGFβ. * p ≤ 0.05 indicates significant difference between Vehicle-DC:T cell and 
TCDD-DC:T cell groups. # p ≤ 0.05 indicates significant difference between CD4+ T cell 
anti-CD3/CD28 stimulation in media alone and media with IL-2/TGFβ. 
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Figure 3.5 
 
 
 
Figure 3.5.  CD4+ CD25+ Foxp3+ iTreg generation with 24h Vehicle-, TCDD-, ITE- or 
Dex-exposed DCs. 24h-exposed Ovap-DCs were co-cultured with FACS-purified naïve 
OTII+ CD4+ CD25- Foxp3eGFP- T cells and the percent of iTregs in (A) media alone or (B) 
media supplemented with IL-2/TGFβ assessed on day 5. CD4+ T cells in DC:T cell co-
cultures displayed as: Vehicle-DCs (solid gray), TCDD-DCs (solid line), ITE-DCs 
(dotted line), and Dex-DCs (long dashed line). (C) Plate-bound anti-CD3/CD28 
stimulated FACS-purified OTII CD4+ T cells in media only or media supplemented with 
IL-2/TGFβ. * p ≤ 0.05 indicates significant difference between Vehicle-DC:T cell and 
exposed-DC:T cell groups. # p ≤ 0.05 indicates significant difference between CD4+ T 
cell anti-CD3/CD28 stimulation in media alone and media with IL-2/TGFβ. 
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iTregs generated in TCDD-DC:CD4+ T cell co-cultures are suppressive 
Because of the potential for TCDD-treated inflammatory BMDCs to induce 
Foxp3+ Tregs, albeit inconsistently, it was necessary to evaluate the suppressive capacity 
of Tregs induced by TCDD-DCs when compared to Veh-DCs. Therefore, the suppressive 
capacity of iTregs generated in both Veh- and TCDD-DC:T cell co-cultures was 
determined. CD4+ CD25+ Foxp3+ iTregs were FACS-purified from DC:T cell co-cultures 
on day 5 and placed into fresh cultures with FACS-purified Cell Trace-labeled naïve 
CD4+ T cells (T responder cells) in the presence of anti-CD3/CD28. iTregs from TCDD-
DC:T cell co-cultures slightly, but significantly inhibited the proliferation of responder 
CD4+ T cells when compared to iTregs from Veh-DC:T cell co-cultures (Figure 3.6). 
However, CD4+ Foxp3- T cells from TCDD-DC:T cell co-cultures displayed a similar 
capacity to suppress responder T cell proliferation (Figure 3.6).  
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Figure 3.6 
 
 
Figure 3.6.  Treg suppressive capacity. iTregs (Tregs) generated and purified on day 5 
from Vehicle-DC and TCDD-DC:T cell co-cultures with FACS-purified naïve CD4+ T 
cells and placed with fresh naïve CD4+ T cell responders (Tresp) at a 1:1 Treg:Tresp 
ratio. CD4+ Foxp3- T cells purified from DC:T cell co-cultures were also placed with 
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Tresp. Tresp proliferation was assessed on day 4. * p ≤ 0.05 indicates significant 
difference between Vehicle-DC:T cell and TCDD-DC:T cell groups.  
AhR-activated DCs do not generate Tr1 regulatory T cells 
Another possible outcome following the co-culture of TCDD-DCs with OTII+ 
CD4+ T cells is that instead of classical CD4+ CD25+ Foxp3+ Treg induction, Tr1 
regulatory cells may be induced. To assess this possibility, DC:T cell co-cultures were 
generated using with OTII+ CD4+ cells from OTII mice and the induction of CD4+ IL-10+ 
T cells in Veh- and TCDD-DC:T cell co-cultures was determined by intracellular 
staining. There was no induction of CD4+ IL-10+ T cells in either Veh- or TCDD-DC:T 
cell co-cultures. In contrast, anti-CD3/CD28 stimulated CD4+ T cell controls did induce 
CD4+ IL-10+ T cells (Figure 3.7). Moreover, the addition of IL-27, which has been 
demonstrated to induce Tr1 cells in an AhR-dependent fashion, failed to induce 
appreciable levels of CD4+ IL-10+ T cells in our DC:T cell co-cultures (Appendix Table 
A.3) (Apetoh et al., 2010).  
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Figure 3.7 
 
Figure 3.7.  Generation of CD4+ IL-10+ T cells in DC:T cell co-cultures. Vehicle-DC and 
TCDD-DCs were co-cultured with enriched OTII+ CD4+ T cells and the percent of CD4+ 
IL-10+ T cells assessed on day 3.  
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DISCUSSION  
Exposure to the prototypical AhR ligand and environmental pollutant TCDD is 
well known to cause immune suppression in various animal models (Harris et al., 1973; 
Kerkvliet, 2002). However, the exact mechanisms underlying TCDD-induced immune 
suppression remain unclear. DCs are professional antigen presenting cells that are 
imperative to T cell activation and polarization. DCs also express high levels of the AhR, 
making them sensitive targets to environmental pollutants capable of activating the AhR. 
In previous studies we have characterized the effects of TCDD-induced AhR activation in 
inflammatory BMDCs (Bankoti et al., 2010b; Simones and Shepherd, 2011). In these 
studies it was demonstrated that AhR activation disrupted BMDC differentiation in an 
AhR-dependent fashion assessed by altered CD11c, MHC II, CD86, CD54 and CD11a 
surface molecule expression (Bankoti et al., 2010b; Simones and Shepherd, 2011). 
Furthermore, immature inflammatory BMDCs exposed to TCDD displayed unique 
changes in gene expression of known immune regulatory proteins (Bankoti et al., 2010b; 
Simones and Shepherd, 2011). Inflammatory DCs were especially sensitive to TCDD-
induced gene alterations, as IDO1 and IDO2 expression was increased more than 20-fold 
over Vehicle-BMDC expression (Bankoti et al., 2010b). TGFβ3 expression was also 
significantly up-regulated following TCDD exposure in inflammatory BMDCs (Bankoti 
et al., 2010b). The significant increases in IDO1, IDO2 and TGFβ3 coupled with the 
changes in surface molecule expression made TCDD-treated inflammatory BMDCs ideal 
candidates to test whether AhR-activated DCs could alter CD4+ T cell responses in vitro. 
There was little difference in the proliferative capacity of OTII+ CD4+ T cells in 
response to Ovap-loaded AhR-activated DCs or Vehicle-DCs. As expected, DCs exposed 
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to the glucocorticoid dexamethasone did inhibit CD4+ T cell proliferation. While the 
proliferative capacity of CD4+ T cells was unaffected, there were significant changes in 
the cytokines produced by Veh- and TCDD-DC-activated CD4+ T cells, with increased 
IL-2 and decreased IFNγ and IL-10 levels being the typical pattern (Appendix Table 
A.4). These data suggest that TCDD-DCs may directly effect CD4+ effector T cells and 
alter the course of an immune response. While IL-2 in association with TGFβ causes the 
generation of Tregs, IL-2 by itself can help drive the expansion of Th1 and Th2 cells as 
well as initiate activation induced cell death (AICD) in T cells (Liao et al., 2011). The 
later effect of IL-2, AICD, may not be pertinent in our DC:T cell co-cultures as there was 
no difference in the number of viable CD4+ T cells between Veh-DC and TCDD-DC 
groups, even though IL-2 levels were significantly increased in TCDD-DC:T cell co-
cultures. The observed effects on IL-2 production in DC:T cell co-cultures with TCDD-
DCs may be an indirect effect through AhR activation in the CD4+ T cells by kynurenine 
produced in the DC:T cell co-cultures. IL-2 contains a number of DREs in its 
promoter/enhancer region and its production is increased in T cells following AhR 
activation in various model systems (Kerkvliet, 2009). To explain the reduction in IFNγ 
and/or IL-10 levels in TCDD-DC:T cell co-cultures, suppressor of cytokine signaling 
(SOCS) gene expression was measured in CD4+ Foxp3- T cells from Veh- and TCDD-
DC:T cell co-cultures on day 5 (data not shown). However, there were no changes in 
either SOCS1 or SOCS3 expression in the purified CD4+ Foxp3- populations expanded 
by Veh- or TCDD-DCs (data not shown). Thus, mechanisms underlying the increased 
production of IL-2 and decreased production of INFγ and IL-10 by CD4+ T cells 
following antigen-specific stimulation with TCDD-DCs remain to be elucidated.    
 143 
Recently, TCDD-induced AhR activation has been shown to play a role in the 
polarization of regulatory T cells (Quintana et al., 2008b; Mezrich et al., 2010; Quintana 
et al., 2010). The generation of Tregs may be an important consequence of AhR 
activation and may underlie the immunosuppressive effects of TCDD. It is possible that 
in our DC:T cell co-culture system that the altered cytokine levels are due to increases in 
Foxp3+ Tregs that are subsequently altering the CD4+ effector T cell response. We did 
observe an increase in Foxp3+ Tregs in TCDD-DC:CD4+ T cell co-cultures; however,  we 
often observe inconsistent induction of Foxp3+ Tregs. There are a number of explanations 
that may have contributed to the inconsistent Foxp3+ Tregs readout. First, as compared to 
steady-state DCs, inflammatory DCs while being highly responsive to TCDD, via AhR 
activation, may not fully differentiate into tolerogenic DCs due to their inherent 
programming as inflammatory cells. However, others have shown that AhR activation in 
inflammatory BMDCs with ligands other than TCDD (ITE, I3C and Indirubin) 
effectively induces Foxp3+ Tregs in vitro (Quintana et al., 2010; Benson and Shepherd, 
2011). Therefore, it is likely that ligand-specific AhR effects exist relative to the 
generation of functionally tolerogenic DCs. Second, the Ova-specific OTII model may be 
less sensitive than other immune models for the generation of Foxp3+ Tregs. For 
example, recent studies have reported significant induction of Foxp3+ Tregs in a myelin 
oligodendrocyte glycoprotein (MOG)-specific 2D2 CD4+ T cell model using ITE-treated 
inflammatory BMDCs (Quintana et al., 2010). However, we were unable to replicate 
these results with ITE-treated inflammatory BMDCs using the Ova-specific DC:T cell 
model, suggesting that inherent differences may exist in the generation of Foxp3+ Tregs 
between these antigen-specific DC:T cell models in vitro. It is also possible that there are 
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strain-specific differences. For example, when DC:T cell co-cultures were set up using 
inflammatory BMDCs from Balb/c mice and Ovap-specific CD4+ T cells from DO11.10 
mice, we observed a significant increase in the percent of CD4+ CD25+ Foxp3+ Tregs 
following intracellular staining (Appendix Figure A.5). Thus, further investigations into 
possible antigen- and strain-specific effects on the generation of Foxp3+ Tregs with 
TCDD-treated inflammatory BMDCs in vitro are warranted. Third, AhR-activated 
inflammatory BMDCs may not induce Foxp3+ Tregs, but rather generate Tr1 or Th3 type 
regulatory T cells. However, the induction of CD4+ IL-10+ Tr1 cells was not observed in 
our studies and little to no TGFβ1 or TGFβ3 was detected in the DC:T cell co-cultures 
containing AhR-activated inflammatory BMDCs. There remains the possibility that AhR-
activated BMDCs can also induce regulatory or suppressive T cells that are not Foxp3+, 
Tr1 or Th3-type Tregs. This is evident by the fact that in suppression assays CD4+ Foxp3- 
T cells from AhR-activated DC:T cell co-cultures had a similar suppressive capacity as 
CD4+ Foxp3+ Tregs. In addition, in a graft vs. host model, functional CD4+ CD25+ 
Foxp3- Tregs were generated following TCDD exposure rather than Foxp3+ Tregs 
(Funatake et al., 2005b; Marshall et al., 2008). Forth, both DCs and T cells may require 
TCDD-induced AhR activation for full commitment towards Tregs. While this scenario 
better emulates in vivo exposures, no increases were observed in the generation of Tregs 
when TCDD was present throughout the course of a 3 day DC:T cell co-culture 
experiment. Fifth, there may be a timing issue in the generation of Foxp3+ Tregs, in that 
AhR-activated BMDCs may induce Tregs in the first 24 to 48 hours in culture. These 
time points were not assessed in our DC:T cell co-cultures; however, due to the stability 
of Foxp3+ Tregs in the presence of IL-2 and TGFβ it is unlikely that Foxp3+ Tregs 
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generated in the initial 24 to 48 hours of the DC:T cell co-cultures would not be present 
on days 3 through 5 (time points that were assessed). Thus, it is unlikely that a temporal 
component exists for the detection and retention of Foxp3+ Tregs in DC:T cell co-
cultures utilizing AhR-activated BMDCs. Overall, it is likely that TCDD-treated 
inflammatory BMDCs can induce Foxp3+ Tregs in an antigen-specific fashion; however, 
further studies will need to address potential AhR ligand-, antigen- and stain-specific 
differences that may influence the generation of regulatory T cells in vitro. 
Another possible explanation for the observed TCDD-DC:Treg induction 
inconsistencies is that the effects of TCDD in BMDCs, i.e. changes in surface molecule 
expression and increases in regulatory gene expression, were different between 
experiments. However, in nearly all of the DC:T cell co-culture experiments we observed 
the standard TCDD-induced phenotypic surface marker alterations which consisted of 
decreases in CD11c, CD11a, CD54 and increased CD86 expression on a per cell basis 
(Appendix Table A.1). Moreover, there were minimal changes in expression of other 
markers thought to be associated with tolerogenic DCs such as CD103 and TGFβ in 
BMDCs exposed to TCDD (data not shown). In DC:T cell experiments in which gene 
expression was analyzed in Veh- and TCDD-DCs as a quality control measure, there was 
consistent up-regulation of IDO1, IDO2 and TGFβ in TCDD-DCs (Appendix Table A.5). 
There were changes, although inconsistent, in the expression of TGFβ1 and TGFβ2 as 
well as Aldh1a2 between experiments, with significant decreases in TGFβ1 and 
significant increases in TGFβ2 and Aldh1a2 observed from experiment to experiment 
(Appendix Table A.5). Furthermore, it is unclear whether any of these changes in gene 
expression translated into increased protein expression and/or protein activity. In one case 
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where protein levels of IDO and TGFβ1 and TGFβ3 were measured in Veh- and TCDD-
DCs, there was no significant change in their protein expression levels in TCDD-DCs 
when compared to Veh-DC (data not shown). While IDO gene expression may have been 
increased in TCDD-DCs there may be no difference in its ability to catalyze the 
breakdown of tryptophan between Veh- and TCDD-DCs. In addition, IDO activity in 
DCs has been shown to be dependent on the activation status of DCs, with IDO 
enzymatic activity achieved only after additional activation with TNFα or TLR ligands 
(Braun et al., 2005; Pallotta et al., 2011). However, LPS-stimulated BMDCs exposed to 
TCDD did not display a greater ability to induce Tregs than LPS-stimulated Veh-DCs or 
unstimulated Veh- or TCDD-DCs (Appendix Table A.1). Furthermore, natural levels of 
tryptophan in culture media have been shown to influence the generation of Tregs vs. 
Th17 cells and increased Treg induction has been observed in F10 media that lacks 
tryptophan (Veldhoen et al., 2009; Mezrich et al., 2010). However, there was no increase 
in the percent of Tregs generated following interactions with TCDD-DCs in F10 media in 
our DC:T cell co-culture system with inflammatory BMDCs (Appendix Table A.1). 
Taken together our data suggests that while inflammatory BMDCs exposed to TCDD 
significantly up-regulate immune regulatory gene expression, they are not always capable 
of generating Foxp3+ or Tr1 Tregs. 
In summary, we demonstrated that inflammatory AhR-activated BMDCs altered 
antigen-specific CD4+ T cell responses by affecting CD4+ effector T cell cytokine 
production. The altered cytokine levels may be attributed to the generation of Foxp3+ 
Tregs rather than Tr1 Tregs in TCDD-DC:T cell co-cultures. The inconsistent generation 
of Foxp3+ Tregs in our in vitro DC:T cell system may highlight the fact that there are 
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likely additional signals required for AhR-activated DCs to become tolerogenic and that 
the in vitro system lacks these additional signals or is too insensitive to detect to replicate 
the effects that occur in vivo.  
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ABSTRACT 
Environmental pollutants capable of activating the aryl hydrocarbon receptor 
(AhR) cause immunosuppression. AhR activation can induce regulatory T cells (Tregs), 
which may contribute to the observed immunosuppression. However, the mechanisms 
underlying Treg induction and immune modulation following AhR activation are unclear. 
We hypothesized that AhR activation by TCDD generates both regulatory dendritic cells 
(DCs) and Tregs in vivo. To determine if AhR-activation induces antigen-specific Tregs 
in vivo, CD4+ T cells isolated from OTII Foxp3eGFP mice were transferred iv into vehicle- 
or TCDD-exposed mice followed by footpad immunization with ovalbumin (ova) 
peptide-loaded bone marrow-derived BMDCs. The antigen-specific immune response in 
the draining popliteal lymph node was dampened in TCDD-exposed mice as determined 
by a reduction in the number of ova-specific CD4+ T cells and an increase in ova-specific 
CD4+ Foxp3+ Tregs. In addition, CD4+ T cells from the draining lymph node produced 
significantly less IL-2, IFNγ and IL-10 when restimulated with ova peptide. Similar 
results were observed in a second Ovap-specific model in which Vehicle- and TCDD-
exposed mice were immunized with Ovap in adjuvant and DCs and CD4+ T cells 
analyzed in the spleen and poptileal and brachial lymph nodes 10 days later. Overall, 
these results indicate that in vivo exposure to the prototypical AhR ligand, TCDD, 
induces both regulatory DCs and Foxp3+ Tregs, which contribute to the generation of an 
immunosuppressive environment.  
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INTRODUCTION 
It is well known that exposure to the environmental pollutant and prototypical aryl 
hydrocarbon receptor (AhR) ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) causes 
immune suppression in mice (Kerkvliet, 2002). Numerous studies have implicated 
TCDD-induced AhR activation in decreased antibody production, altered CD8+ and 
CD4+ T cell responses and disrupted dendritic cell (DC) fate and function, all of which 
ultimately lead to increased susceptibility to bacterial and viral infections in animal 
models (Kerkvliet et al., 1996; Sulentic et al., 2000; Vorderstrasse et al., 2003; Bankoti et 
al., 2010a). On the other hand, the immunosuppressive effects of TCDD have recently 
been demonstrated to dampen autoimmune disease responses in a murine model of 
multiple sclerosis, in which researchers uncovered that TCDD exposure causes the 
induction of Foxp3+ regulatory T cells (Tregs) (Quintana et al., 2008b). The 
immunosuppressive nature of TCDD may be at least in part due to its ability to induce 
Tregs. However, AhR activation with 6-formylindolo[3,2-b]carbazole (FICZ), an 
endogenous AhR ligand, can induce pro-inflammatory Th17 cells rather than Tregs 
during experimental autoimmune encephalomyelitis (EAE) in mice (Quintana et al., 
2008b; Veldhoen et al., 2008). In addition, AhR activation has been implicated in the 
control of Th17 cells that produce copious amounts of IL-22 (Veldhoen et al., 2008; 
Alam et al., 2010; Stockinger et al., 2011). Somewhat in contrast to studies, Kerkvliet 
and co-workers discovered a novel population of suppressive CD4+ CD25+ Foxp3- T cells 
that arose during graft vs. host responses in the presence of TCDD (Funatake et al., 
2005b). These in vivo studies have demonstrated that the AhR plays an integral role in 
CD4+ T cell polarization. However, is unclear whether AhR activation induces murine 
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Tregs or Th17 cells in models other than EAE or whether TCDD-exposure induces 
Foxp3- suppressor T cells in various antigen-specific immune response models. 
Here we show that TCDD exposure decreases antigen-specific CD4+ T cell 
responses in two separate murine models designed to better understand the role of AhR 
activation in both DCs and T cells and the subsequent generation of Tregs. First, we 
studied the effects of TCDD exposure during Ovalbumin-specific CD4+ T cell responses 
initiated by Ovalbumin peptide-loaded DCs transferred into host mice through the hind 
footpad. In this adoptive transfer model CD4+ T cell responses are decreased in mice 
exposed to TCDD and Tregs generated, but only when a mixed population containing 
Ovap-specific naïve CD4+ T cells and natural Treg populations are transferred into host 
mice prior to TCDD exposure. When purified Ovap-specific CD4+ CD25- Foxp3- 
populations are transferred into host mice, no iTregs are generated, although the localized 
CD4+ T cell response is decreased following TCDD exposure. Second, in a systemic 
Ovalbumin-specific adjuvant model, TCDD exposure decreased antibody production, 
reduced the number of splenic CD4+ T cells and CD11c+ MHC II+ DCs and increased the 
frequency of CD4+ CD25+ Foxp3+ Tregs in the spleen and lymph nodes. Moreover, 
TCDD-exposure in this model increased the frequency of iTregs generated from antigen-
specific naïve CD4+ CD25-Foxp3-.      
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MATERIALS AND METHODS 
Animals 6-8 week old male and female C57Bl/6 and CD45.1 mice were purchased from 
Jackson Laboratory (Bar Harbor, ME) and bred at the University of Montana. OTII 
Foxp3eGFP reporter mice were kindly provided by Dr. Randolph Noelle (Dartmouth 
Medical School, Lebanon, NH) who originally obtained these mice from Dr. Alexander 
Rudensky (University of Washington School of Medicine, Seattle, WA). All animals 
were housed and maintained at UM and provided water and chow ad libitum. All animal 
experiments were approved by the UM IACUC and adhered to the current NIH 
guidelines for animal usage. 
 
Chemicals and Reagents TCDD was purchased and supplied in anisole from Cambridge 
Isotope Laboratories (Andover, MA). Bone marrow-derived DCs (BMDCs) were grown 
in complete RPMI (cRPMI): 20mM HEPES, 1.5mM sodium pyruvate, 50ug/ml 
gentamicin and 10% fetal bovine serum (Hyclone Thermo Fisher Scientific Waltman, 
MA).  All other media reagents were obtained from Invitrogen (Carlsbad, CA). Ova-
peptide, Ova323-339, was obtained from Mimotopes (Clayton, Victoria Australia). 
Recombinant human IL-2 and TGFβ1 were purchased from Peprotech (Rocky Hill, NJ) 
and Biolegend (San Diego, CA). Violet Dye Cell Trace was purchased from Invitrogen. 
 
Flow Cytometry DCs and T cells were analyzed by flow cytometry as described 
previously (Shepherd et al., 2001). Briefly, 1x105 - 1x106 cells were washed with PBS 
containing 1% bovine serum albumin and 0.1% NaN3 and resuspended in Fc block, anti-
CD16/CD23 antibody generated and purified from 2.4G2 hybridoma cells, to block non-
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specific binding. The cells were then stained with fluorochrome-conjugated antibodies 
for 10-15min on ice. Appropriate isotype controls were used in conjunction with the 
primary antibody staining. Intracellular Foxp3 staining was performed using a mouse 
Treg Flow Kit from BioLegend, following manufacturer’s instructions. Antibodies 
utilized for DC sating: CD45.2 PerCpCy5.5 (30-F11), MHC class II-PE (M5/114.15.12), 
CD80-PE (16-10A1), CD86-Pacific Blue (GL-1), CD103 (2E7) from BioLegend; and 
CD11c-APC (HL3) and CD40 (3/23) from BDPharmingen (San Diego, CA). For T cell 
staining: CD45.2 PerCpCy5.5 (30-F11), CD4 APC, AF700 or Pacific Blue (GK1.5), 
CD25 APC or PerCpCy5.5 (PC61) and Vα2 PE (B20.1) from BioLegend. All samples 
were analyzed on a FACSAria flow cytometer using BD FACS Diva software, version 
4.0 (BD Biosciences San Jose, CA). Figures were generated using FlowJo, version 8.8.6 
(Tree Star Inc, Ashland OR).  
 
Bone Marrow-Derived Dendritic cells (BMDCs) BMDCs were generated using 
methods as previously described (Inaba et al., 1992; Bankoti et al., 2010b). Briefly, bone 
marrow cells from the tibia and femur were flushed using cRPMI. Progenitor cells were 
separated from RBCs and debris by centrifugation using lympholyte M (Cederlane 
Laboratories; Burlington, NC) and were grown in cRPMI supplemented with 30ng/mL 
granulocyte macrophage-colony stimulating factor (GM-CSF) purchased from PeproTech 
or Biolegend. On days 3 and 5, non-adherent cells were removed, washed and reseeded in 
fresh media containing GM-CSF. On day 6-7 non-adherent BMDCs were harvested, 
enumerated and cell viability assessed using Trypan Blue (Sigma-Aldrich). CD11c+ DCs 
were purified using magnetic separation techniques to ≥ 95% with CD11c-MicroBeads 
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and an autoMACS Cell Separator (Miltenyi Biotec Inc. Auburn, CA). CD11c+ BMDCs 
were loaded with 50µg/mL Ova-peptide (Ovap) in cRPMI for 2-24h. Ovap-loaded 
BMDCs were washed twice with cRPMI to remove excess Ovap and resuspended in 
Hanks balanced salt solution (HBSS) (Invitrogen). 
 
Ovap-DC Footpad Immunization Adoptive Transfer Model Antigen-specific Treg 
generation in vivo was assessed using an OTII adoptive transfer model as previously 
described (Bankoti et al., 2010b; Simones and Shepherd, 2011). Briefly, CD45.2+ OTII+ 
CD4+ T cells were isolated from the spleen and popliteal and brachial lymph nodes of 
OTII Foxp3eGFP reporter mice. OTII+ CD4+ T cells were enriched to ≥ 75% CD45.2+ 
OTII+ CD4+ with a CD4+ T cell Isolation kit and an autoMACS Cell Separator (Miltenyi 
Biotec Inc). Enriched OTII+ CD4+ T cells were washed, resuspended in HBSS and 1x106 
cells transferred into CD45.1 host mice intravenously. In separate experiments to assess 
the generation of iTregs, enriched OTII+ CD4+ T cells were further purified to ≥ 99% 
CD4+ CD25- Foxp3eGFP- via fluorescence cell activated cell sorting (FACS) with a 
FACSAria flow cytometer and CD24.2+ CD4+ CD25- Foxp3eGFP- T cells (1x106) 
transferred intravenously into CD45.1 host mice. 24h post-CD4+ T cell transfer, CD45.1 
host mice were gavaged with vehicle (anisole in peanut oil) or TCDD (15µg/kg). Ovap-
loaded CD45.2+ CD11c+ BMDCs were then injected (1x106 - 2x106) into each hind 
footpad of host mice 24h after vehicle and TCDD exposure. The popliteal and brachial 
lymph nodes were harvested 4-5 days post-BMDC immunization and the Ovap-loaded 
donor BMDCs (CD45.2+ CD11c+) and antigen-specific OTII+ T cell (CD45.2+ CD4+) 
populations analyzed by flow cytometry. One hundred thousand cells from the popliteal 
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lymph node were restimulated in 96-well plates with Ovap (100µg/mL) or with anti-CD3 
(5µg/mL) and anti-CD28 (5µg/mL) antibody-coated wells. 
 
Ovap Sigma Adjuvant System Model The generation of tolerogenic DCs and Tregs 
following TCDD exposure was assessed in an adjuvant-induced inflammatory model. 
CD45.1+ host mice were gavaged with vehicle or TCDD (15µg/kg). Twenty four hours 
post-vehicle and TCDD exposure, host mice were immunized i.p. with Ovap (1mg/mL) 
suspended in Sigma Adjuvant System following manufacturer’s instructions (Sigma 
Aldrich). Mice were euthanized 10 days post-immunization and blood, spleen and 
popliteal and brachial lymph nodes collected. Single cell suspensions were prepared from 
the spleen and combined popliteal and brachial lymph nodes and DC and CD4+ T cell 
phenotypes assessed by flow cytometry. Foxp3+ Tregs were quantified via intracellular 
Foxp3 staining. One hundred thousand cells from the spleen or lymph nodes were 
restimulated with Ovap (100µg/mL) or plate-bound anti-CD3 (5µg/mL) and anti-CD28 
(5ug/mL) and IL-2, IFNγ and IL-10 production assessed via ELISA. Splenic CD11c+ 
DCs were enriched using a mouse CD11c DC isolation kit according to manufacturer’s 
instructions (Invitrogen) and were further purified by FACS to a purity of 50-90% 
CD11c+. A fraction of purified DCs were used for qRT-PCR studies and the remainder 
were loaded with Ovap (50µg/mL) and cultured with enriched Violet Dye Cell Trace-
labeled OTII+ CD4+ T cells from naïve OTII Foxp3eGFP reporter mice in the presence of 
IL-2 (100U/mL) and TGFβ (5ng/mL). Splenic Ovap-DC:T cell co-cultures were 
harvested on day 5 and CD4+ T cell proliferation and CD4+ CD25+ Foxp3+ generation 
determined by flow cytometry.    
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In a separate Ovap/adjuvant experiment, FACS-purified (≥ 98%) OTII+ CD4+ 
CD25- Foxp3eGFP- T cells were transferred into CD45.1+ host mice 24h before vehicle and 
TCDD exposure. The CD45.1+ host mice were gavaged and immunized as described 
above. On day 10 post-immunization, antigen-specific CD45.2+ CD4+ CD25+ Foxp3eGFP+ 
Tregs were assessed from the spleen and popliteal and brachial lymph nodes. Host 
CD45.1+ CD4+ CD25+ Foxp3+ Tregs were also analyzed via intracellular Foxp3 staining.  
  
Antibody and Cytokine Measurement Total IgG, IgG2a and IgM and Ovap-specific 
IgG, IgG2a and IgM levels were measured in the plasma of individual mice by ELISA 
following manufacturer’s instructions (Southern Biotech, Birmingham AL). Ova-specific 
IgG, IgG2a and IgM levels were quantified using whole ovalbumin (50µg/mL) coated 
plates. Supernatants DC:T cell co-cultures were collected and stored at -20oC until further 
analysis. IL-2, IFNγ and IL-10 cytokine production was measured using ELISAs per the 
manufacturer’s instructions (BD Biosciences). IL-22 levels were measured using ELISA 
from R&D Systems (Minneapolis, MN) according to manufacturer’s instructions. 
 
Quantitative Real-Time Reverse Transcription-polymerase Chain Reaction (qRT-
PCR) Splenic DC gene expression was assessed by qRT-PCR as previously described 
(Bankoti et al., 2010b). FACS-purified splenic DCs were washed twice in PBS and 
resuspended in Trizol (Invitrogen) to isolate RNA. Primers for indoleamine 2,3-
dioxygenase 1 (Ido1) and Ido2, aldehyde dehydrogenase family 1, subfamily A2 
(Aldh1a1) and Aldh1a2, Arginase (Arg1), transforming growth factor β1 (Tgfβ1), Tgfβ2 
and Tgfβ3, transforming growth factor beta receptor II (TgfβRII), aryl hydrocarbon 
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receptor (Ahr), aryl hydrocarbon receptor repressor (Ahrr), Cytochrome P450 1a1 
(Cyp1a1) and interleukin-6 (IL-6), IL-10, IL-23 and IL-27 were purchased from 
SABiosciences (Frederick, MD) or IDT (San Diego CA). mRNA levels were determined 
using SYBR green in qRT-PCR reactions (SABiosciences) on a BIO-RAD IQ 5 Light 
Cycler (BIO-RAD; Hercules, CA).  
 
Statistical Analysis Student’s t tests were used to compare two individual samples. The 
delta delta Ct method was used to calculate fold changes in qRT-PCR studies, with 
Student’s t test used to measure significance. p values ≤ 0.05 were considered significant. 
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Figure 4.1 
 
 
 
 
Figure 4.1.  In vivo adoptive transfer models. 
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RESULTS 
TCDD-induced AhR activation decreases antigen-specific CD4+ T cell responses 
Antigen-specific interactions between DCs and T cells were assessed in vivo to 
determine whether TCDD-induced AhR activation causes the generation of tolerogenic 
DCs and Tregs. Initially, CD45.1+ host mice were seeded with enriched ~75% CD45.2+ 
OTII+ CD4+ T cells from naïve OTII Foxp3+ reporter mice (Figure 4.1A). This Ovap-
specific CD4+ T cell population contained both naïve CD4+ T cells as well as ~5% 
Foxp3eGFP+ natural Tregs. CD45.1+ host mice were exposed to vehicle or TCDD 24h after 
the CD4+ T cell transfer. Following transfer of CD4+ T cells, Ovap-loaded CD11c+ 
BMDCs were injected into the hind footpads of host mice to elicit an antigen-specific 
immune response primarily in the draining popliteal lymph nodes (PLNs) when 
compared to the distal brachial lymph nodes (BLNs) (Figure 4.1A). On day 4 post-DC 
footpad immunization, a significant increase in the total number of cells in the PLNs was 
observed, which correlated with a significant increase in the frequency and number of 
Ovap-specific CD45.2+ CD4+ OTII T cells when compared to BLN samples (Figure 4.2). 
In TCDD-exposed mice there was a significant reduction in both the percent and number 
of Ovap-loaded donor DCs and CD45.2+ CD4+ T cells in the PLNs when compared to 
Vehicle-treated samples from the PLN (Figure 4.2). However, there was a significant 
increase in the frequency of CD45.2+ CD4+ CD25+ Foxp3+ Tregs in the PLNs of mice 
exposed to TCDD (Figure 4.1B). Because there was a significant reduction in total cell 
numbers in the PLNs of TCDD-exposed mice, the increased Treg frequency did not 
correlate with an increased number of CD45.2+ CD4+ CD25+ Foxp3+ Tregs.  
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Antigen-specific CD45.2+ CD4+ OTII T cells from the PLNs of TCDD-exposed 
mice displayed significantly reduced levels of both CD62L and CD25 surface molecules 
when compared to expression levels on CD45.2+ CD4+ T cells from PLNs of Vehicle-
mice. To assess the CD4+ T effector response in the draining lymph node, cells from the 
PLNs of Vehicle- and TCDD-exposed mice were restimulated with Ovap or anti-
CD3/CD28 for 48h and cytokine levels measured. As expected there was an increased 
production of IL-2, IFNγ and IL-10 following Ovap or anti-CD3/CD28 stimulation when 
compared to unstimulated PLN samples (Figure 4.2D). Cells from the PLNs of TCDD-
exposed mice produced significantly less IL-2, IFNγ and IL-10 following restimulation 
when compared to cells from Vehicle-treated mice (Figure 4.2D). 
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Figure 4.2 
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Figure 4.2.  TCDD exposure disrupts antigen-specific immune responses in adoptively 
transferred mice. CD45.1+ host mice were intravenously seeded with CD45.2+ OTII+ 
CD4+ T cells enriched from OTII CD4 Foxp3eGFP reporter mice and gavaged with vehicle 
or TCDD (15µg/kg) 24h later. Ovap-loaded CD11c+ BMDCs were injected into host 
mouse hind footpads 24h post-Vehicle or TCDD exposure. The distal brachial lymph 
nodes (BLNs) and proximal popliteal lymph nodes (PLNs) were harvested 4 days after 
Ovap-DC footpad immunizations. (A) Total PLN and BLN cell numbers were assessed 
and the frequency of CD45.2+ CD4+ Ovap-specific T cells and CD45.2+ CD11c+ DCs 
determined via flow cytometry. (B) Overall frequency and calculated numbers of Ovap-
specific CD45.2+ CD4+ T cells and CD45.2+ CD4+ CD25+ Foxp3eGFP+ Tregs in the PLNs 
and BLNs of Vehicle- and TCDD-exposed mice. (C) Activation status of CD45.2+ CD4+ 
T cells in the PLNs, percent and mean fluorescence intensity (MFI). Samples represented 
as isotype; staining grey line, Vehicle-mice; solid black line, TCDD-exposed mice; heavy 
black dashed line. (D) Cytokine levels in 48h restimulation cultures with 100,000 cells 
from the PLNs of Vehicle- and TCDD-treated mice. No stim denotes cells in media 
alone. * indicates significance with p ≤ 0.05 between Vehicle and TCDD groups. # 
indicates significant difference between (A) BLN and PLN samples and (D) No stim and 
stimulation samples. Data are represented as mean ± standard error of the mean (SEM) 
with n = 6 from one experiment. 
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TCDD does not induced antigen-specific iTregs in the Ovap-DC model 
Expansion of Foxp3+ regulatory T cells in the periphery can be attributed to either 
expansion of nTregs and/or the generation of iTregs from naïve CD4+ T cells. While AhR 
activation can induce both Treg and Th17 cells during autoimmune inflammatory 
responses, it is unclear whether AhR activation leads to the generation of iTregs or the 
expansion on nTregs in other immune models (Quintana et al., 2008b; Veldhoen et al., 
2008; Quintana et al., 2010). In the first Ovap-DC adoptive transfer experiment, host 
mice were seeded with an enriched population of antigen-specific CD4+ T cells, which 
contained a small fraction (≤ 5%) of CD4+ CD25+ Foxp3+ nTregs.  To determine if 
TCDD-induced AhR activation causes the induction of antigen-specific iTregs following 
interactions with Ovap-DCs, CD45.1+ host mice were seeded with FACS-purified 
CD45.2+ CD4+ CD25- Foxp3- T cells from OTII Foxp3eGFP mice. In this experimental 
design, the generation of Foxp3+ Tregs in the draining PLN is attributable exclusively via 
the induction of iTregs due to the absence of nTregs. Similar to the first Ovap-DC 
footpad immunization adoptive transfer experiment, there was a significant increase in 
total cell numbers in the PLNs when compared to the BLNs on day 5 post-DC footpad 
immunizations (Figure 4.3A). There was no significant difference in the frequency of 
Ovap-loaded donor DCs in the PLNs between vehicle- and TCDD-exposed mice (Figure 
4.3A). However, there was a significant reduction in total PLN cell numbers in TCDD-
exposed mice when compared to the Vehicle-treated controls. This reduction in overall 
cell number corresponded to a significant reduction in the number of Ovap-loaded donor 
DCs (Figure 4.3A). Additionally, the frequency and number of Ovap-specific CD45.2+ 
CD4+ T cells was significantly reduced in the PLNs following TCDD-exposure when 
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compared to the Vehicle-treated controls (Figure 4.3B). Although we expected to see an 
increase in the frequency of Foxp3+ iTregs in TCDD-exposed mice, Foxp3+ iTregs were 
not observed in the PLNs of either Vehicle- or TCDD-exposed mice (Figure 4.3B). This 
may have been due to lack of antigen-specific CD4+ T cell responsiveness. However, 
FACS-purified CD4+ CD25- Foxp3- T cells were responsive to anti-CD3/CD28 
simulation in vitro, and under optimal Treg induction conditions with IL-2 and TGFβ 
there was a 57% increase in Foxp3+ iTregs (Figure 4.3B).  
While there was no induction of iTregs in TCDD-exposed mice, CD4+ effector 
cells from TCDD-exposed mice displayed significantly reduced expression of CD62L, 
CD25 and CD44 (Figure 4.3C). Furthermore, CD4+ T cell responses were diminished 
following ex vivo restimulation. In response to Ovap, cells from the PLNs of TCDD-
exposed mice produced significantly less IL-2 and IL-10, while there was trend toward 
decreased IFNγ production when compared to stimulated PLN cells from Vehicle-mice 
(Figure 4.3C). There were no significant differences between Vehicle and TCDD PLN 
groups following stimulation with anti-CD3/CD28 (Figure 4.3C).  
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Figure 4.3 
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Figure 4.3.  TCDD does not induce iTregs during an Ovap-specific immune response in 
adoptively transferred mice. CD45.1+ host mice were intravenously seeded with FACS-
purified CD45.2+ CD4+ CD25- Foxp3- T cells from OTII CD4 Foxp3eGFP reporter mice 
and gavaged with vehicle or TCDD (15µg/kg) 24h later. Ovap-loaded CD11c+ BMDCs 
were injected into host mouse hind footpads 24h post-Vehicle and TCDD exposure. The 
BLNs and PLNs were harvested 5 days after Ovap-DC footpad immunizations. (A) Total 
PLN and BLN cell numbers were assessed and the frequency of CD45.2+ CD4+ Ovap-
specific T cells and CD45.2+ CD11c+ DCs determined by flow cytometry. (B) Overall 
frequency and calculated numbers of Ovap-specific CD45.2+ CD4+ T cells and CD45.2+ 
CD4+ CD25+ Foxp3eGFP+ Tregs in the PLNs and BLNs of Vehicle- and TCDD-treated 
mice. (C) Activation status of CD45.2+ CD4+ T cells in the PLNs, percent and mean 
fluorescence intensity (MFI). Samples represented as isotype; staining grey line, Vehicle-
mice; solid black line, TCDD-exposed mice; heavy black dashed line. (D) Cytokine 
levels in 48h restimulation cultures with 100,000 cells from the PLNs of Vehicle- and 
TCDD-exposed mice. No stim denotes cells in media alone. * indicates significance with 
p ≤ 0.05 between Vehicle and TCDD groups. # indicates significant difference between 
(A) BLN and PLN samples and (D) No stim and stimulation groups. Data is 
representative of two independent experiments and represented as mean ± SEM of n = 6. 
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TCDD exposure suppresses Ovap/adjuvant responses and induces Foxp3+ Tregs 
The Ovap-DC footpad immunization adoptive transfer model is useful for 
analyzing antigen-specific CD4+ T cell activation, polarization and expansion under 
relatively low inflammatory circumstances in the draining lymph node. However, to 
evaluate the effects of TCDD on the generation of regulatory T cells during the course of 
an antigen-specific immune response in an inflamed environment, we employed a model 
in which mice were exposed to Vehicle or TCDD and then immunized with Ovap 
suspended in Sigma Adjuvant System. DCs and CD4+ T cells were characterized 10 days 
post-immunization in the spleen and combined popliteal and brachial lymph nodes 
(PBLNs). This experimental approach better models antigen-specific immune responses 
under inflammatory conditions in which TCDD exposure has been shown to cause Treg 
polarization (Quintana et al., 2008b).  
To assess the antigen-specific T cell-mediated humoral immune response on day 
10, total IgG, IgG2a and IgM and Ovap-specific IgG, IgG2a and IgM levels were 
measured in the plasma of Vehicle- and TCDD-exposed following immunization with 
Ovap/adjuvant. When compared to non-immunized mice, an increase in total Ig levels 
was detected in immunized mice (Table 4.2). Total IgG, IgG2a and IgM and Ovap-
specific IgG and IgM antibody levels were significantly reduced in Ovap/adjuvant 
immunized mice exposed to TCDD when compared to Vehicle-treated mice (Table 4.2). 
Ovap-specific IgG2a levels were below detection in both Vehicle- and TCDD-exposed 
immunized mice. Decreased antibody production following TCDD exposure is a well-
characterized effect in Ova adjuvant models and well as other antigen-specific mouse 
models (Shepherd et al., 2000; Sulentic et al., 2000; Ito et al., 2002; Nohara et al., 2002; 
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Inouye et al., 2003). We observed similar decreases in overall antibody production in our 
Ovap/adjuvant system.  
In Ovap/adjuvant immunized mice total cellularity in the spleen was significantly 
decreased, while it was increased in the PBLNs of TCDD-exposed mice (Figure 4.4A). 
The frequency of CD4+ T cells in the spleen and PBLNs remained unchanged between 
immunized Vehicle- and TCDD-exposed mice (Figure 4.4B). However, there was a 
significant reduction in the number of splenic CD4+ T cells in TCDD-exposed mice when 
compared to the number of splenic CD4+ T cells in Vehicle-treated mice (Figure 4.4B). 
To determine if TCDD had any effect on Foxp3+ Tregs, the frequency and number of 
CD4+ CD25+ Foxp3+ T cells were assessed in the spleen and PBLNs. In the spleens of 
immunized TCDD-exposed mice the percent of CD4+ CD25+ Foxp3+ Tregs was 
significantly increased while the number of Tregs did not significantly differ when 
compared to Vehicle-treated mice (Figure 4.4B). In the PBLNs of immunized TCDD-
exposed mice there was a significant increase in both the frequency and number of CD4+ 
CD25+ Foxp3+ Tregs when compared to the PBLNs of Vehicle-treated mice (Figure 
4.4B).  
In both the spleen and PBLNs there was an increased frequency of CD4+ T cells 
expressing CD25 in TCDD-mice (Figure 4.4C). However, on a per cell basis CD25 
expression was significantly decreased on CD4+ T cells from TCDD-exposed mice, while 
there was no change in CD44 expression when compared to Vehicle-treated controls. 
Moreover, the expression of GITR on CD4+ CD25+ Foxp3+ Tregs was not significantly 
altered in the spleen, while it was increased on Tregs in the PBLNs of TCDD-exposed 
mice (Figure 4.4C). To further assess the CD4+ T cell response, cells from the spleen and 
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PBLNs were restimulated ex vivo with Ovap or anti-CD3/CD28. IL-2 levels were 
significantly increased in splenic samples from immunized TCDD-exposed mice in 
response to anti-CD3/CD28 stimulation (Figure 4.4C). IFNγ levels in response to Ovap 
were significantly decreased in both splenic and PBLN samples from immunized TCDD-
exposed mice, while IL-10 levels were below detection in Ovap restimulation groups 
(Figure 4.4C). IL-10 was detectable in anti-CD3/CD38 cultures with a significant 
reduction only seen in anti-CD3/CD28-stimulated PBLN samples from immunized 
TCDD-exposed mice (Figure 4.4C). 
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Table 4.1 
A. 
Antibody (µg/mL) Naïve Vehicle  TCDD 
Total IgG 407 ± 14 1653 ± 246  634 ± 152 * 
Total IgG2a 15 ± 0.4 2308 ± 17 1066 ± 19 * 
Total IgM 207 ± 17 773 ± 169 445 ± 104 * 
Ovap-specific IgG 54 ± 2.2 1022 ± 400 345 ± 62 * 
Ovap-specific IgG2a B.D. B.D. B.D. 
Ovap-specific IgM 222 ± 0.9 4171 ± 907 1653 ± 246 * 
 
 
 
B. 
Antibody (µg/mL) Naïve Vehicle  TCDD 
Total IgG 407 ± 14 814 ± 171 288 ± 88 * 
Total IgG2a 15 ± 0.4 11.7 ± 1.3 2.2 ± 0.3 * 
Total IgM 207 ± 17 725 ± 162 435 ± 149  
Total IgG1 − 20.8 ± 0.8 19.0 ± 1.8  
Ovap-specific IgG 54 ± 2.2 123 ± 18 76.9 ± 22  
Ovap-specific IgG2a B.D. B.D. B.D. 
Ovap-specific IgM 222 ± 0.9 1304 ± 433 951 ± 437  
 
Table 4.1. TCDD-exposure reduces antibody levels following Ovap/adjuvant 
immunization. (A) Day 10 plasma Ig levels in mice exposed to Vehicle or TCDD and 
immunized with Ovap in Sigma Adjuvant System. (B) Day 10 plasma Ig levels in host 
mice exposed to Vehicle or TCDD, seeded with Ovap-specific CD4+ T cells and 
immunized with Ovap in Sigma Adjuvant System. Naïve non-exposed non-immunized 
mice plasma Ig levels were measured for comparison. Data is represented as mean ± 
standard error of the mean (SEM) with (A) vehicle n = 9 and TCDD n = 12 and (B) 
Vehicle and TCDD n = 6. * indicates significance with p ≤ 0.05 between Vehicle and 
TCDD samples. B.D. below detection. 
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Figure 4.4 
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Figure 4.4.  CD4+ T cell characterization in TCDD-treated Ovap/Adjuvant immunized 
mice. Mice were gavaged with Vehicle or TCDD (15µg/mL) and 24h later immunized 
with Ovap (1mg/mL) suspended in Sigma Adjuvant System. (A) Spleens and popliteal 
and brachial lymph nodes (PBLNs) were harvested on day 10 post-immunization and 
cells enumerated. (B) CD4+ T cells and CD4+ CD25+ Foxp3+ Tregs were assessed. Foxp3 
expression was detected by intracellular staining. (C) Activation status of CD4+ T cells in 
the spleen and PBLNs and GITR expression on CD4+ CD25+ Foxp3+ Tregs, percent and 
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mean fluorescence intensity (MFI). Samples represented as isotype; staining grey line, 
Vehicle-mice; solid black line, TCDD-exposed mice; heavy black dashed line. (D). 
Cytokine levels in 5 day restimulation cultures with 100,000 cells from the spleen or 
PBLNs of immunized Vehicle- and TCDD-exposed mice. * indicates significance with p 
≤ 0.05 between Vehicle and TCDD groups. Data are represented as mean ± SEM of six 
samples from two independent experiments. 
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TCDD reduces splenic DCs in Ovap/adjuvant immunized mice without altering their 
APC function ex vivo 
 TCDD exposure in naïve mice causes the deletion of stimulatory CD11chigh 
33D1+ DCs in the spleen, while tolerogenic CD11clow DEC205+ DCs are retained 
(Bankoti et al., 2010a). The retention of the CD11clow DEC205+ tolerogenic DC 
population in the spleen could contribute to the induction of Foxp3+ Tregs and 
subsequent immune suppression in TCDD-exposed mice following Ovap/adjuvant 
immunization. In immunized mice exposed to TCDD there was a significant reduction in 
the frequency and number of CD11c+ MHC II+ DCs (Figure 4.5A). In the CD11c+ MHC 
II+ DC fraction present in mice exposed to TCDD there was an increased frequency of 
DCs expressing CD86 CD40 and CD103 when compared to CD11c+ MHC II+ DCs 
present in the spleen of Vehicle-treated mice (Figure 4.5B). Furthermore, splenic CD11c+ 
DCs purified from TCDD-exposed mice had elevated gene expression of IDO1, IDO2 
and Aldh1a2 when compared to CD11c+ DCs from Vehicle-treated mice (Table 4.2). 
However, purified splenic CD11c+ DCs from immunized TCDD-exposed mice failed to 
induce Foxp3+ Tregs in ex vivo co-cultures with naïve Ovap-specific CD4+ T cells 
enriched from naïve OTII Foxp3eGFP reporter mice when compared to CD11c+ DCs from 
Vehicle-treated mice (Figure 4.5D). There was a slight reduction in overall CD4+ T cell 
proliferation following interactions with CD11c+ DCs from TCDD-exposed mice (Figure 
4.5C). In addition, IL-2 and IL-10 cytokine production in these CD11c+ DC:OTII+ CD4+ 
T cell co-cultures was similar between Vehicle- and TCDD-DC groups, while IFNγ 
levels were significantly reduced in TCDD-DC:T cell co-cultures (Figure 4.5E).  
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Figure 4.5 
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Figure 4.5. DC characterization in TCDD-trated Ovap/adjuvant immunized mice. Mice 
were gavaged with Vehicle or TCDD (15µg/mL) and 24h later immunized with Ovap in 
Sigma Adjuvant System. (A) CD11c+ MHC II+ DC in the spleens and popliteal and 
brachial lymph node (PBLN) day 10-post immunization. (B) Activation marker 
expression on CD11c+ MHC II+ splenic DCs. (C and D) Enriched Cell Trace-labeled 
CD4+ T cells from naïve OTII Foxp3eGFP reporter mice were co-cultured with CD11c+ 
Ovap-loaded splenic DCs isolated and purifed from immunized Vehicle and TCDD-
exposed mice. Co-cultures were harvested on day 5 and the percent of Foxp3+ Tregs and 
CD4+ T cell proliferation assessed by flow cytometry. (E) Cytokine levels in CD4+ T 
cell:DC co-cultures. * indicates significance with p ≤ 0.05 between Vehicle and TCDD 
groups. Data are represented as mean ± SEM of six samples from one experiment. 
 
 
 
 
 
 
 
 
 
 
 
 180 
Table 4.2 
 
A. Naïve mice 48h TCDD 
exposure 
 B. Naïve mice 10-
day TCDD exposure 
 C. TCDD-exposed 
Ovap/adjuvant 
immunized mice day 10 
Gene Fold Change p-value  
 Fold 
Change p-value  
 Fold 
Change p-value  
Ido1 6.8 * 0.007  9.1 * 0.002  11.3 * 0.001 
Ido2 28.2 * 0.004  15.4 * 0.03  76.0 * 0.001 
Aldh1a1 0.4 0.1  − −  0.7 0.4 
Aldh1a2 0.4 0.053  − −  4.0 * 0.0001 
Arginase − −  − −  1.0 0.9 
Tgfβ1 0.9 0.8  0.6 * 0.01  0.8 * 0.02 
Tgfβ2 3.4 * 0.03  0.4 * 0.04  1.4 0.6 
Tgfβ3 7.1 * 0.02  0.7 0.11  1.2 0.8 
TgfβrII − −  − −  0.7 0.2 
AhR − −  − −  0.4 * 0.01 
AhRR − −  − −  12.7 * 0.002 
Cyp1a1 1.6 0.4  1.0 1.0  0.9 0.9 
Il-1β − −  − −  0.3 * 0.02 
Il-6 − −  − −  1.4 0.2 
Il-10 1.1 0.9     0.9 0.2 
Il-23 − −  − −  0.8 0.6 
Il-27 − −  − −  0.6 0.2 
 
Table 4.2. Gene expression in purified CD11c+ splenic DCs. Gene expression was 
evaluated with qRT-PCR. (A) DCs isolated from naive mice 48h after Vehicle or TCDD 
exposure. (B) DCs isolated from naïve mice 10 days post-Vehicle or TCDD exposure. 
(C) DCs isolated from mice exposed to Vehicle or TCDD and immunized with 
Ovap/Sigma Adjuvant System on day 10 post-immunization. Results are expressed as 
TCDD-induced fold change in comparison to Vehicle-treated mice after normalization to 
housekeeping gene β-actin expression, with (A and B) n = 3 per treatment group and (C) 
Vehicle n = 3 and TCDD n = 2. * p ≤ 0.05 indicates significance between Vehicle and 
TCDD-exposed mice. Data is representative of one experiment for each group A-C. 
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Antigen-specific iTregs are generated in response to TCDD-induced AhR activation in 
an Ovap/adjuvant OTII+ CD4+ adoptive transfer model     
To better track the induction of Foxp3+ iTregs in the Ovap/adjuvant model, 
CD45.2+ CD4+ CD25- Foxp3eGFP- T cells purified from OTII Foxp3eGFP reporter mice 
were transferred into CD45.1+ host mice. These naïve CD45.2+ CD4+ T cells were 
allowed to seed the spleen and lymph nodes of host mice for 24h before oral exposure to 
Vehicle or TCDD (15µg/mL). Mice were then immunized with Ovap/adjuvant and the 
induction of iTregs assessed in the spleen and PBLNs 10 days post-immunization. 
Similar to the Ovap/adjuvant system without the transfer of Ovap-specific CD4+ T cells, 
a significant reduction in the number of cells in the spleen was observed in immunized 
TCDD-exposed mice when compared to Vehicle-treated mice (Figure 4.6A). There was 
no difference in the overall cell number in the PBLNs between immunized Vehicle-mice 
and TCDD-exposed mice (Figure 4.6A). In the spleen, TCDD-induced AhR activation 
caused a significant reduction in both the frequency and number of Ovap-specific 
CD45.2+ CD4+ T cells (Figure 4.6B). The frequency of CD45.2+ CD4+ T cells was 
greatly reduced in the PBLNs as compared to the frequency of CD45.2+ CD4+ T cells in 
the spleen of immunized mice (Figure 4.6B). The percent of splenic antigen-specific 
CD45.2+ CD4+ CD25+ Foxp3eGFP+ iTregs was significantly increased when compared to 
splenic iTregs in immunized Vehicle-treated mice (Figure 4.6C). In splenic ex vivo 
restimulation cultures with Ovap or anti-CD3/CD28, cells from TCDD-exposed mice 
produced less IFNγ and IL-10 in response to Ovap or anti-CD3/CD28 stimulus, 
respectively (Figure 4.6C).   
 182 
Consistent with previous Ovap/Adjuvant experiments, the frequency and number 
of splenic CD11c+ MHC II+ DCs were significantly decreased in immunized TCDD-
exposed mice (Figure 4.7A). Furthermore, splenic DCs from TCDD-treated mice 
expressed increased levels of CD86 and CD103 (Figure 4.7B). In the PBLNs there was 
an increase in the number of CD11c+ MHC II+ DCs, but the expression of CD86 and 
CD103 on DCs did not differ significantly between TCDD-treated and Vehicle-treated 
mice (Figure 4.7B).   
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Figure 4.6 
 
 
 
 
 
 
 
 
Figure 4.6.  Antigen-specific CD4+ T cell responses in adoptively transferred TCDD-
treated and immunized mice. CD45.1+ host mice were intravenously seeded with 1x106 
FACS-purified CD45.2+ CD4+ CD25- Foxp3- T cells from OTII Foxp3eGFP reporter mice. 
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24h after the transfer of antigen-specific naïve CD4+ T cells, host mice were gavaged 
with Vehicle or TCDD and 24h later immunized with Ovap in Sigma Adjuvant System. 
(A) Spleens and PBLNs were harvested on day 10 post-immunization and cells 
enumerated. (B) CD45.2+ CD4+ and CD4+ CD25+ Foxp3eeGFP+ T cells were assessed. (C) 
Cytokine levels in 48h restimulation cultures with 100,000 cells from the spleen or 
PBLNs of immunized Vehicle- and TCDD-exposed mice. * indicates significance with p 
≤ 0.05 between Vehicle and TCDD groups. Data are displayed as mean ± SEM with n = 
6 from one experiment. 
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Figure 4.7 
 
 
 
Figure 4.7. DC characterization in adoptively transferred TCDD-treated immunized 
mice. (A) CD11c+ MHC II+ DC in the spleens and PBLNs day 10 post-immunization. (B) 
Activation marker expression on CD11c+ MHC II+ splenic DCs. Data is representative of 
one experiment. * indicates significance with p ≤ 0.05 between Vehicle and TCDD 
groups. Data are displayed as mean ± SEM with n = 6.  
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DISCUSSION 
The AhR, while being a well-known steroid-like transcription factor in toxicology 
has recently come into the limelight for its potential role in the polarization of Tregs and 
Th17 effector cells in mice (Quintana et al., 2008b; Veldhoen et al., 2008; Stockinger et 
al., 2011). However, few studies have examined the role of TCDD-induced AhR 
activation in DCs and whether AhR activation in vivo causes the generation of 
tolerogenic DCs capable of inducing regulatory T cells ex vivo. In previous Ovap-DC 
footpad immunization adoptive transfer experiments we have shown that TCDD exposure 
significantly dampens the Ovap-specific CD4+ T cell response as determined by a 
reduction in both the frequency and number of Ovap-specifc CD4+ T cells in the PLNs of 
TCDD-treated mice (our unpublished data). Furthermore, when cells from the PLNs of 
TCDD-exposed mice were restimulated with Ovap they produced significantly less IL-2, 
IFNγ and IL-10 when compared to cells from Vehicle-treated control mice. In these 
studies, TCDD exposure could be causing the generation Foxp3+ Tregs during the initial 
course of the Ovap-sepcific CD4+ T cell immune response in the draining lymph node, 
which could subsequently dampen the overall CD4+ T cell effector response as well as 
DC function. To examine this possibility, Ova-specific CD4+ T cells from OTII 
Foxp3eGFP reporter mice were used to track the generation of Foxp3+ Tregs in the 
draining lymph node following TCDD exposure and Ovap-DC footpad immunizations. In 
the first experiment, CD4+ T cells containing a small fraction of nTregs were transferred 
into CD45.1+ host mice and on day 4 there was a significant increase in Foxp3+ Tregs in 
the draining lymph nodes of mice exposed to TCDD. Similar to previous experiments we 
observed a reduction in both Ovap-DCs and OTII+ CD4+ T cells in TCDD-exposed mice. 
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It is possible that the increased frequency of Foxp3+ Tregs is creating a suppressive 
environment in the draining lymph node that is directly inhibiting the Ovap-specific 
CD4+ T cell effector response. To determine whether the induction of Tregs in TCDD-
exposed mice was a preferential expansion of nTregs or iTregs, the Ovap-DC footpad 
immunization adoptive transfer experiments were repeated, this time utilizing FACS-
purified OTII+ CD4+ CD25- Foxp3- T cells. Unexpectedly, on day 4 there was no 
induction of Foxp3+ iTregs, in either Vehicle- or TCDD-exposed mice, yet there was still 
a significant reduction in the frequency and number of OTII+ CD4+ T cells in TCDD-
exposed mice. One explanation for the lack of Foxp3+ iTregs in TCDD-exposed mice that 
received naïve OTII+ CD4+ T cells is that TCDD-induced AhR activation causes the 
expansion or retention of nTregs rather than the generation of iTregs from naïve CD4+ T 
cells. It may also be possible that the transferred Ovap-specific naïve CD4+ T cells were 
unresponsive following ex vivo isolation, enrichment, FACS purification and transfer into 
host mice. However, as a control, a fraction of FACS-purified OTII+ CD4+ CD25- Foxp3- 
T cells were stimulated for 4 days with plate-bound anti-CD3/CD28 in media alone or 
media supplemented with IL-2 and TGFβ. The CD4+ T cells in these ex vivo control 
cultures were responsive to anti-CD3/CD28 stimulation and in the presence of IL-
2/TGFβ there was a significant induction of Foxp3 iTregs. These results likely rule out 
that the transferred OTII+ CD4+ CD25- Foxp3- T cells were unresponsive.  
In addition to the possible expansion or retention of nTregs, TCDD significantly 
reduced the number of Ovap-DCs in the PLNs. The reduction of Ovap-DCs could be 
responsible for the observed decreases in antigen-specific CD4+ T cells in the draining 
lymph nodes of TCDD-exposed mice. Furthermore, it is likely that AhR activation in the 
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transferred Ovap-DCs is altering their functional capacity to present antigen and 
stimulate CD4+ T cells as we have previously shown in vitro that TCDD-induced AhR 
activation disrupts BMDC differentiation and induces an immature DC phenotype 
(Bankoti et al., 2010b). It is also possible that TCDD is directly affecting the OTII+ CD4+ 
T cells either leading to apoptosis or altering their responsiveness to antigen presented by 
DCs. It is interesting that in both Ova-DC footpad immunization adoptive transfer 
experiments that the CD4+ effector T cells down-regulated CD62L and CD25 expression. 
Activated CD4+ effector cells typically down-regulate CD62L expression while 
increasing CD25 expression. It is possible that TCDD-induced AhR activation in OTII+ 
CD4+ T cells is causing emigration from the draining lymph node in a unique semi-
activated state following interactions with AhR-activated DCs. Taken together, TCDD 
exposure affects both DC and CD4+ effector T cell populations, and TCDD-exposure in 
the context of an antigen-specific CD4+ T cell response under minimal inflammatory 
conditions may lead to the expansion, retention or increased functional capacity of 
nTregs rather than the induction of iTregs. 
The lack of effects on regulatory T cells in the Ovap-DC footpad immunization 
adoptive transfer experiments may be due to a lack of inflammation. In instances when 
Treg and Th17 polarization has been observed following TCDD-induced AhR activation, 
it has usually been with a highly inflammed disease state (Quintana et al., 2008b; 
Veldhoen et al., 2008). This is supported by the observation that following 
Ovap/adjuvant immunization there was a significant increase in host CD4+ CD25+ 
Foxp3+ Tregs as well as a substantial increase in antigen-specific Foxp3+ iTregs when 
Ovap-specific CD4+ CD25- Foxp3- T cells were transferred into host mice before TCDD 
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exposure and Ovap/adjuvant immunization. The induction of regulatory T cells may be 
mediated by tolerogenic DCs induced following TCDD exposure. Previously, Bankoti 
and colleagues demonstrated that TCDD exposure in naïve mice preferentially causes the 
deletion of stimulatory CD11chigh CD8- 33D1+ and retention of tolerogeinc 
CD11cintermedate CD8+ DEC205+ splenic DCs (Bankoti et al., 2010a). In the Ovap/adjuvant 
immunization model we observed a similar decrease in CD11chigh DCs in the spleen 
following TCDD exposure. While we did not fully characterize the DC subsets in the 
spleen or PBLNs in this model, we did observe an increase in CD11c+ MHC II+ CD103+ 
DCs in the spleens and PBLNs of TCDD-exposed immunized mice. CD103+ DCs in 
mucosal sites as well as the spleen have been shown to be highly tolerogenic and can 
directly induce Tregs (Coombes et al., 2007; Yamazaki et al., 2008; Del Rio et al., 2010). 
Furthermore, splenic DCs from TCDD-exposed immunized mice displayed increased 
gene expression of IDO1 and IDO2 and Aldh1a2. These particular proteins have been 
associated with tolerogenic DC function and the induction of Tregs in an AhR-dependent 
manner (Vogel et al., 2008; Mezrich et al., 2010; Quintana et al., 2010). However, when 
splenic DCs were isolated from mice exposed to TCDD they failed to induce antigen-
specific CD4+ CD25+ Foxp3+ iTregs in in vitro DC:T cell co-cultures. Thus, there may be 
additional signals that are required for the generation of iTregs in vitro. It is also possible 
that AhR activation by TCDD is required in CD4+ T cells for Treg polarization following 
interactions with AhR-activated DCs.  
To date this is the first study to assess the generation of Tregs in response to 
TCDD-induced AhR activation and Ovap/adjuvant immunization. However, previous 
studies by Ito and co-workers showed that oral TCDD exposure followed by immediate 
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i.p. immunization with whole Ovalbumin absorbed to Alum suppressed Ova-specific 
IgG1 production and decreased the total number of cells in the spleen as well as splenic 
CD3+ T cell numbers (Ito et al., 2002). They also showed that splenic cells from TCDD-
exposed mice when restimulated with Ova for 48h produced less IL-5, while IL-2, IL-4 
and IL-6 levels remained unchanged when compared to Vehicle restimualtion groups (Ito 
et al., 2002). Moreover, Shepherd and colleagues using a DO11.10 adoptive transfer 
model in which naïve Balb/c mice were orally exposed to Vehicle or TCDD and seeded 
with Ovap-specific DO11.10 CD4+ T cells then immunized with Ova emulsified in CFA 
demonstrated that TCDD exposure reduced total IgG and IgM and Ova-specific IgG2a 
levels on day 10 post-immunization (Shepherd et al., 2000). The frequency of DO11.10+ 
CD4+ T cells in the spleen of TCDD-exposed mice were also significantly reduced, yet 
there was no change in IL-2 or IFNγ production following a 3 day ex vivo restimulation 
with Ova (Shepherd et al., 2000). Similar to these studies we demonstrated that B6 mice 
exposed to TCDD and immunized with Ovap suspended in Sigma Adjuvant System, 
similar to CFA, produced less total IgG and IgM and Ovap-specific IgG and IgM, 
displayed reduced numbers of splenic CD4+ T cells and disrupted CD4+ T cell activation 
status. Following restimulation with Ovap, splenic cells from TCDD/immunized mice 
produce less IFNγ. In our Ovap/adjuvant immunization adoptive transfer model with 
OTII+ CD4+ CD25- Foxp3-, similar results were observed including a reduction in total Ig 
levels, reduced antigen-specific T cell populations in the spleen and altered cytokine 
production following restimulation.  
In conclusion, we have demonstrated that the generation of regulatory T cells 
following TCDD-induced AhR activation is likely dependent on an inflammatory 
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environment. With natural Tregs expanding in the presence of AhR activation under 
minimal inflammation conditions and antigen-specific inducible Tregs being generated 
during adjuvant-induced inflammatory responses. TCDD-induced tolerogenic DCs may 
be responsible for the induction of iTregs in our adoptive transfer immunization model; 
however, further studies are required to fully evaluate the role of TCDD-induced 
tolerogenic DCs in vivo. 
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CHAPTER 5 
CONCLUSIONS 
In the last half-century the understanding of AhR biology has grown immensely. 
Since the discovery of the AhR numerous studies utilizing different animal models have 
shown that low-dose exposure to TCDD, the prototypical AhR ligand, causes immune 
suppression. However, the mechanisms underlying the observed immune suppression 
have been difficult to define and remain to be fully elucidated. TCDD-induced AhR 
activation impairs both innate and adaptive immune responses by effecting the fate and 
function of the cells involved in generating successful immune responses. To date, AhR 
research has been primarily centered on the effects in lymphocytes. In comparison, 
relatively little research has been conducted on how AhR activation in DCs affects their 
fate and function. Immature DCs, in contrast to naïve lymphocytes, constitutively express 
high levels of the AhR and due to their sentinel and APC functions in the immune system 
are likely to be key cells mediating the immunosuppressive effects of TCDD. The studies 
in this dissertation have (1) examined the effects of AhR-activation in steady-state 
BMDCs; (2) investigated the capacity of AhR-activated inflammatory BMDCs to 
dampen CD4+ effector T cell responses and induce regulatory T cells in vitro; and (3) 
examined the effects of TCDD-induced AhR activation on the generation of tolerogenic 
DCs and regulatory T cells in vivo.  
AhR-Activation in Steady-State BMDCs  
The seminal study examining the fate and function of DCs demonstrated that 
naïve mice exposed to TCDD displayed a reduced number of splenic DCs, with the 
remaining DCs displaying an altered surface molecule phenotype (Vorderstrasse and 
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Kerkvliet, 2001b). Subsequent studies by Bankoti and colleagues demonstrated that the 
loss of splenic DCs was to due to a selective loss of CD11cHigh DCs in AhR-dependent 
manner (Bankoti et al., 2010a). Furthermore, both splenic DCs and lymph node DCs in 
TCDD-treated mice displayed altered expression of key surface molecules (Bankoti et 
al., 2010a). To better understand the consequences of AhR activation in steady-state DCs 
we utilized a Flt3L-BMDC model, which generates DCs in vitro that are similar to 
steady-state DCs found in peripheral immune tissues such as the spleen and lymph nodes 
(Brasel et al., 2000; Naik et al., 2007; Shortman and Naik, 2007a). Continual AhR 
activation with TCDD altered steady-state BMDC differentiation and generated a 
phenotypically distinct semi-mature BMDCs. These effects on DC differentiation were 
AhR-dependent, but not entirely DRE-dependent, highlighting the possibility that these 
changes may occur via non-canonical AhR signaling in DCs. These alterations were 
observed with the prototypical AhR ligand TCDD; however, the classification of AhR as 
an orphan receptor has been challenged recently by the discovery of a variety of 
endogenous AhR ligands. Steady-state BMDCs grown in the presence of FICZ or ITE, 
two endogenous AhR ligands, displayed similar surface molecule alterations as those 
grown in the presence of TCDD. While ligand-specific effects have been characterized in 
different cell types, AhR activation by the endogenous ligands FICZ and ITE caused 
similar changes in surface molecule expression as TCDD in steady-state BMDCs.    
In response to several TLR agonists including LPS, CpG and Imiquimod, AhR-
activated steady-state BMDCs produced less IL-6, TNFα, IL-10 and IL-12. The reduced 
cytokine production may be in part due the altered NF-κB signaling, as TCDD-exposure 
increased RelB binding activity, while reducing p65 activity in response to LPS or CpG 
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stimulation. In light of these observations, steady-state BMDCs grown in the presence of 
TCDD did not alter antigen-specific CD4+ T cell immune responses in vivo in an Ovap-
DC adoptive transfer model. However, in vitro AhR-activated steady-state BMDCs 
increased the frequency of antigen-specific CD4+ CD25+ Foxp3+ Tregs in co-cultures 
with CD4+ T cells, isolated from OTII Foxp3eGFP reporter mice, in an IDO-dependent 
fashion. This was not surprising as gene expression studies revealed that TCDD-induced 
AhR activation in steady-state BMDCs up-regulated the expression of IDO2, a well-
characterized immunoregulatory enzyme involved in the generation of regulatory T cells.  
This study was novel because it was the first study to examine the effects of AhR 
activation in an in vitro model of Ftl3L-derived steady-state BMDCs. Extrapolating these 
results to an in vivo exposure situation, it is possible that TCDD-induced AhR activation 
alters steady-state DC differentiation, either in the bone marrow during DC development 
from common myeloid and lymphoid progenitor cells or in the spleen where pre-DCs 
help contribute to the maintenance of resident DC populations (Shortman and Naik, 
2007a; Wu and Liu, 2007). AhR activation could effectively induce semi-mature AhR-
activated steady-state DCs that are not only less responsive to danger signals from 
microbial pathogens, but are able to induce Tregs in the periphery. Taken together, the 
decreased innate responsiveness and Treg-induction capabilities of AhR-activated steady-
state BMDCs offer plausible mechanisms underlying the immunosuppressive effects of 
TCDD.  
AhR Activation in Inflammatory BMDCs 
The effects of AhR activation in GM-CSF-derived inflammatory BMDCs have 
been previously described (Lee et al., 2007; Bankoti et al., 2010b). In contrast to Flt3L-
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derived steady-state BMDCs, AhR activation in GM-CSF-derived inflammatory BMDCs 
induces the expression of IDO1 and TGFβ3 along with the expression of IDO2. Because 
AhR activation induces immunoregulatory gene expression as well as alters expression of 
key immune proteins on inflammatory BMDCs, we hypothesized that AhR-activated 
inflammatory BMDCs would suppress antigen-specific T cell-mediated immune 
responses in vitro.  
While AhR-activated inflammatory BMDCs had no effect on CD4+ T cell 
proliferation, they consistently altered IL-2, IFNγ and IL-10 production by T cells in 
DC:T cell co-cultures. The observed alterations in cytokine secretion demonstrate that 
AhR-activated inflammatory BMDCs are capable of altering CD4+ T cell immune 
responses in vitro. Interestingly, similar alterations in cytokine production were observed 
almost a decade earlier following ex vivo restimulation with CD4+ T cell samples from 
mice exposed to TCDD and immunized with Ova antigen and adjuvant (Shepherd et al., 
2000; Ito et al., 2002). Our studies demonstrated that TCDD-induced AhR activation in 
inflammatory BMDCs dampens effector CD4+ T cell responses in vitro. These data 
coupled with in vivo studies suggest that AhR activation in DCs may cause immune 
deviation and/or inhibit the generation of successful effector T cell responses, ultimately 
resulting in immune suppression. In addition, the observed immune suppression 
following exposure to TCDD may be mediated by the generation of tolerogenic DCs that 
are capable of inducing regulatory T cells in the periphery. 
AhR Activation In vivo and Altered Immune Responses 
The AhR following ligand-induced activation plays a role in the polarization of 
regulatory T cells and Th17 cells during inflammatory autoimmune responses in vivo 
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(Quintana et al., 2008b; Veldhoen et al., 2008; Stockinger et al., 2011). Our in vitro 
studies demonstrated that AhR activation leads to the generation of tolerogenic DCs in 
two distinct DC populations, both of which were capable of suppressing antigen-specific 
CD4+ T cell responses. Knowing that the AhR plays a role in the generation of regulatory 
T cells and the fact that in vitro AhR activation disrupts DC function we sought to 
examine the generation of both tolerogenic DCs and Tregs in vivo during antigen-specific 
immune responses. Unexpectedly, Foxp3+ Tregs were generated only when naïve CD4+ T 
cells and nTregs were transferred into host mice exposed to TCDD and immunized with 
Ova-DCs. These results suggest that in a less inflamed environment AhR activation may 
help to maintain or expand nTreg populations rather than generate iTregs. In contrast, 
during periods of increased inflammation, AhR activation may instead lead to the 
generation of iTregs rather than the expansion of nTregs, as we observed a significant 
increase in the frequency of Foxp3+ Tregs in our Ovap/adjuvant model with FACS-
purified CD4+ CD25- Foxp3- T cell transfers. Furthermore, ex vivo restimulation of cells 
from TCDD-exposed mice in both models caused altered cytokine responses, similar to 
those seen in our in vitro experiments. Regardless of the generation of Foxp3+ Tregs, 
TCDD-induced AhR activation dampened in vivo immune responses in our antigen-
specific exposure experiments. While TCDD-induced AhR activation may play a role in 
the generation of Tregs it is also directly affecting effector T cell responses. Further 
studies are needed to fully assess the role and requirement of AhR-induced tolerogenic 
DCs and regulatory T cells in vivo.  
Overall, we have demonstrated that AhR activation alters the differentiation of 
steady-state BMDCs and induces a tolerogenic phenotype in inflammatory BMDCs, 
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which dampens antigen-specific CD4+ effector T cell responses in vitro. In vivo TCDD 
exposure suppresses antigen-specific immune responses and induces Foxp3+ regulatory T 
cells. Collectively, these data enhance our understanding of how TCDD exposure causes 
immune suppression. 
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APPENDIX 
 
Abbreviations 
 
Std. Standard 
N.C. No change 
N.A. Not available 
− No data collected 
 Significant increase 
 Significant decrease 
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Appendix Figure A.1 
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Appendix Figure A.1.  DC:T cell co-cultures with Vehicle- and TCDD-DCs generated 
from Balb/c mice and CD4+ T cells from DO11.10 mice. Ovap-DCs were cultured with 
FACS-purified naïve CD4+ CD25- T cells as described in Chapter 3 Methods and 
Materials. DC:T cell co-cultures were harvested on day 5. (A) Male and female BMDC 
surface molecule phenotype following 7 days in growth with Vehicle or TCDD. (B) Male 
and (C) Female Vehicle- and TCDD-DC:T cell co-cultures, frequency of CD4+ Foxp3+ 
and CD4+ CD25+ Foxp3+ Tregs assessed on Day 5. (D) Male and Female DO11.10+ 
CD4+ T cells stimulated with plate-bound anti-CD3/CD28 in media only or media 
supplemented with IL-2/TGFβ. Data representative of one experiment with n = 3. * 
indicates, p ≤ 0.05, significant difference between Vehicle and TCDD groups. 
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Appendix Figure A.2 
 
 
 
Appendix Figure A.2.  Veh- and TCDD-DC:T cell co-cultures with 1-MT and anti-
TGFβ Treg inhibitors. Vehicle-DC and TCDD-DCs were co-cultured with enriched 
OTII+ CD4+ T cells and the percent of CD4+ CD25+ Foxp3+ Tregs assessed on day 3. The 
number of Tregs in culture was calculated from the total cell number and the percent 
CD4+ CD25+ Foxp3+ Tregs present on day 3. (A) and (B) are two independent 
experiments with n = 4. * p ≤ 0.05 indicates significant difference between Vehicle-DC:T 
cell and TCDD-DC:T cell groups.  
 
 
